Compositions and Methods for Inhibiting Expression of RRM2 Genes

ABSTRACT

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

PRIORITY TO RELATED APPLICATION(S)

This application is a continuation of U.S. patent application Ser. No. 15/906,054, filed Feb. 27, 2018, which is a continuation of U.S. patent application Ser. No. 15/415,415, filed 25 Jan. 2017, which is a continuation of U.S. patent application Ser. No. 14/578,716, filed 22 Dec. 2014, now abandoned, which is a continuation of U.S. patent application Ser. No. 13/275,377, filed 18 Oct. 2011, now U.S. Pat. No. 8,946,176, which claims the benefit of European Patent Application No. 10187851.0, filed Oct. 18, 2010, all of which are hereby incorporated by reference in their entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing, which is provided in electronic format. The Sequence Listing is provided as a file entitled 27028US4_SequenceListing.txt, created 26 Feb. 2018, and is approximately 294 KB in size. The Sequence Listing is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Cancer remains an important area of high unmet medical need. The majority of current treatments provide small gains in overall survival requiring a delicate balance between efficacy and toxicity. Cancer is a disease characterized by uncontrolled growth and survival driven by improper regulation of the cell cycle. The cell cycle is divided up into four stages culminating in cytokinesis with checkpoint controls ensuring accurate completion of each phase. The cell cycle is designed to duplicate cellular material equally partitioning this material into what will become two new cells. DNA replication occurs during S-phase requiring pools of nucleic acid as the building blocks (dNTP) for new DNA as well as to repair DNA damage. Ribonucleotide reductase (RR) converts ribonucleoside 5′-diphosphates into 2′-deoxyribonucleotides which serve as the dNTP source for DNA synthesis and repair. RR catalyzes the rate-limiting step in the generation of dNTPs and represents an important part of cancer cell growth and repair. (RR) is made up of two subunits called RRM1 and RRM2 both of which are required for catalytic RR activity. RRM2 is overexpressed in a range of tumor types and elevated expression is associated with malignant transformation and metastasis. Overexpression of RRM2 cooperates with other oncogenes to drive the transformation and progression of normal cells. Tumor cells are particularly sensitive to changes in their dNTP pools because they have a high proliferation rate and lack checkpoint controls to monitor and repair DNA damage. Inhibition of RRM2 in tumor cells is expected to enhance DNA damage from a lack of sufficient dNTPs producing an apoptotic response. In nontransformed cells, checkpoint controls monitor the level of dNTPs and have the signaling ability to arrest cells before completing DNA replication and repair protecting cells from incurring incompletely replicated DNA or poorly repaired DNA damage.

Despite significant advances in the field of RNA interference (RNAi) and advances in the treatment of fibrosis and proliferative disorders, like cancers, there remains a need for an agent that can selectively and efficiently silence the RRM2 gene. A specific RRM2 inhibitor is expected to provide an improved therapeutic index over existing inhibitors because it is more selective and tumors cells lacking checkpoint controls are dependent on large dNTP pools to support their rapid proliferation and DNA repair. Also, preclinical data supports the potent tumor cell killing effects following RRM2 inhibition.

RRM2 mRNA overexpression is associated with rapidly proliferating tumor cells. RRM2 expression is cell cycle regulated peaking at S-phase when DNA replication and repair occur followed by rapid degradation during mitosis. RRM2 is overexpressed in Acute myeloid leukemia (AML), bladder cancer, prostate cancer, Non Small Cell Lung Cancer (NSCLC), breast cancer, Hepatocellular Carcinoma (HCC), and colorectal cancers to name a few.

Double-stranded ribonucleic acid (dsRNA) molecules have been shown to block gene expression in a highly conserved regulatory mechanism known as RNA interference (RNAi), which is a viable pathway in the development of therapeutically active substances for the treatment of a wide range of proliferating diseases. Accordingly, inhibition of RRM2 expression with the dsRNA molecules of this invention may be used in the treatment of cancer including but not limited to Hepatocellular Carcinoma (HCC) and leukemia as well as other solid tumor types.

SUMMARY OF THE INVENTION

The invention provides double-stranded ribonucleic acid molecules (dsRNAs), as well as compositions and methods for inhibiting the expression of the RRM2 gene, in particular the expression of the RRM2 gene, in a cell, tissue or mammal using such dsRNA. The invention also provides compositions and methods for treating pathological conditions and diseases caused by the expression of the RRM2 gene such as in proliferative disorders like cancer and inflammation.

In one preferred embodiment the described dsRNA molecule is capable of inhibiting the expression of a RRM2 gene by at least 60%, preferably by at least 70%, most preferably by at least 80%. The invention also provides compositions and methods for specifically targeting the liver with RRM2 dsRNA, for treating pathological conditions and diseases caused by the expression of the RRM2 gene including those described above.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides double-stranded ribonucleic acid (dsRNA) molecules able to selectively and efficiently decrease the expression of RRM2. The use of RRM2 RNAi provides a method for the therapeutic and/or prophylactic treatment of diseases/disorders which are associated with inflammation and proliferative disorders, like cancers. Particular disease/disorder states include the therapeutic and/or prophylactic treatment of inflammation and proliferative disorders, like cancers, particularly HCC, leukemia and solid tumors, which method comprises administration of dsRNA targeting RRM2 to a human being or animal.

In one embodiment, the invention provides double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of a RRM2 gene, in particular the expression of the mammalian or human RRM2 gene. The dsRNA comprises at least two sequences that are complementary to each other. The dsRNA comprises a sense strand comprising a first sequence and an antisense strand comprising a second sequence, see sequences provided in the sequence listing and also the specific dsRNA pairs in the appended table 1 and table 2. In one embodiment the sense strand comprises a sequence which has an identity of at least 90% to at least a portion of an mRNA encoding RRM2. Said sequence is located in a region of complementarity of the sense strand to the antisense strand, preferably within nucleotides 2-7 of the 5′ terminus of the antisense strand. In one preferred embodiment the dsRNA specifically targets the human RRM2 gene.

In one embodiment, the antisense strand comprises a nucleotide sequence which is substantially complementary to at least part of an mRNA encoding said RRM2 gene, and the region of complementarity is most preferably less than 30 nucleotides in length. Furthermore, it is preferred that the length of the herein described inventive dsRNA molecules (duplex length) is in the range of about 16 to 30 nucleotides, in particular in the range of about 18 to 28 nucleotides. Particularly useful in context of this invention are duplex lengths of about 19, 20, 21, 22, 23 or 24 nucleotides. Most preferred are duplex stretches of 19, 21 or 23 nucleotides.

The dsRNA, upon delivery to a cell expressing a RRM2 gene, inhibits the expression of a RRM2 gene in vitro by at least 60%, preferably by at least 70%, and most preferably by 80%.

Appended Table 1 relates to preferred molecules to be used as dsRNA in accordance with this invention. Also modified dsRNA molecules are provided herein and are in particular disclosed in appended table 2, providing illustrative examples of modified dsRNA molecules of the present invention. As pointed out herein above, Table 2 provides for illustrative examples of modified dsRNAs of this invention (whereby the corresponding sense strand and antisense strand is provided in this table). The relation of the unmodified preferred molecules shown in Table 1 to the modified dsRNAs of Table 2 is illustrated in Table 5. Yet, the illustrative modifications of these constituents of the inventive dsRNAs are provided herein as examples of modifications.

Tables 3 and 4 provide for selective biological, clinical and pharmaceutical relevant parameters of certain dsRNA molecules of this invention.

Some of the preferred dsRNA molecules are provided in the appended table 1 and, inter alia and preferably, wherein the sense strand is selected from the group consisting of the nucleic acid sequences depicted in SEQ ID NOs: 8, 39, 56, 3, 82, 33, 9, 29, 444, 492 and 442 and the antisense strand is selected from the group consisting of the nucleic acid sequences depicted in SEQ ID NOs: 241, 272, 289, 236, 315, 266, 242, 262, 806, 852 and 851 Accordingly, the inventive dsRNA molecule may, inter alia, comprise the sequence pairs selected from the group consisting of SEQ ID NOs: 8/241, 39/272, 56/289, 3/236, 82/315, 33/266, 9/242, 29/262 444/806, 492/852 and 442/851. In the context of specific dsRNA molecules provided herein, pairs of SEQ ID NOs relate to corresponding sense and antisense strands sequences (5′ to 3′) as also shown in the tables.

In one embodiment the dsRNA molecules comprise an antisense strand with a 3′ overhang of 1-5 nucleotides in length, preferably 1-2 nucleotides in length. Preferably said overhang of the antisense strand comprises uracil or nucleotides which are complementary to the mRNA encoding RRM2. In another preferred embodiment, said dsRNA molecules comprise a sense strand with a 3′ overhang of 1-5 nucleotides in length, preferably 1-2 nucleotides in length. Preferably said overhang of the sense strand comprises uracil or nucleotides which are identical to the mRNA encoding RRM2.

In another preferred embodiment, the dsRNA molecules comprise a sense strand with a 3′ overhang of 1-5 nucleotides in length, preferably 1-2 nucleotides in length, and an antisense strand with a 3′ overhang of 1-5 nucleotides in length, preferably 1-2 nucleotides in length.

Preferably said overhang of the sense strand comprises uracil or nucleotides which are at least 90% identical to the mRNA encoding RRM2 and said overhang of the antisense strand comprises uracil or nucleotides which are at least 90% complementary to the mRNA encoding RRM2.

The dsRNA molecules of the invention may be comprised of naturally occurring nucleotides or may be comprised of at least one modified nucleotide, such as a 2′-O-methyl modified nucleotide, inverted deoxythymidine, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. 2′ modified nucleotides may have the additional advantage that certain immunostimulatory factors or cytokines are suppressed when the inventive dsRNA molecules are employed in vivo, for example in a medical setting. Alternatively and non-limiting, the modified nucleotide may be chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. In one preferred embodiment the dsRNA molecules comprises at least one of the following modified nucleotides: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group and a deoxythymidine. Preferred dsRNA molecules comprising modified nucleotides are given in table 2. In another preferred embodiment one of those deoxythymidine nucleotides at the 3′ of both strand is a inverted deoxythymidine.

In a preferred embodiment the inventive dsRNA molecules comprise modified nucleotides as detailed in the sequences given in table 2. In one preferred embodiment the inventive dsRNA molecule comprises sequence pairs selected from the group consisting of SEQ ID NOs: 8/241, 39/272, 56/289, 3/236, 82/315, 33/266, 9/242, 29/262, 444/806, 492/852 and 442/851, and comprises overhangs at the antisense and/or sense strand of 1-2 deoxythymidines. In one preferred embodiment the inventive dsRNA molecule comprises sequence pairs selected from the group consisting of SEQ ID NOs: 8/241, 39/272, 56/289, 3/236, 82/315, 33/266, 9/242, 29/262 444/806, 492/852 and 442/851, and comprise modifications as detailed in table 2. Preferred dsRNA molecules comprising modified nucleotides are listed in table 2-4, with the most preferred dsRNA molecules depicted in SEQ ID Nos: 469/742, 475/884, 477/839, 497/711, 501/842, 553/968, 507/841, 525/885, 552/891, 477/963, 526/967 and 476/966.

In another embodiment, the inventive dsRNAs comprise modified nucleotides on positions different from those disclosed in table 2. In one preferred embodiment two deoxythymidine nucleotides are found at the 3′ of both strands of the dsRNA molecule. Preferably said deoxythymidine nucleotides form an overhang.

In one embodiment the dsRNA molecules of the invention comprise a sense and an antisense strand wherein both strands have a half-life of at least 0.9 hours. In one preferred embodiment the dsRNA molecules of the invention comprise a sense and an antisense strand wherein both strands have a half-life of at least 48 hours, preferably in human serum. In another embodiment the dsRNA molecules of the invention are non-immunostimulatory, e.g. do not stimulate INF-alpha (INF-α) and TNF-alpha (TNF-α) in vitro. In another embodiment, the dsRNA molecules of the invention do stimulate INF-α and TNF-α in vitro to a very minor degree.

In another embodiment, a nucleic acid sequence encoding a sense strand and/or an antisense strand comprised in the dsRNAs as defined herein are provided.

The invention also provides for cells comprising at least one of the dsRNAs of the invention. The cell is preferably a mammalian cell, such as a human cell. Furthermore, tissues and/or non-human organisms comprising the herein defined dsRNA molecules are an embodiment of this invention, whereby said non-human organisms are particularly useful for research purposes or as research tools, for example in drug testing.

Furthermore, the invention relates to a method for inhibiting the expression of a RRM2 gene, in particular a mammalian or human RRM2 gene, in a cell, tissue or organism comprising the following steps:

-   -   a) introducing into the cell, tissue or organism a         double-stranded ribonucleic acid (dsRNA) as defined herein; and     -   b) maintaining said cell, tissue or organism produced in         step (a) for a time sufficient to obtain degradation of the mRNA         transcript of a RRM2 gene, thereby inhibiting expression of a         RRM2 gene in a given cell.

The invention also relates to pharmaceutical compositions comprising the inventive dsRNAs of the invention. These pharmaceutical compositions are particularly useful in the inhibition of the expression of a RRM2 gene in a cell, a tissue or an organism. The pharmaceutical composition comprising one or more of the dsRNA of the invention may also comprise (a) pharmaceutically acceptable carrier(s), diluent(s) and/or excipient(s).

In another embodiment, the invention provides methods for treating, preventing or managing inflammation and/or proliferative disorders like cancers which are associated with RRM2, said method comprising administering to a subject in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the dsRNAs of the invention. Preferably, said subject is a mammal, most preferably a human patient.

In one embodiment, the invention provides a method for treating a subject having a pathological condition mediated by the expression of a RRM2 gene. Such conditions comprise disorders associated with inflammation and proliferative disorders, like cancers, as described above. In this embodiment, the dsRNA acts as a therapeutic agent for controlling the expression of a RRM2 gene. The method comprises administering a pharmaceutical composition of the invention to the patient (e.g., human), such that expression of a RRM2 gene is silenced. Because of their high specificity, the dsRNAs of the invention specifically target mRNAs of a RRM2 gene. In one preferred embodiment the described dsRNAs specifically decrease RRM2 mRNA levels and do not directly affect the expression and/or mRNA levels of off-target genes in the cell.

In one preferred embodiment the described dsRNA decrease RRM2 mRNA levels in the liver by at least 60%, preferably by at least 70%, and most preferably by at least 80% in vivo. In another embodiment the described dsRNAs decrease RRM2 mRNA levels in vivo for at least 4 days. In another preferred embodiment, the dsRNAs of the invention are used for the preparation of a pharmaceutical composition for the treatment of inflammation and proliferative disorders, like cancer. Cancers to be treated with said pharmaceutical composition comprise but are not limited to: HCC, AML, leukemia, bladder cancer, prostate cancer, NSCLC, breast cancer and colorectal cancer.

In another embodiment, the invention provides vectors for inhibiting the expression of a RRM2 gene in a cell, in particular a RRM2 gene comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA molecules of the invention.

In another embodiment, the invention provides a cell comprising a vector for inhibiting the expression of a RRM2 gene in a cell. Said vector comprises a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA molecule of the invention. Yet, it is preferred that said vector comprises, besides said regulatory sequence a sequence that encodes at least one “sense strand” of the inventive dsRNA and at least one “anti-sense strand” of said dsRNA. It is also envisaged that the claimed cell comprises two or more vectors comprising, besides said regulatory sequences, the herein defined sequence(s) that encode(s) at least one strand of the dsRNA molecules of the invention.

In one embodiment, the method comprises administering a composition comprising a dsRNA, wherein the dsRNA comprises a nucleotide sequence which is complementary to at least a part of an RNA transcript of a RRM2 gene of the mammal to be treated. As pointed out above, also vectors and cells comprising nucleic acid molecules that encode for at least one strand of the herein defined dsRNA molecules can be used as pharmaceutical compositions and may, therefore, also be employed in the herein disclosed methods of treating a subject in need of medical intervention. It is also of note that these embodiments relating to pharmaceutical compositions and to corresponding methods of treating a (human) subject also relate to approaches like gene therapy approaches. RRM2 specific dsRNA molecules as provided herein or nucleic acid molecules encoding individual strands of these inventive dsRNA molecules may also be inserted into vectors and used as gene therapy vectors for human patients. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

In another aspect of the invention, RRM2 specific dsRNA molecules that modulate RRM2 gene expression activity are expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Skillern, A., et al., International PCT Publication No. WO 00/22113). These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be incorporated and inherited as a transgene integrated into the host genome. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).

The individual strands of a dsRNA can be transcribed by promoters on two separate expression vectors and co-transfected into a target cell. Alternatively, each individual strand of the dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In a preferred embodiment, a dsRNA is expressed as an inverted repeat joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

The recombinant dsRNA expression vectors are preferably DNA plasmids or viral vectors. dsRNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus (for a review, see Muzyczka, et al., Curr. Topics Micro. Immunol. (1992) 158:97-129)); adenovirus (see, for example, Berkner, et al., BioTechniques (1998) 6:616), Rosenfeld et al. (1991, Science 252:431-434), and Rosenfeld et al. (1992), Cell 68:143-155)); or alphavirus as well as others known in the art. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see, e.g., Danos and Mulligan, Proc. Natl. Acad. Sci. USA (1998) 85:6460-6464). Recombinant retroviral vectors capable of transducing and expressing genes inserted into the genome of a cell can be produced by transfecting the recombinant retroviral genome into suitable packaging cell lines such as PA317 and Psi-CRIP (Comette et al., 1991, Human Gene Therapy 2:5-10; Cone et al., 1984, Proc. Natl. Acad. Sci. USA 81:6349). Recombinant adenoviral vectors can be used to infect a wide variety of cells and tissues in susceptible hosts (e.g., rat, hamster, dog, and chimpanzee) (Hsu et al., 1992, J. Infectious Disease, 166:769), and also have the advantage of not requiring mitotically active cells for infection.

The promoter driving dsRNA expression in either a DNA plasmid or viral vector of the invention may be a eukaryotic RNA polymerase I (e.g. ribosomal RNA promoter), RNA polymerase II (e.g. CMV early promoter or actin promoter or U1 snRNA promoter) or preferably RNA polymerase III promoter (e.g. U6 snRNA or 7SK RNA promoter) or a prokaryotic promoter, for example the T7 promoter, provided the expression plasmid also encodes T7 RNA polymerase required for transcription from a T7 promoter. The promoter can also direct transgene expression to the pancreas (see, e.g. the insulin regulatory sequence for pancreas (Bucchini et al., 1986, Proc. Natl. Acad. Sci. USA 83:2511-2515)).

In addition, expression of the transgene can be precisely regulated, for example, by using an inducible regulatory sequence and expression systems such as a regulatory sequence that is sensitive to certain physiological regulators, e.g., circulating glucose levels, or hormones (Docherty et al., 1994, FASEB 1 8:20-24). Such inducible expression systems, suitable for the control of transgene expression in cells or in mammals include regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl-β-D1-thiogalactopyranoside (EPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the dsRNA transgene.

Preferably, recombinant vectors capable of expressing dsRNA molecules are delivered as described below, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of dsRNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the dsRNAs bind to target RNA and modulate its function or expression. Delivery of dsRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

dsRNA expression DNA plasmids are typically transfected into target cells as a complex with cationic lipid carriers (e.g. Oligofectamine) or non-cationic lipid-based carriers (e.g. Transit-TKO™). Multiple lipid transfections for dsRNA-mediated knockdowns targeting different regions of a single RRM2 gene or multiple RRM2 genes over a period of a week or more are also contemplated by the invention. Successful introduction of the vectors of the invention into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of ex vivo cells can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.

The following detailed description discloses how to make and use the dsRNA and compositions containing dsRNA to inhibit the expression of a target RRM2 gene, as well as compositions and methods for treating diseases and disorders caused by the expression of said RRM2 gene.

Definitions

For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in other parts of this specification and its definition provided in this section, the definition in this section shall prevail.

“G”, “C”, “A”, “U”, and “T” or “dT” respectively, each generally stand for a nucleotide that contains guanine, cytosine, adenine, uracil and deoxythymidine as a base, respectively. However, the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. Sequences comprising such replacement moieties are embodiments of the invention. As detailed below, the herein described dsRNA molecules may also comprise “overhangs”, i.e. unpaired, overhanging nucleotides which are not directly involved in the RNA double helical structure normally formed by the herein defined pair of “sense strand” and “anti-sense strand”. Often, such an overhanging stretch comprises the deoxythymidine nucleotide, in most embodiments, 2 deoxythymidines in the 3′ end. Such overhangs will be described and illustrated below.

The term “RRM2” as used herein relates in particular to the ribonucleotide reductase M2, also known as the ribonucleotide reductase M2 polypeptide, ribonucleoside-diphosphate reductase subunit M2, ribonucleotide reductase small chain, ribonucleotide reductase small subunit, with synonyms R2, RR2, RR2M, and the like and said term relates to the corresponding gene, encoded mRNA, encoded protein/polypeptide as well as functional fragments of the same. Preferred is the human RRM2 gene. In other preferred embodiments the dsRNAs of the invention target the RRM2 gene of human (H. sapiens) and cynomolgous monkey (Macaca fascicularis) RRM2 gene. Also dsRNAs targeting the rat (Rattus norvegicus) and mouse (Mus musculus) RRM2 gene are part of this invention. The term “RRM2 gene/sequence” does not only relate to (the) wild-type sequence(s) but also to mutations and alterations which may be comprised in said gene/sequence. Accordingly, the present invention is not limited to the specific dsRNA molecules provided herein. The invention also relates to dsRNA molecules that comprise an antisense strand that is at least 85% complementary to the corresponding nucleotide stretch of an RNA transcript of a RRM2 gene that comprises such mutations/alterations.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a RRM2 gene, including mRNA that is a product of RNA processing of a primary transcription product.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature. However, as detailed herein, such a “strand comprising a sequence” may also comprise modifications, like modified nucleotides.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence. “Complementary” sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled.

Sequences referred to as “fully complementary” comprise base-pairing of the oligonucleotide or polynucleotide comprising the first nucleotide sequence to the oligonucleotide or polynucleotide comprising the second nucleotide sequence over the entire length of the first and second nucleotide sequence.

However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they may form one or more, but preferably not more than 13 mismatched base pairs upon hybridization.

The terms “complementary”, “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a dsRNA and a target sequence, as will be understood from the context of their use.

The term “double-stranded RNA”, “dsRNA molecule”, or “dsRNA”, as used herein, refers to a ribonucleic acid molecule, or complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands. The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop”. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker”. The RNA strands may have the same or a different number of nucleotides. In addition to the duplex structure, a dsRNA may comprise one or more nucleotide overhangs. The nucleotides in said “overhangs” may comprise between 0 and 5 nucleotides, whereby “0” means no additional nucleotide(s) that form(s) an “overhang” and whereas “5” means five additional nucleotides on the individual strands of the dsRNA duplex. These optional “overhangs” are located in the 3′ end of the individual strands. As will be detailed below, also dsRNA molecules which comprise only an “overhang” in one of the two strands may be useful and even advantageous in context of this invention. The “overhang” comprises preferably between 0 and 2 nucleotides. Most preferably 2 “dT” (deoxythymidine) nucleotides are found at the 3′ end of both strands of the dsRNA. Also 2 “U” (uracil) nucleotides can be used as overhangs at the 3′ end of both strands of the dsRNA. Accordingly, a “nucleotide overhang” refers to the unpaired nucleotide or nucleotides that protrude from the duplex structure of a dsRNA when a 3′-end of one strand of the dsRNA extends beyond the 5′-end of the other strand, or vice versa. For example the antisense strand comprises 23 nucleotides and the sense strand comprises 21 nucleotides, forming a 2 nucleotide overhang at the 3′ end of the antisense strand. Preferably, the 2 nucleotide overhang is fully complementary to the mRNA of the target gene. “Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the dsRNA, i.e., no nucleotide overhang. A “blunt ended” dsRNA is a dsRNA that is double-stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule.

The term “antisense strand” refers to the strand of a dsRNA which includes a region that is substantially complementary to a target sequence. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence. Where the region of complementarity is not fully complementary to the target sequence, the mismatches are most tolerated outside nucleotides 2-7 of the 5′ terminus of the antisense strand

The term “sense strand,” as used herein, refers to the strand of a dsRNA that includes a region that is substantially complementary to a region of the antisense strand. “Substantially complementary” means preferably at least 85% of the overlapping nucleotides in sense and antisense strand are complementary.

“Introducing into a cell”, when referring to a dsRNA, means facilitating uptake or absorption into the cell, as is understood by those skilled in the art. Absorption or uptake of dsRNA can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. The meaning of this term is not limited to cells in vitro; a dsRNA may also be “introduced into a cell”, wherein the cell is part of a living organism. In such instance, introduction into the cell will include the delivery to the organism. For example, for in vivo delivery, dsRNA can be injected into a tissue site or administered systemically. It is, for example envisaged that the dsRNA molecules of this invention be administered to a subject in need of medical intervention. Such an administration may comprise the injection of the dsRNA, the vector or a cell of this invention into a diseased site in said subject, for example into liver tissue/cells or into cancerous tissues/cells, like liver cancer tissue. In addition, the injection is preferably in close proximity to the diseased tissue envisaged. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection.

As used herein, “proliferating” and “proliferation” refer to cells undergoing mitosis. Throughout this application, the term “proliferative disorder” refers to any disease/disorder marked by unwanted or aberrant proliferation of tissue. As used herein, the term “proliferative disorder” also refers to conditions in which the unregulated and/or abnormal growth of cells can lead to the development of an unwanted condition or disease, which can be cancerous or non-cancerous.

The term “inflammation” as used herein refers to the biologic response of body tissue to injury, irritation, or disease which can be caused by harmful stimuli, for example; pathogens, damaged cells, or irritants. Inflammation is typically characterized by pain and swelling. Inflammation is intended to encompass both acute responses, in which inflammatory processes are active neutrophils and leukocytes), and chronic responses, which are marked by slow progress, a shift in the type of cell present at the site of inflammation, and the formation of connective tissue.

Cancers to be treated comprise, but are again not limited to leukemia, AML, solid tumors, liver cancer, brain cancer, breast cancer, lung cancer, NSCLC, colorectal cancer, bladder cancer and prostate cancer, whereby said liver cancer may, inter alia, be selected from the group consisting of hepatocellular carcinoma (HCC), hepatoblastoma, a mixed liver cancer, a cancer derived from mesenchymal tissue, a liver sarcoma or a cholangiocarcinoma.

The terms “silence”, “inhibit the expression of” and “knock down”, in as far as they refer to a RRM2 gene, herein refer to the at least partial suppression of the expression of a RRM2 gene, as manifested by a reduction of the amount of mRNA transcribed from a RRM2 gene which may be isolated from a first cell or group of cells in which a RRM2 gene is transcribed and which has or have been treated such that the expression of a RRM2 gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells). The degree of inhibition is usually expressed in terms of

${\frac{\left( {{mRNA}\mspace{14mu} {in}\mspace{14mu} {control}\mspace{14mu} {cells}} \right) - \left( {{mRNA}\mspace{14mu} {in}\mspace{14mu} {treated}\mspace{14mu} {cells}} \right)}{\left( {{mRNA}\mspace{14mu} {in}\mspace{14mu} {control}\mspace{14mu} {cells}} \right)} \cdot 100}\%$

Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to the RRM2 gene transcription, e.g. the amount of protein encoded by a RRM2 gene which is secreted by a cell, or the number of cells displaying a certain phenotype. As illustrated in the appended examples and in the appended tables provided herein, the inventive dsRNA molecules are capable of inhibiting the expression of a human RRM2 by at least about 60%, preferably by at least 70%, most preferably by at least 80% in vitro assays, i.e. in vitro. The term “in vitro” as used herein includes but is not limited to cell culture assays. In another embodiment the inventive dsRNA molecules are capable of inhibiting the expression of a mouse or rat RRM2 by at least 60% preferably by at least 70%, most preferably by at least 80%. The person skilled in the art can readily determine such an inhibition rate and related effects, in particular in light of the assays provided herein.

The term “off target” as used herein refers to all non-target mRNAs of the transcriptome that are predicted by in silico methods to hybridize to the described dsRNAs based on sequence complementarity. The dsRNAs of the present invention preferably do specifically inhibit the expression of RRM2, i.e. do not inhibit the expression of any off-target.

The term “half-life” as used herein is a measure of stability of a compound or molecule and can be assessed by methods known to a person skilled in the art, especially in light of the assays provided herein.

The term “non-immunostimulatory” as used herein refers to the absence of any induction of a immune response by the invented dsRNA molecules. Methods to determine immune responses are well known to a person skilled in the art, for example by assessing the release of cytokines, as described in the examples section.

The terms “treat”, “treatment”, and the like, mean in context of this invention the relief from or alleviation of a disorder related to RRM2 expression, like inflammation and proliferative disorders, like cancers.

As used herein, a “pharmaceutical composition” comprises a pharmacologically effective amount of a dsRNA and a pharmaceutically acceptable carrier. However, such a “pharmaceutical composition” may also comprise individual strands of such a dsRNA molecule or the herein described vector(s) comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of a sense or an antisense strand comprised in the dsRNAs of this invention. It is also envisaged that cells, tissues or isolated organs that express or comprise the herein defined dsRNAs may be used as “pharmaceutical compositions”. As used herein, “pharmacologically effective amount,” “therapeutically effective amount” or simply “effective amount” refers to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result.

The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives as known to persons skilled in the art.

It is in particular envisaged that the pharmaceutically acceptable carrier allows for the systemic administration of the dsRNAs, vectors or cells of this invention. Whereas also the enteric administration is envisaged the parenteral administration and also transdermal or transmucosal (e.g. insufflation, buccal, vaginal, anal) administration as well as inhalation of the drug are feasible ways of administering to a patient in need of medical intervention the compounds of this invention. When parenteral administration is employed, this can comprise the direct injection of the compounds of this invention into the diseased tissue or at least in close proximity. However, also intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, intradermal, intrathecal and other administrations of the compounds of this invention are within the skill of the artisan, for example the attending physician.

For intramuscular, subcutaneous and intravenous use, the pharmaceutical compositions of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. In a preferred embodiment, the carrier consists exclusively of an aqueous buffer. In this context, “exclusively” means no auxiliary agents or encapsulating substances are present which might affect or mediate uptake of dsRNA in the cells that express a RRM2 gene. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. The pharmaceutical compositions useful according to the invention also include encapsulated formulations to protect the dsRNA against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in PCT publication WO 91/06309 which is incorporated by reference herein.

As used herein, a “transformed cell” is a cell into which at least one vector has been introduced from which a dsRNA molecule or at least one strand of such a dsRNA molecule may be expressed. Such a vector is preferably a vector comprising a regulatory sequence operably linked to nucleotide sequence that encodes at least one sense strand or antisense strand of a dsRNA of the present invention.

It can be reasonably expected that shorter dsRNAs comprising one of the sequences in Table 1 and 4 minus only a few nucleotides on one or both ends may be similarly effective as compared to the dsRNAs described above.

In one preferred embodiment the inventive dsRNA molecules comprise nucleotides 1-19 of the sequences given in Table 1.

As pointed out above, in most embodiments of this invention, the dsRNA molecules provided herein comprise a duplex length (i.e. without “overhangs”) of about 16 to about 30 nucleotides.

Particular useful dsRNA duplex lengths are about 19 to about 25 nucleotides. Most preferred are duplex structures with a length of 19 nucleotides. In the inventive dsRNA molecules, the antisense strand is at least partially complementary to the sense strand.

The dsRNA of the invention can contain one or more mismatches to the target sequence. In a preferred embodiment, the dsRNA of the invention contains no more than 13 mismatches. If the antisense strand of the dsRNA contains mismatches to a target sequence, it is preferable that the area of mismatch not be located within nucleotides 2-7 of the 5′ terminus of the antisense strand. In another embodiment it is preferable that the area of mismatch not be located within nucleotides 2-9 of the 5′ terminus of the antisense strand.

As mentioned above, at least one end/strand of the dsRNA may have a single-stranded nucleotide overhang of 1 to 5, preferably 1 or 2 nucleotides. dsRNAs having at least one nucleotide overhang have unexpectedly superior inhibitory properties than their blunt-ended counterparts. Moreover, the present inventors have discovered that the presence of only one nucleotide overhang strengthens the interference activity of the dsRNA, without affecting its overall stability. dsRNA having only one overhang has proven particularly stable and effective in vivo, as well as in a variety of cells, cell culture mediums, blood, and serum. Preferably, the single-stranded overhang is located at the 3′-terminal end of the antisense strand or, alternatively, at the 3′-terminal end of the sense strand. The dsRNA may also have a blunt end, preferably located at the 5′-end of the antisense strand. Preferably, the antisense strand of the dsRNA has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

The dsRNA of the present invention may also be chemically modified to enhance stability. The nucleic acids of the invention may be synthesized and/or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry”, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Chemical modifications may include, but are not limited to 2′ modifications, introduction of non-natural bases, covalent attachment to a ligand, and replacement of phosphate linkages with thiophosphate linkages, inverted deoxythymidines. In this embodiment, the integrity of the duplex structure is strengthened by at least one, and preferably two, chemical linkages. Chemical linking may be achieved by any of a variety of well-known techniques, for example by introducing covalent, ionic or hydrogen bonds; hydrophobic interactions, van der Waals or stacking interactions; by means of metal-ion coordination, or through use of purine analogues. Preferably, the chemical groups that can be used to modify the dsRNA include, without limitation, methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)amine; N-acetyl-N′-(p-glyoxylbenzoyl)cystamine; 4-thiouracil; and psoralen. In one preferred embodiment, the linker is a hexa-ethylene glycol linker. In this case, the dsRNA are produced by solid phase synthesis and the hexa-ethylene glycol linker is incorporated according to standard methods (e.g., Williams, D. J., and K. B. Hall, Biochem. (1996) 35:14665-14670). In a particular embodiment, the 5′-end of the antisense strand and the 3′-end of the sense strand are chemically linked via a hexaethylene glycol linker. In another embodiment, at least one nucleotide of the dsRNA comprises a phosphorothioate or phosphorodithioate groups. The chemical bond at the ends of the dsRNA is preferably formed by triple-helix bonds.

In certain embodiments, a chemical bond may be formed by means of one or several bonding groups, wherein such bonding groups are preferably poly-(oxyphosphinicooxy-1,3-propandiol)- and/or polyethylene glycol chains. In other embodiments, a chemical bond may also be formed by means of purine analogs introduced into the double-stranded structure instead of purines. In further embodiments, a chemical bond may be formed by azabenzene units introduced into the double-stranded structure. In still further embodiments, a chemical bond may be formed by branched nucleotide analogs instead of nucleotides introduced into the double-stranded structure. In certain embodiments, a chemical bond may be induced by ultraviolet light.

In yet another embodiment, the nucleotides at one or both of the two single strands may be modified to prevent or inhibit the activation of cellular enzymes, for example certain nucleases. Techniques for inhibiting the activation of cellular enzymes are known in the art including, but not limited to, 2′-amino modifications, 2′-amino sugar modifications, 2′-F sugar modifications, 2′-F modifications, 2′-alkyl sugar modifications, uncharged backbone modifications, morpholino modifications, 2′-O-methyl modifications, and phosphoramidate (see, e.g., Wagner, Nat. Med. (1995) 1:1116-8). Thus, at least one 2′-hydroxyl group of the nucleotides on a dsRNA is replaced by a chemical group, preferably by a 2′-amino or a 2′-methyl group. Also, at least one nucleotide may be modified to form a locked nucleotide. Such locked nucleotide contains a methylene bridge that connects the 2′-oxygen of ribose with the 4′-carbon of ribose. Introduction of a locked nucleotide into an oligonucleotide improves the affinity for complementary sequences and increases the melting temperature by several degrees.

Modifications of dsRNA molecules provided herein may positively influence their stability in vivo as well as in vitro and also improve their delivery to the (diseased) target side. Furthermore, such structural and chemical modifications may positively influence physiological reactions towards the dsRNA molecules upon administration, e.g. the cytokine release which is preferably suppressed. Such chemical and structural modifications are known in the art and are, inter alia, illustrated in Nawrot (2006) Current Topics in Med Chem, 6, 913-925.

Conjugating a ligand to a dsRNA can enhance its cellular absorption as well as targeting to a particular tissue. In certain instances, a hydrophobic ligand is conjugated to the dsRNA to facilitate direct permeation of the cellular membrane. Alternatively, the ligand conjugated to the dsRNA is a substrate for receptor-mediated endocytosis. These approaches have been used to facilitate cell permeation of antisense oligonucleotides. For example, cholesterol has been conjugated to various antisense oligonucleotides resulting in compounds that are substantially more active compared to their non-conjugated analogs. See M. Manoharan Antisense & Nucleic Acid Drug Development 2002, 12, 103. Other lipophilic compounds that have been conjugated to oligonucleotides include 1-pyrene butyric acid, 1,3-bis-O-(hexadecyl)glycerol, and menthol. One example of a ligand for receptor-mediated endocytosis is folic acid. Folic acid enters the cell by folate-receptor-mediated endocytosis. dsRNA compounds bearing folic acid would be efficiently transported into the cell via the folate-receptor-mediated endocytosis. Attachment of folic acid to the 3′-terminus of an oligonucleotide results in increased cellular uptake of the oligonucleotide (Li, S.; Deshmukh, H. M.; Huang, L. Pharm. Res. 1998, 15, 1540). Other ligands that have been conjugated to oligonucleotides include polyethylene glycols, carbohydrate clusters, cross-linking agents, porphyrin conjugates, and delivery peptides.

In certain instances, conjugation of a cationic ligand to oligonucleotides often results in improved resistance to nucleases. Representative examples of cationic ligands are propylammonium and dimethylpropylammonium. Interestingly, antisense oligonucleotides were reported to retain their high binding affinity to mRNA when the cationic ligand was dispersed throughout the oligonucleotide. See M. Manoharan Antisense & Nucleic Acid Drug Development 2002, 12, 103 and references therein.

The ligand-conjugated dsRNA of the invention may be synthesized by the use of a dsRNA that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the dsRNA. This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto. The methods of the invention facilitate the synthesis of ligand-conjugated dsRNA by the use of, in some preferred embodiments, nucleoside monomers that have been appropriately conjugated with ligands and that may further be attached to a solid-support material. Such ligand-nucleoside conjugates, optionally attached to a solid-support material, are prepared according to some preferred embodiments of the methods of the invention via reaction of a selected serum-binding ligand with a linking moiety located on the 5′ position of a nucleoside or oligonucleotide. In certain instances, an dsRNA bearing an aralkyl ligand attached to the 3′-terminus of the dsRNA is prepared by first covalently attaching a monomer building block to a controlled-pore-glass support via a long-chain aminoalkyl group. Then, nucleotides are bonded via standard solid-phase synthesis techniques to the monomer building-block bound to the solid support. The monomer building block may be a nucleoside or other organic compound that is compatible with solid-phase synthesis.

The dsRNA used in the conjugates of the invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

Teachings regarding the synthesis of particular modified oligonucleotides may be found in the following U.S. patents: U.S. Pat. No. 5,218,105, drawn to polyamine conjugated oligonucleotides; U.S. Pat. Nos. 5,541,307, drawn to oligonucleotides having modified backbones; U.S. Pat. No. 5,521,302, drawn to processes for preparing oligonucleotides having chiral phosphorus linkages; U.S. Pat. No. 5,539,082, drawn to peptide nucleic acids; U.S. Pat. No. 5,554,746, drawn to oligonucleotides having β-lactam backbones; U.S. Pat. No. 5,571,902, drawn to methods and materials for the synthesis of oligonucleotides; U.S. Pat. No. 5,578,718, drawn to nucleosides having alkylthio groups, wherein such groups may be used as linkers to other moieties attached at any of a variety of positions of the nucleoside; U.S. Pat. No. 5,587,361 drawn to oligonucleotides having phosphorothioate linkages of high chiral purity; U.S. Pat. No. 5,506,351, drawn to processes for the preparation of 2′-O-alkyl guanosine and related compounds, including 2,6-diaminopurine compounds; U.S. Pat. No. 5,587,469, drawn to oligonucleotides having N-2 substituted purines; U.S. Pat. No. 5,587,470, drawn to oligonucleotides having 3-deazapurines; U.S. Pat. No. 5,608,046, both drawn to conjugated 4′-desmethyl nucleoside analogs; U.S. Pat. No. 5,610,289, drawn to backbone-modified oligonucleotide analogs; U.S. Pat. No. 6,262,241 drawn to, inter alia, methods of synthesizing 2′-fluoro-oligonucleotides.

In the ligand-conjugated dsRNA and ligand-molecule bearing sequence-specific linked nucleosides of the invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. Oligonucleotide conjugates bearing a variety of molecules such as steroids, vitamins, lipids and reporter molecules, has previously been described (see Manoharan et al., PCT Application WO 93/07883). In a preferred embodiment, the oligonucleotides or linked nucleosides of the invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to commercially available phosphoramidites.

The incorporation of a 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-allyl, 2′-O-aminoalkyl or 2′-deoxy-2′-fluoro group in nucleosides of an oligonucleotide confers enhanced hybridization properties to the oligonucleotide. Further, oligonucleotides containing phosphorothioate backbones have enhanced nuclease stability. Thus, functionalized, linked nucleosides of the invention can be augmented to include either or both a phosphorothioate backbone or a 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-aminoalkyl, 2′-O-allyl or 2′-deoxy-2′-fluoro group.

In some preferred embodiments, functionalized nucleoside sequences of the invention possessing an amino group at the 5′-terminus are prepared using a DNA synthesizer, and then reacted with an active ester derivative of a selected ligand. Active ester derivatives are well known to those skilled in the art. Representative active esters include N-hydrosuccinimide esters, tetrafluorophenolic esters, pentafluorophenolic esters and pentachlorophenolic esters. The reaction of the amino group and the active ester produces an oligonucleotide in which the selected ligand is attached to the 5′-position through a linking group. The amino group at the 5′-terminus can be prepared utilizing a 5′-Amino-Modifier C6 reagent. In a preferred embodiment, ligand molecules may be conjugated to oligonucleotides at the 5′-position by the use of a ligand-nucleoside phosphoramidite wherein the ligand is linked to the 5′-hydroxy group directly or indirectly via a linker. Such ligand-nucleoside phosphoramidites are typically used at the end of an automated synthesis procedure to provide a ligand-conjugated oligonucleotide bearing the ligand at the 5′-terminus.

In one preferred embodiment of the methods of the invention, the preparation of ligand conjugated oligonucleotides commences with the selection of appropriate precursor molecules upon which to construct the ligand molecule. Typically, the precursor is an appropriately-protected derivative of the commonly-used nucleosides. For example, the synthetic precursors for the synthesis of the ligand-conjugated oligonucleotides of the invention include, but are not limited to, 2′-aminoalkoxy-5′-ODMT-nucleosides, 2′-6-aminoalkylamino-5′-ODMT-nucleosides, 5′-6-aminoalkoxy-2′-deoxy-nucleosides, 5′-6-aminoalkoxy-2-protected-nucleosides, 3′-6-aminoalkoxy-5′-ODMT-nucleosides, and 3′-aminoalkylamino-5′-ODMT-nucleosides that may be protected in the nucleobase portion of the molecule. Methods for the synthesis of such amino-linked protected nucleoside precursors are known to those of ordinary skill in the art.

In many cases, protecting groups are used during the preparation of the compounds of the invention. As used herein, the term “protected” means that the indicated moiety has a protecting group appended thereon. In some preferred embodiments of the invention, compounds contain one or more protecting groups. A wide variety of protecting groups can be employed in the methods of the invention. In general, protecting groups render chemical functionalities inert to specific reaction conditions, and can be appended to and removed from such functionalities in a molecule without substantially damaging the remainder of the molecule.

Representative hydroxyl protecting groups, as well as other representative protecting groups, are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed., John Wiley & Sons, New York, 1991, and Oligonucleotides And Analogues A Practical Approach, Ekstein, F. Ed., IRL Press, N.Y., 1991.

Amino-protecting groups stable to acid treatment are selectively removed with base treatment, and are used to make reactive amino groups selectively available for substitution. Examples of such groups are the Fmoc (E. Atherton and R. C. Sheppard in The Peptides, S. Udenfriend, J. Meienhofer, Eds., Academic Press, Orlando, 1987, volume 9, p. 1) and various substituted sulfonylethyl carbamates exemplified by the Nsc group (Samukov et al., Tetrahedron Lett., 1994, 35:7821.

Additional amino-protecting groups include, but are not limited to, carbamate protecting groups, such as 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenylyl)-ethoxycarbonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenyl-methyloxycarbonyl (Fmoc), and benzyloxycarbonyl (Cbz); amide protecting groups, such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl; sulfonamide protecting groups, such as 2-nitrobenzenesulfonyl; and imine and cyclic imide protecting groups, such as phthalimido and dithiasuccinoyl. Equivalents of these amino-protecting groups are also encompassed by the compounds and methods of the invention.

Many solid supports are commercially available and one of ordinary skill in the art can readily select a solid support to be used in the solid-phase synthesis steps. In certain embodiments, a universal support is used. A universal support allows for the preparation of oligonucleotides having unusual or modified nucleotides located at the 3′-terminus of the oligonucleotide. For further details about universal supports see Scott et al., Innovations and Perspectives in solid-phase Synthesis, 3rd International Symposium, 1994, Ed. Roger Epton, Mayflower Worldwide, 115-124]. In addition, it has been reported that the oligonucleotide can be cleaved from the universal support under milder reaction conditions when the oligonucleotide is bonded to the solid support via a syn-1,2-acetoxyphosphate group which more readily undergoes basic hydrolysis. See Guzaev, A. I.; Manoharan, M. J. Am. Chem. Soc. 2003, 125, 2380.

The nucleosides are linked by phosphorus-containing or non-phosphorus-containing covalent internucleoside linkages. For the purposes of identification, such conjugated nucleosides can be characterized as ligand-bearing nucleosides or ligand-nucleoside conjugates. The linked nucleosides having an aralkyl ligand conjugated to a nucleoside within their sequence will demonstrate enhanced dsRNA activity when compared to like dsRNA compounds that are not conjugated.

The aralkyl-ligand-conjugated oligonucleotides of the invention also include conjugates of oligonucleotides and linked nucleosides wherein the ligand is attached directly to the nucleoside or nucleotide without the intermediacy of a linker group. The ligand may preferably be attached, via linking groups, at a carboxyl, amino or oxo group of the ligand. Typical linking groups may be ester, amide or carbamate groups.

Specific examples of preferred modified oligonucleotides envisioned for use in the ligand-conjugated oligonucleotides of the invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined here, oligonucleotides having modified backbones or internucleoside linkages include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of the invention, modified oligonucleotides that do not have a phosphorus atom in their intersugar backbone can also be considered to be oligonucleosides.

Specific oligonucleotide chemical modifications are described below. It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modifications may be incorporated in a single dsRNA compound or even in a single nucleotide thereof.

Preferred modified internucleoside linkages or backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free-acid forms are also included.

Representative United States Patents relating to the preparation of the above phosphorus-atom-containing linkages include, but are not limited to, U.S. Pat. Nos. 4,469,863; 5,023,243; 5,264,423; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233 and 5,466,677, each of which is herein incorporated by reference in their entirety.

Preferred modified internucleoside linkages or backbones that do not include a phosphorus atom therein (i.e., oligonucleosides) have backbones that are formed by short chain alkyl or cycloalkyl intersugar linkages, mixed heteroatom and alkyl or cycloalkyl intersugar linkages, or one or more short chain heteroatomic or heterocyclic intersugar linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents relating to the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,214,134; 5,216,141; 5,264,562; 5,466,677; 5,470,967; 5,489,677; 5,602,240 and 5,663,312, each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleoside units are replaced with novel groups. The nucleobase units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligonucleotide, an oligonucleotide mimetic, that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide-containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to atoms of the amide portion of the backbone. Teaching of PNA compounds can be found for example in U.S. Pat. No. 5,539,082.

Some preferred embodiments of the invention employ oligonucleotides with phosphorothioate linkages and oligonucleosides with heteroatom backbones, and in particular —CH₂NH—O—CH₂, —CH₂—N(CH₃)—O—CH₂—[known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂—, and —O—N(CH₃)—CH₂—CH₂—[wherein the native phosphodiester backbone is represented as —O—P—O—CH₂] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

The oligonucleotides employed in the ligand-conjugated oligonucleotides of the invention may additionally or alternatively comprise nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in the Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligonucleotides of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-Methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Id., pages 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-methoxyethyl sugar modifications.

Representative United States patents relating to the preparation of certain of the above-noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 5,134,066; 5,459,255; 5,552,540; 5,594,121 and 5,596,091 all of which are hereby incorporated by reference.

In certain embodiments, the oligonucleotides employed in the ligand-conjugated oligonucleotides of the invention may additionally or alternatively comprise one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl, O-, S-, or N-alkenyl, or O, S- or N-alkynyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_(n)O]_(m)CH₃, O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy [2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE], i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2′-DMAOE, as described in U.S. Pat. No. 6,127,533, filed on Jan. 30, 1998, the contents of which are incorporated by reference.

Other preferred modifications include 2′-methoxy (2′-O—CH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides.

As used herein, the term “sugar substituent group” or “2′-substituent group” includes groups attached to the 2′-position of the ribofuranosyl moiety with or without an oxygen atom. Sugar substituent groups include, but are not limited to, fluoro, O-alkyl, O-alkylamino, O-alkylalkoxy, protected O-alkylamino, O-alkylaminoalkyl, O-alkyl imidazole and polyethers of the formula (O-alkyl)_(m), wherein m is 1 to about 10. Preferred among these polyethers are linear and cyclic polyethylene glycols (PEGs), and (PEG)-containing groups, such as crown ethers and, inter alia, those which are disclosed by Delgardo et. al. (Critical Reviews in Therapeutic Drug Carrier Systems 1992, 9:249), which is hereby incorporated by reference in its entirety. Further sugar modifications are disclosed by Cook (Anti-fibrosis Drug Design, 1991, 6:585-607). Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl amino substitution is described in U.S. Pat. No. 6,166,197, entitled “Oligomeric Compounds having Pyrimidine Nucleotide(s) with 2′ and 5′ Substitutions,” hereby incorporated by reference in its entirety.

Additional sugar substituent groups amenable to the invention include 2′-SR and 2′-NR₂ groups, wherein each R is, independently, hydrogen, a protecting group or substituted or unsubstituted alkyl, alkenyl, or alkynyl. 2′-SR Nucleosides are disclosed in U.S. Pat. No. 5,670,633, hereby incorporated by reference in its entirety. The incorporation of 2′-SR monomer synthons is disclosed by Hamm et al. (J. Org. Chem., 1997, 62:3415-3420). 2′-NR nucleosides are disclosed by Goettingen, M., J. Org. Chem., 1996, 61, 6273-6281; and Polushin et al., Tetrahedron Lett., 1996, 37, 3227-3230. Further representative 2′-substituent groups amenable to the invention include those having one of formula I or II:

wherein,

-   -   E is C₁-C₁₀ alkyl, N(Q₃)(Q₄) or N═C (Q₃)(Q₄); each Q₃ and Q₄ is,         independently, H, C₁-C₁₀ alkyl, dialkylaminoalkyl, a nitrogen         protecting group, a tethered or untethered conjugate group, a         linker to a solid support; or Q₃ and Q₄, together, form a         nitrogen protecting group or a ring structure optionally         including at least one additional heteroatom selected from N and         0;     -   q₁ is an integer from 1 to 10;     -   q₂ is an integer from 1 to 10;     -   q₃ is 0 or 1;     -   q₄ is 0, 1 or 2;     -   each Z₁, Z₂ and Z₃ is, independently, C₄-C₇ cycloalkyl, C₅-C₁₄         aryl or C₃-C₁₅ heterocyclyl, wherein the heteroatom in said         heterocyclyl group is selected from oxygen, nitrogen and sulfur;     -   Z₄ is OM₁, SM₁, or N(M1)₂; each M₁ is, independently, H, C₁-C₈         alkyl, C₁-C₈ haloalkyl, C(═NH)N(H)M₂, C(═O)N(H)M₂ or         OC(═O)N(H)M₂; M₂ is H or C₁-C₈ alkyl; and     -   Z₅ is C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀         alkynyl, C₆-C₁₄ aryl, N(Q₃)(Q₄), OQ₃, halo, SQ₃ or CN.

Representative 2′-O-sugar substituent groups of formula I are disclosed in U.S. Pat. No. 6,172,209, entitled “Capped 2′-Oxyethoxy Oligonucleotides,” hereby incorporated by reference in its entirety. Representative cyclic 2′-O-sugar substituent groups of formula II are disclosed in U.S. Pat. No. 6,271,358, entitled “RNA Targeted 2′-Modified Oligonucleotides that are Conformationally Preorganized,” hereby incorporated by reference in its entirety.

Sugars having O-substitutions on the ribosyl ring are also amenable to the invention. Representative substitutions for ring O include, but are not limited to, S, CH₂, CHF, and CF₂.

Oligonucleotides may also have sugar mimetics, such as cyclobutyl moieties, in place of the pentofuranosyl sugar. Representative United States patents relating to the preparation of such modified sugars include, but are not limited to, U.S. Pat. Nos. 5,359,044; 5,466,786; 5,519,134; 5,591,722; 5,597,909; 5,646,265 and 5,700,920, all of which are hereby incorporated by reference.

Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide. For example, one additional modification of the ligand-conjugated oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more additional non-ligand moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties, such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 111; Kabanov et al., FEBS Lett., 1990, 259, 327; Svinarchuk et al., Biochimie, 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651; Shea et al., Nucl. Acids Res., 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923).

The invention also includes compositions employing oligonucleotides that are substantially chirally pure with regard to particular positions within the oligonucleotides. Examples of substantially chirally pure oligonucleotides include, but are not limited to, those having phosphorothioate linkages that are at least 75% Sp or Rp (Cook et al., U.S. Pat. No. 5,587,361) and those having substantially chirally pure (Sp or Rp) alkylphosphonate, phosphoramidate or phosphotriester linkages (Cook, U.S. Pat. Nos. 5,212,295 and 5,521,302).

In certain instances, the oligonucleotide may be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to oligonucleotides in order to enhance the activity, cellular distribution or cellular uptake of the oligonucleotide, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Typical conjugation protocols involve the synthesis of oligonucleotides bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the oligonucleotide still bound to the solid support or following cleavage of the oligonucleotide in solution phase. Purification of the oligonucleotide conjugate by HPLC typically affords the pure conjugate.

Alternatively, the molecule being conjugated may be converted into a building block, such as a phosphoramidite, via an alcohol group present in the molecule or by attachment of a linker bearing an alcohol group that may be phosphorylated.

Importantly, each of these approaches may be used for the synthesis of ligand conjugated oligonucleotides. Amino linked oligonucleotides may be coupled directly with ligand via the use of coupling reagents or following activation of the ligand as an NHS or pentfluorophenolate ester. Ligand phosphoramidites may be synthesized via the attachment of an aminohexanol linker to one of the carboxyl groups followed by phosphitylation of the terminal alcohol functionality. Other linkers, such as cysteamine, may also be utilized for conjugation to a chloroacetyl linker present on a synthesized oligonucleotide.

The person skilled in the art is readily aware of methods to introduce the molecules of this invention into cells, tissues or organisms. Corresponding examples have also been provided in the detailed description of the invention above. For example, the nucleic acid molecules or the vectors of this invention, encoding for at least one strand of the inventive dsRNAs may be introduced into cells or tissues by methods known in the art, like transfections etc.

Also for the introduction of dsRNA molecules, means and methods have been provided. For example, targeted delivery by glycosylated and folate-modified molecules, including the use of polymeric carriers with ligands, such as galactose and lactose or the attachment of folic acid to various macromolecules allows the binding of molecules to be delivered to folate receptors. Targeted delivery by peptides and proteins other than antibodies, for example, including RGD-modified nanoparticles to deliver siRNA in vivo or multicomponent (nonviral) delivery systems including short cyclodextrins, adamantine-PEG are known. Yet, also the targeted delivery using antibodies or antibody fragments, including (monovalent) Fab-fragments of an antibody (or other fragments of such an antibody) or single-chain antibodies are envisaged.

Injection approaches for target directed delivery comprise, inter alia, hydrodynamic i.v. injection. Also cholesterol conjugates of dsRNA may be used for targeted delivery, whereby the conjugation to lipohilic groups enhances cell uptake and improve pharmacokinetics and tissue biodistribution of oligonucleotides. Also cationic delivery systems are known, whereby synthetic vectors with net positive (cationic) charge to facilitate the complex formation with the polyanionic nucleic acid and interaction with the negatively charged cell membrane. Such cationic delivery systems comprise also cationic liposomal delivery systems, cationic polymer and peptide delivery systems. Other delivery systems for the cellular uptake of dsRNA/siRNA are aptamer-ds/siRNA. Also gene therapy approaches can be used to deliver the inventive dsRNA molecules or nucleic acid molecules encoding the same. Such systems comprise the use of non-pathogenic virus, modified viral vectors, as well as deliveries with nanoparticles or liposomes. Other delivery methods for the cellular uptake of dsRNA are extracorporeal, for example ex vivo treatments of cells, organs or tissues. Certain of these technologies are described and summarized in publications, like Akhtar (2007), Journal of Clinical Investigation 117, 3623-3632, Nguyen et al. (2008), Current Opinion in Moleculare Therapeutics 10, 158-167, Zamboni (2005), Clin. Cancer Res. 11, 8230-8234 or Ikeda et al. (2006), Pharmaceutical Research 23, 1631-1640

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

The above provided embodiments and items of the present invention are now illustrated with the following, non-limiting examples.

DESCRIPTION OF FIGURES AND APPENDED TABLES

-   Table 1. Core sequences of dsRNAs targeting human RRM2 gene Letters     in capitals represent RNA nucleotides. -   Table 2. Characterization of dsRNAs targeting human RRM2: Activity     testing with single dose in HeLa-S3 cells. Letters in capitals     represent RNA nucleotides, lower case letters “c”, “g”, “a” and “u”     represent 2′-O-methyl-modified nucleotides, “s” represents     phosphorothioate, “dT” deoxythymidine, and “p” represents     5′-phosphate group (sequences without a “p” are lacking a     5′-phosphate group). S.d.=standard deviation, % mRNA=mean mRNA     knockdown. -   Table 3. Characterization of dsRNAs targeting human RRM2: Activity     testing for dose response in HeLa-S3 cells. IC 50: 50% inhibitory     concentration, IC 80: 80% inhibitory concentration, IC 20: 20%     inhibitory concentration. -   Table 4. Characterization of dsRNAs targeting human RRM2: Stability     and Cytokine Induction. t 1/2: half-life of a strand as defined in     examples, PBMC: Human peripheral blood mononuclear cells. -   Table 5. Core sequences of dsRNAs targeting human RRM2 gene and     their modified counterparts. Letters in capitals represent RNA     nucleotides, lower case letters “c”, “g”, “a” and “u” represent     2′-O-methyl-modified nucleotides, “s” represents phosphorothioate,     “dT” deoxythymidine, and “p” represents 5′-phosphate group     (sequences without a “p” in columns 6 and 8 are lacking a     5′-phosphate group). -   Table 6. Sequences of bDNA probes for determination of human RRM2.     LE=label extender, CE=capture extender, BL=blocking probe. -   Table 7. Sequences of bDNA probes for determination of human GAPDH.     LE=label extender, CE=capture extender, BL=blocking probe. -   Table 8. mRNA knockdown and cell viability dose-response curves,     IC50 summary. -   Table 9. Time course of mRNA knockdown: >80% mRNA knockdown observed     at 24 hr, Percent mRNA knockdown with 5 nM siRNA, relative to mock     transfection. -   FIG. 1. RRM2 protein knockdown dose-response 24 h post-transfection.     A: Western blot B: Quantitation of RRM2 protein in Western blot. -   FIG. 2. Cell cycle analysis of HepG2 cells with dsRNA 477/839: FACS     analysis following propidium iodide staining indicates that     following siRNA treatment cells accumulate in S-phase. -   FIG. 3. Cell cycle analysis of HepG2 cells with dsRNA 477/839: FACS     analysis following propidium iodide staining indicates that     following siRNA treatment cells accumulate in S-phase. -   FIG. 4. Cell cycle analysis of HLF cells with dsRNA 477/839: FACS     analysis following propidium iodide staining indicates that     following siRNA treatment cells accumulate in S-phase. -   FIG. 5. Cell cycle analysis of HLF cells with dsRNA 477/839: FACS     analysis following propidium iodide staining indicates that     following siRNA treatment cells accumulate in S-phase. -   FIG. 6. Apoptosis assay in HepG2 cells. dsRNA 477/839 activates     caspase-3/7. -   FIG. 7. Apoptosis assay in HLF cells. dsRNA 477/839 activates     caspase-3/7. -   FIG. 8. Effects on components of DNA damage pathway 48 hr     post-transfection with RRM2 siRNA (5 nM). RRM2 knockdown activates     the pathway (pChk1 and γ-H2AX) even in the absence of     phleomycin-induced DNA damage.

EXAMPLES

Identification of dsRNAs for Therapeutic Use

dsRNA design was carried out to identify dsRNAs specifically targeting human RRM2 for therapeutic use. First, the known mRNA sequences of human (Homo sapiens) RRM2 (NM_001034.3 and NM_001165931.1 listed as SEQ ID NO. 1013 and 1014) were downloaded from NCBI Genbank.

The cynomolgous monkey (Macaca fascicularis) RRM2 gene was sequenced (see SEQ ID NO. 1015)

The cynomolgus monkey sequence (SEQ ID NO. 1015) was examined together with the human RRM2 mRNA sequences (SEQ ID NO. 1013 and 1014) by computer analysis to identify homologous sequences of 19 nucleotides that yield RNA interference (RNAi) agents cross-reactive to both sequences.

In identifying RNAi agents, the selection was limited to 19mer sequences having at least 2 mismatches to any other sequence in the human RefSeq database (release 38), which we assumed to represent the comprehensive human transcriptome, by using a proprietary algorithm.

All sequences containing 4 or more consecutive U's (poly-U sequences) or G's (poly-G sequences) were excluded from the synthesis.

The sequences thus identified formed the basis for the synthesis of the RNAi agents in appended Tables 1, 2 and 5. dsRNAs cross-reactive to human as well as cynomolgous monkey were defined as most preferable for therapeutic use.

dsRNA Synthesis

Where the source of a reagent is not specifically given herein, such reagent may be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

Single-stranded RNAs were produced by solid phase synthesis on a scale of 1 mole using an Expedite 8909 synthesizer (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany) and controlled pore glass (CPG, 500 Å, Proligo Biochemie GmbH, Hamburg, Germany) as solid support. RNA and RNA containing 2′-O-methyl nucleotides were generated by solid phase synthesis employing the corresponding phosphoramidites and 2′-O-methyl phosphoramidites, respectively (Proligo Biochemie GmbH, Hamburg, Germany). These building blocks were incorporated at selected sites within the sequence of the oligoribonucleotide chain using standard nucleoside phosphoramidite chemistry such as described in Current protocols in nucleic acid chemistry, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA. Phosphorothioate linkages were introduced by replacement of the iodine oxidizer solution with a solution of the Beaucage reagent (Chruachem Ltd, Glasgow, UK) in acetonitrile (1%). Further ancillary reagents were obtained from Mallinckrodt Baker (Griesheim, Germany).

Deprotection and purification of the crude oligoribonucleotides by anion exchange HPLC were carried out according to established procedures. Yields and concentrations were determined by UV absorption of a solution of the respective RNA at a wavelength of 260 nm using a spectral photometer (DU 640B, Beckman Coulter GmbH, Unterschleißheim, Germany). Double stranded RNA was generated by mixing an equimolar solution of complementary strands in annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM sodium chloride), heated in a water bath at 85-90° C. for 3 minutes and cooled to room temperature over a period of 3-4 hours. The annealed RNA solution was stored at −20° C. until use.

Activity Testing

The activity of the RRM2 dsRNAs for therapeutic use described above was tested in HeLa-S3 cells. Cells in culture were used for quantitation of RRM2 mRNA by branched DNA in total mRNA derived from cells incubated with RRM2-targeting dsRNAs.

HeLa-S3 cells were obtained from American Type Culture Collection (Rockville, Md., cat. No. CCL-2.2) and cultured in Ham's F12 (Biochrom AG, Berlin, Germany, cat. No. FG 0815) supplemented to contain 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany, cat. No. S0115), Penicillin 100 U/ml, Streptomycin 100 mg/ml (Biochrom AG, Berlin, Germany, cat. No. A2213) at 37° C. in an atmosphere with 5% CO₂ in a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany).

Cell seeding and transfection of dsRNA were performed at the same time. For transfection with dsRNA, cells were seeded at a density of 2.0 times.10.sup.4 cells/well in 96-well plates. Transfection with dsRNA was carried out with lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Germany, cat.No. 11668-019) as described by the manufacturer. In a first single dose experiment dsRNAs were transfected at a concentration of 50 nM. In a second single dose experiment most active dsRNAs were reanalyzed at 500 pM. Most potent dsRNAs and modification variants thereof were tested for improved silencing of RRM2 in single dose at 30 pM. Very effective dsRNAs from single dose screens were further characterized by dose response curves. For this, transfections were performed as described for the single dose screen above, but with the following concentrations of dsRNA (nM): 24, 6, 1.5, 0.375, 0.0938, 0.0234, 0.0059, 0.0015, 0.0004 and 0.0001 nM. After transfection cells were incubated for 24 h at 37° C. and 5% CO₂ in a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany). bDNA Assay Kit QuantiGene 2.0 (Panomics/Affymetrix, Fremont, USA, Cat-No: 15735) was used for quantification of RRM2 mRNA, while QuantiGene Assay 1.0 (Panomics/Affymetrix, Fremont, USA, Cat-No: QG0004) was used for quantification of GAPDH mRNA. 24 hours after transfection cells were harvested and lysed at 53° C. following procedures recommended by the manufacturer Panomics/Affymetrix for bDNA quantitation of mRNA. Afterwards, 50 μl of the lysates were incubated with probesets specific to human RRM2 and human GAPDH (sequence of probesets see appended tables 7 and 8) and processed according to the manufacturer's protocol for QuantiGene Assay Kit 1 or 2, respectively. Chemoluminescence was measured in a Victor2-Light (Perkin Elmer, Wiesbaden, Germany) as RLUs (relative light units) and values obtained with the human RRM2 probeset were normalized to the respective human GAPDH values for each well. Unrelated control dsRNAs were used as a negative control.

Inhibition data are given in appended tables 2 and 3.

Stability of dsRNAs

Stability of dsRNAs targeting human RRM2 was determined in in vitro assays with either human or mouse serum by measuring the half-life of each single strand.

Measurements were carried out in triplicates for each time point, using 3 μl 50 μM dsRNA sample mixed with 30 μl human serum (Sigma) or mouse serum (Sigma). Mixtures were incubated for either 0 min, 30 min, 1 h, 3 h, 6 h, 24 h, or 48 h at 37° C. As control for unspecific degradation dsRNA was incubated with 30 μl 1×PBS pH 6.8 for 48 h. Reactions were stopped by the addition of 4 μl proteinase K (20 mg/ml), 25 μl of—“Tissue and Cell Lysis Solution” (Epicentre) and 38 μl Millipore water for 30 min at 65° C. Samples were afterwards spin filtered through a 0.2 m 96 well filter plate at 1400 rpm for 8 min, washed with 55 μl Millipore water twice and spin filtered again.

For separation of single strands and analysis of remaining full length product (FLP), samples were run through an ion exchange Dionex Summit HPLC under denaturing conditions using as eluent A 20 mM Na3PO4 in 10% ACN pH=1 and for eluent B 1 M NaBr in eluent A.

The following gradient was applied:

Time % A % B −1.0 min 75 25 1.00 min 75 25 19.0 min 38 62 19.5 min 0 100 21.5 min 0 100 22.0 min 75 25 24.0 min 75 25

For every injection, the chromatograms were integrated automatically by the Dionex Chromeleon 6.60 HPLC software, and were adjusted manually if necessary. All peak areas were corrected to the internal standard (IS) peak and normalized to the incubation at t=0 min. The area under the peak and resulting remaining FLP was calculated for each single strand and triplicate separately. Half-life (t1/2) of a strand was defined by the average time point [h] for triplicates at which half of the FLP was degraded. Results are given in appended table 4.

Cytokine Induction

Potential cytokine induction of dsRNAs was determined by measuring the release of INF-α and TNF-α in an in vitro PBMC assay.

Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coat blood of two donors by Ficoll centrifugation at the day of transfection. Cells were transfected in quadruplicates with dsRNA and cultured for 24 h at 37° C. at a final concentration of 130 nM in Opti-MEM, using either Gene Porter 2 (GP2) or DOTAP. dsRNA sequences that were known to induce INF-α and TNF-α in this assay, as well as a CpG oligo, were used as positive controls. Chemical conjugated dsRNA or CpG oligonucleotides that did not need a transfection reagent for cytokine induction, were incubated at a concentration of 500 nM in culture medium. At the end of incubation, the quadruplicate culture supernatant were pooled.

INF-α and TNF-α was then measured in these pooled supernatants by standard sandwich ELISA with two data points per pool. The degree of cytokine induction was expressed relative to positive controls using a score from 0 to 5, with 5 indicating maximum induction. Results are given in appended table 4.

Cell Culture and siRNA Transfections.

HepG2, HLF and A549 cells were obtained from ATCC and maintained in the recommended media, supplemented with 10% fetal bovine serum and 2 mM 1-Glutamine (HepG2: MEME; HLF and A549: DMEM). Cells were transfected using 0.1 μl DharmaFect 1 (Thermo Fisher) per well of a 96-well plate, with each well containing a final volume of 100 μl growth media. Transfections in 6-well plates were carried out in a similar manner, with volumes adjusted for the larger well size. Transfections were performed using a “reverse transfection” protocol, in which cells (HepG2: 5,000 cells; HLF: 2,000 cells; A540: 4,000 cells) were mixed with transfection mix immediately prior to plating.

bDNA Assay.

QuantiGene branched DNA assays (Affymetrix) for mRNA quantitation were run according to the manufacturer's directions using probe sets designed and synthesized by Affymetrix. 40 μl of lysate were used, and signal was normalized to expression of cyclophin B. Results are summarized in table 8 and 9.

Cell Growth Assays.

Cell-Titer Glo assays (Promega) were performed according to the manufacturer's directions. Real-time growth assays were performed on the xCELLigence instrument (Roche) using E-Plate 96 plates. Cell index was measured every hour, and area under the curve calculated at particular time points. Results are summarized in table 8.

Western Blots.

Antibodies for Western blots were obtained from the following sources: Santa Cruz Biotechnology, Inc. (goat polyclonal anti-RRM2, catalog number sc-10844; goat anti-mouse-HRP, catalog number sc-2005); Cell Signaling Technology (rabbit polyclonal anti-Chk1, catalog number 2345; rabbit polyclonal anti-pChk1 (S317), catalog number 2344; goat anti-rabbit-HRP, catalog number 7074; loading control antibody sampler kit (HRP conjugate), catalog number 4670); R&D Systems (mouse monoclonal anti-H2AX, catalog number MAB3406; rabbit polyclonal anti-gamma-H2AX, catalog number AF2288); Promega (donkey anti-goat-HRP, catalog number V8051).

Cells were transfected in 6-well plates and lysed with Pierce M-PER Mammalian Protein Extraction Reagent containing Pierce Halt Protease and Phosphatase Inhibitor Cocktail, according to the manufacturer's recommendations. Protein concentrations were determined using the Pierce Micro BCA Protein Assay Kit. Lysates were run on Novex NuPAGE 4-12% Bis-Tris gels. Protein was transferred to nitrocellulose using the Invitrogen iBlot Dry Blotting System. Western blots were probed using dilutions of antibodies recommended by the manufacturers, and detected using Amersham ECL Plus Western Blotting Detection Reagents. Gel images were collected on a FujiFilm LAS-4000 instrument and quantitated using Multi Gauge v3.1 software. RRM2 protein knock-down dose-response results are shown in FIG. 1. Effects on components of DNA damage pathway (in vivo pharmacodynamic markers) are shown in FIG. 8.

Cell Cycle Assay.

Cells were transfected in 6-well plates and harvested at 24, 48, 72 and 96 hours after transfection. Media was removed and collected in a 50-ml conical tube. Wells were washed with 2 ml PBS and added to the corresponding tubes. Cells were trypsinized, and, once displaced, added to the appropriate tubes. Tubes were centrifuged at 2,000 rpm for 10 min, washed once with 2 ml PBS, and then centrifuged again at 2,000 rpm for 5 min. Supernatants were carefully removed. To fix cells, tubes were tapped to loosen the pellets, and 1.2 ml cold 70% ETOH was added. After vortexing, samples were stored at −20° C. overnight. After thawing cells at room temperature for 20-30 min, 1.2 ml cold PBS was added, and tubes were centrifuged at 2,000 rpm for 10 min. Pellets were washed with 2 ml PBS and centrifuged again at 2,000 rpm. To the pellets was added 0.5 ml propidium iodide/RNase staining buffer (BD Pharmingen, catalog number 550825). Following a 15-min incubation at 37° C., data was collected on FACS LSRII instrument (BD) using DIVA software (10,000 events per sample) and analyzed using FlowJo software. Results are shown in FIGS. 2-5.

Caspase Assay.

Activation of caspase 3/7 was determined using the Apo-ONE Homogeneous Caspase-3/7 assay (Promega), according to the manufacturer's recommendations. Results are shown in FIGS. 6 and 7.

All ranges recited herein encompass all combinations and subcombinations included within that range limit. All patents and publications cited herein are hereby incorporated by reference in their entirety.

TABLE 1 SEQ  SEQ ID Sense strand  ID Antisense strand NO sequence (5′-3′) NO sequence (5′-3′)   1 UUGUGGCAGACAGACUUAU 234 AUAAGUCUGUCUGCCACAA   2 CCUGAUGUUCAAACACCUG 235 CAGGUGUUUGAACAUCAGG   3 AGUCCAACAGAGAAUUCUU 236 AAGAAUUCUCUGUUGGACU   4 UAGGCGAGUAUCAGAGGAU 237 AUCCUCUGAUACUCGCCUA   5 GGCGAGUAUCAGAGGAUGG 238 CCAUCCUCUGAUACUCGCC   6 UGUUCAAACACCUGGUACA 239 UGUACCAGGUGUUUGAACA   7 GGGUGACCCUUUAGUGAGC 240 GCUCACUAAAGGGUCACCC   8 GAAGGAAAGACUAACUUCU 241 AGAAGUUAGUCUUUCCUUC   9 UUCUGAAAUGUAUAGUCUU 242 AAGACUAUACAUUUCAGAA  10 CUGUGUAGCUACCUCACAA 243 UUGUGAGGUAGCUACACAG  11 UGCACUCUAAUGAAGCAAU 244 AUUGCUUCAUUAGAGUGCA  12 CCCAUUUGACUUUAUGGAG 245 CUCCAUAAAGUCAAAUGGG  13 AAAUGUAUAGUCUUCUUAU 246 AUAAGAAGACUAUACAUUU  14 UACAUUGAGUUUGUGGCAG 247 CUGCCACAAACUCAAUGUA  15 CAAUACAUUGAGUUUGUGG 248 CCACAAACUCAAUGUAUUG  16 GAACAGGAGUUCCUCACUG 249 CAGUGAGGAACUCCUGUUC  17 AUCCCAUGUUCUGGCUUUC 250 GAAAGCCAGAACAUGGGAU  18 GUAGGUUGUGUGAGUUAAU 251 AUUAACUCACACAACCUAC  19 AUAGUCUUCUUAUUGACAC 252 GUGUCAAUAAGAAGACUAU  20 AUUGCACUCUAAUGAAGCA 253 UGCUUCAUUAGAGUGCAAU  21 UUAUCAAUGCUGUUCGGAU 254 AUCCGAACAGCAUUGAUAA  22 AGAAACGAGGACUGAUGCC 255 GGCAUCAGUCCUCGUUUCU  23 CAUUGAGUUUGUGGCAGAC 256 GUCUGCCACAAACUCAAUG  24 ACAUUCAGCACUGGGAAUC 257 GAUUCCCAGUGCUGAAUGU  25 UGAUGUUCAAACACCUGGU 258 ACCAGGUGUUUGAACAUCA  26 GGAUAGAACAGGAGUUCCU 259 AGGAACUCCUGUUCUAUCC  27 AAUAUUUCACUGGAAGGAA 260 UUCCUUCCAGUGAAAUAUU  28 AAUAAACAUUGUUUGUACU 261 AGUACAAACAAUGUUUAUU  29 UCCCAUGUUCUGGCUUUCU 262 AGAAAGCCAGAACAUGGGA  30 UUCGGAUAGAACAGGAGUU 263 AACUCCUGUUCUAUCCGAA  31 AAGUAGGUUGUGUGAGUUA 264 UAACUCACACAACCUACUU  32 UUAUAGUGCUGGUAGUAUC 265 GAUACUACCAGCACUAUAA  33 CUUCUUAUUGACACUUACA 266 UGUAAGUGUCAAUAAGAAG  34 UACAGAAGCCCGCUGUUUC 267 GAAACAGCGGGCUUCUGUA  35 GUGACCCUUUAGUGAGCUU 268 AAGCUCACUAAAGGGUCAC  36 AUAGAACAGGAGUUCCUCA 269 UGAGGAACUCCUGUUCUAU  37 CUGGCACUUUACAAACAAA 270 UUUGUUUGUAAAGUGCCAG  38 UCUAAUGAAGCAAUACAUU 271 AAUGUAUUGCUUCAUUAGA  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA  40 UGUUCGGAUAGAACAGGAG 273 CUCCUGUUCUAUCCGAACA  41 AGUACCAUGAUAUCUGGCA 274 UGCCAGAUAUCAUGGUACU  42 CAGAGAUGAGGGUUUACAC 275 GUGUAAACCCUCAUCUCUG  43 GAAACGAGGACUGAUGCCU 276 AGGCAUCAGUCCUCGUUUC  44 AAGAGAGUAGGCGAGUAUC 277 GAUACUCGCCUACUCUCUU  45 CAUUAGCUGAAUAAUGUGA 278 UCACAUUAUUCAGCUAAUG  46 AGUAGAGAACCCAUUUGAC 279 GUCAAAUGGGUUCUCUACU  47 AGGCGAGUAUCAGAGGAUG 280 CAUCCUCUGAUACUCGCCU  48 UAGACUAAGCAUGUAAUUU 281 AAAUUACAUGCUUAGUCUA  49 AACAUUGUUUGUACUCACA 282 UGUGAGUACAAACAAUGUU  50 GAUGGGAGUGAUGUCAAGU 283 ACUUGACAUCACUCCCAUC  51 CAGACCAUUUCCUAAUCAG 284 CUGAUUAGGAAAUGGUCUG  52 GAUUACAGAAGCCCGCUGU 285 ACAGCGGGCUUCUGUAAUC  53 CAUUGAAACGAUGCCUUGU 286 ACAAGGCAUCGUUUCAAUG  54 ACUUAUGCUGGAACUGGGU 287 ACCCAGUUCCAGCAUAAGU  55 GUCGACAAGGAGAACACGC 288 GCGUGUUCUCCUUGUCGAC  56 AGGAAAGACUAACUUCUUU 289 AAAGAAGUUAGUCUUUCCU  57 CAAGACCGCGAGGAGGAUC 290 GAUCCUCCUCGCGGUCUUG  58 GACAAUGGCAGUCUUGGCU 291 AGCCAAGACUGCCAUUGUC  59 AUGCCUUGUGUCAAGAAGA 292 UCUUCUUGACACAAGGCAU  60 GCCUCACUGCUUCAACGCA 293 UGCGUUGAAGCAGUGAGGC  61 UACCUCACAACCAGUCCUG 294 CAGGACUGGUUGUGAGGUA  62 GAGAAGAGAGUAGGCGAGU 295 ACUCGCCUACUCUCUUCUC  63 AGACUUAUGCUGGAACUGG 296 CCAGUUCCAGCAUAAGUCU  64 UUACAGAAGCCCGCUGUUU 297 AAACAGCGGGCUUCUGUAA  65 UUAUGCUGGAACUGGGUUU 298 AAACCCAGUUCCAGCAUAA  66 AUAAACAUUGUUUGUACUC 299 GAGUACAAACAAUGUUUAU  67 UCAAUGCCAUUGAAACGAU 300 AUCGUUUCAAUGGCAUUGA  68 AUAGUGCUGGUAGUAUCAC 301 GUGAUACUACCAGCACUAU  69 CAGCCUCACUGCUUCAACG 302 CGUUGAAGCAGUGAGGCUG  70 UCUUGGCUUUAAAGUGAGG 303 CCUCACUUUAAAGCCAAGA  71 GGCUGUGACUUACCAUAGC 304 GCUAUGGUAAGUCACAGCC  72 GGCUACCUAUGGUGAACGU 305 ACGUUCACCAUAGGUAGCC  73 CGCGAGGAGGAUCUUCCAG 306 CUGGAAGAUCCUCCUCGCG  74 GCCAUUGAAACGAUGCCUU 307 AAGGCAUCGUUUCAAUGGC  75 AGCCUCACUGCUUCAACGC 308 GCGUUGAAGCAGUGAGGCU  76 GGCAGACAGACUUAUGCUG 309 CAGCAUAAGUCUGUCUGCC  77 GUGACUAAAGUAAGUUAAA 310 UUUAACUUACUUUAGUCAC  78 AGUUAUUGUUACCUAAAGU 311 ACUUUAGGUAACAAUAACU  79 GCCUUUAUGUUUGGGAGAA 312 UUCUCCCAAACAUAAAGGC  80 UUCAGAGUAGAGAACCCAU 313 AUGGGUUCUCUACUCUGAA  81 AAACGAGGACUGAUGCCUG 314 CAGGCAUCAGUCCUCGUUU  82 GUAGGCGAGUAUCAGAGGA 315 UCCUCUGAUACUCGCCUAC  83 AAGCCCGCUGUUUCUAUGG 316 CCAUAGAAACAGCGGGCUU  84 UCAGCACUGGGAAUCCCUG 317 CAGGGAUUCCCAGUGCUGA  85 GAAUAAUGUGAGGAUUAAC 318 GUUAAUCCUCACAUUAUUC  86 UGUGGCAGACAGACUUAUG 319 CAUAAGUCUGUCUGCCACA  87 AGAGAUAAAUGUUGAUCUU 320 AAGAUCAACAUUUAUCUCU  88 UACCAUGAUAUCUGGCAGA 321 UCUGCCAGAUAUCAUGGUA  89 CUUCCAAAUUGCCAUGGAA 322 UUCCAUGGCAAUUUGGAAG  90 ACCGCGAGGAGGAUCUUCC 323 GGAAGAUCCUCCUCGCGGU  91 GAAAUGUAUAGUCUUCUUA 324 UAAGAAGACUAUACAUUUC  92 AUGUUCAAACACCUGGUAC 325 GUACCAGGUGUUUGAACAU  93 AGGGAAUUUCUCUUCAAUG 326 CAUUGAAGAGAAAUUCCCU  94 CCCUGUUAAGUGGUGAAAU 327 AUUUCACCACUUAACAGGG  95 GAUGAGGGUUUACACUGUG 328 CACAGUGUAAACCCUCAUC  96 UGUGUGAGUUAAUUCAUUU 329 AAAUGAAUUAACUCACACA  97 UUGCCUGAUGUUCAAACAC 330 GUGUUUGAACAUCAGGCAA  98 AAACUUGUGUAGACUAAGC 331 GCUUAGUCUACACAAGUUU  99 UAUAUCCCAUGUUCUGGCU 332 AGCCAGAACAUGGGAUAUA 100 UUGUGUAGACUAAGCAUGU 333 ACAUGCUUAGUCUACACAA 101 AUGCUGUUCGGAUAGAACA 334 UGUUCUAUCCGAACAGCAU 102 AAUUAUCAAUGCUGUUCGG 335 CCGAACAGCAUUGAUAAUU 103 GCCUGAUGUUCAAACACCU 336 AGGUGUUUGAACAUCAGGC 104 CAUAGCAGUGACAAUGGCA 337 UGCCAUUGUCACUGCUAUG 105 UGUGAGUUAAUUCAUUUAU 338 AUAAAUGAAUUAACUCACA 106 AGUGCUGGUAGUAUCACCU 339 AGGUGAUACUACCAGCACU 107 UAUCAAUGCUGUUCGGAUA 340 UAUCCGAACAGCAUUGAUA 108 GACUAAAGUAAGUUAAACU 341 AGUUUAACUUACUUUAGUC 109 AAUGCUGUUCGGAUAGAAC 342 GUUCUAUCCGAACAGCAUU 110 AGAAUAUUUCACUGGAAGG 343 CCUUCCAGUGAAAUAUUCU 111 AUCUGGCAGAUGUAUAAGA 344 UCUUAUACAUCUGCCAGAU 112 UAUAGUGCUGGUAGUAUCA 345 UGAUACUACCAGCACUAUA 113 GGCCAGCAAGACCGCGAGG 346 CCUCGCGGUCUUGCUGGCC 114 CCAUGAUAUCUGGCAGAUG 347 CAUCUGCCAGAUAUCAUGG 115 UUAAACUUGUGUAGACUAA 348 UUAGUCUACACAAGUUUAA 116 UUCAAUGCCAUUGAAACGA 349 UCGUUUCAAUGGCAUUGAA 117 AGAAAGCUGAGACAUUGCA 350 UGCAAUGUCUCAGCUUUCU 118 CUAUGGCUUCCAAAUUGCC 351 GGCAAUUUGGAAGCCAUAG 119 AAGUGACUAAAGUAAGUUA 352 UAACUUACUUUAGUCACUU 120 UGACUAAAGUAAGUUAAAC 353 GUUUAACUUACUUUAGUCA 121 UGCUGUUCGGAUAGAACAG 354 CUGUUCUAUCCGAACAGCA 122 GCGAGUAUCAGAGGAUGGG 355 CCCAUCCUCUGAUACUCGC 123 GGGCCUUGCGCUGGAUUGG 356 CCAAUCCAGCGCAAGGCCC 124 ACCUCACAACCAGUCCUGU 357 ACAGGACUGGUUGUGAGGU 125 ACUAAGUGACUAAAGUAAG 358 CUUACUUUAGUCACUUAGU 126 AUUACAGAAGCCCGCUGUU 359 AACAGCGGGCUUCUGUAAU 127 GAGUAGGCGAGUAUCAGAG 360 CUCUGAUACUCGCCUACUC 128 CAGUGACAAUGGCAGUCUU 361 AAGACUGCCAUUGUCACUG 129 GGCCUUGCGCUGGAUUGGG 362 CCCAAUCCAGCGCAAGGCC 130 UUCUUAUUGACACUUACAU 363 AUGUAAGUGUCAAUAAGAA 131 UUCACUAAGUGACUAAAGU 364 ACUUUAGUCACUUAGUGAA 132 GUGUGAGUUAAUUCAUUUA 365 UAAAUGAAUUAACUCACAC 133 CCCGCUCGCGCCCAUCACG 366 CGUGAUGGGCGCGAGCGGG 134 GUAAGUUAAACUUGUGUAG 367 CUACACAAGUUUAACUUAC 135 CGGAAGUUGGAAUCAGGUU 368 AACCUGAUUCCAACUUCCG 136 AUGUGAGGAUUAACUUCUG 369 CAGAAGUUAAUCCUCACAU 137 UUAAGUGGUGAAAUCAACU 370 AGUUGAUUUCACCACUUAA 138 UGUAGACUAAGCAUGUAAU 371 AUUACAUGCUUAGUCUACA 139 AUAAUGUGAGGAUUAACUU 372 AAGUUAAUCCUCACAUUAU 140 GGCUGGCUGUGACUUACCA 373 UGGUAAGUCACAGCCAGCC 141 AAGAGGCUACCUAUGGUGA 374 UCACCAUAGGUAGCCUCUU 142 CAGAUUACAGAAGCCCGCU 375 AGCGGGCUUCUGUAAUCUG 143 UGAGGCCUUGCCUGUGAAG 376 CUUCACAGGCAAGGCCUCA 144 AUAAUUAUCAAUGCUGUUC 377 GAACAGCAUUGAUAAUUAU 145 GUGACUUACCAUAGCAGUG 466 CACUGCUAUGGUAAGUCAC 146 UAGGGCUACUUUGAAUUAA 378 UUAAUUCAAAGUAGCCCUA 147 UGGCAGAUGUAUAAGAAGG 379 CCUUCUUAUACAUCUGCCA 148 AUAGCUUGAUUUAUUUGGU 380 ACCAAAUAAAUCAAGCUAU 149 CAGCAAGACCGCGAGGAGG 381 CCUCCUCGCGGUCUUGCUG 150 GACUGAUGCCUGGCCUCAC 382 GUGAGGCCAGGCAUCAGUC 151 UUACCUUGGAUGCUGACUU 383 AAGUCAGCAUCCAAGGUAA 152 AUUCAGCACUGGGAAUCCC 384 GGGAUUCCCAGUGCUGAAU 153 AGCAAGACCGCGAGGAGGA 385 UCCUCCUCGCGGUCUUGCU 154 AGGGCUACUUUGAAUUAAU 386 AUUAAUUCAAAGUAGCCCU 155 UAAGUUAUUGUUACCUAAA 387 UUUAGGUAACAAUAACUUA 156 UUUAUAGUGCUGGUAGUAU 388 AUACUACCAGCACUAUAAA 157 GCAAGACCGCGAGGAGGAU 389 AUCCUCCUCGCGGUCUUGC 158 UCUAUGGCUUCCAAAUUGC 390 GCAAUUUGGAAGCCAUAGA 159 AAAGACUAACUUCUUUGAG 391 CUCAAAGAAGUUAGUCUUU 160 ACCAUGAUAUCUGGCAGAU 392 AUCUGCCAGAUAUCAUGGU 161 GACCAUUUCCUAAUCAGUU 393 AACUGAUUAGGAAAUGGUC 162 UUACCAUAGCAGUGACAAU 394 AUUGUCACUGCUAUGGUAA 163 AAUGUGAGGAUUAACUUCU 395 AGAAGUUAAUCCUCACAUU 164 UAGUGUCCUGGGAUUCUCU 396 AGAGAAUCCCAGGACACUA 165 UGUUAAGUGGUGAAAUCAA 397 UUGAUUUCACCACUUAACA 166 ACAAAUAUUCUUAAUAGGG 398 CCCUAUUAAGAAUAUUUGU 167 GCGGAAGUUGGAAUCAGGU 399 ACCUGAUUCCAACUUCCGC 168 AACUUGUGUAGACUAAGCA 400 UGCUUAGUCUACACAAGUU 169 AUUCUUAAUAGGGCUACUU 401 AAGUAGCCCUAUUAAGAAU 170 CCUAAAGUUAAUCCAGAUU 402 AAUCUGGAUUAACUUUAGG 171 UAUUGUUACCUAAAGUUAA 403 UUAACUUUAGGUAACAAUA 172 GUGCUGGUAGUAUCACCUU 404 AAGGUGAUACUACCAGCAC 173 CUGUGACUUACCAUAGCAG 405 CUGCUAUGGUAAGUCACAG 174 GAGCUUCUUAAGUUAAAUC 406 GAUUUAACUUAAGAAGCUC 175 CUGUUCGGAUAGAACAGGA 407 UCCUGUUCUAUCCGAACAG 176 GUUAUUGUUACCUAAAGUU 408 AACUUUAGGUAACAAUAAC 177 UAAUGUGAGGAUUAACUUC 409 GAAGUUAAUCCUCACAUUA 178 ACCACUAAUGGGAGCCAAU 410 AUUGGCUCCCAUUAGUGGU 179 UGUGUAGACUAAGCAUGUA 411 UACAUGCUUAGUCUACACA 180 UGGGCCUUGCGCUGGAUUG 412 CAAUCCAGCGCAAGGCCCA 181 AGGAGCUUCUUAAGUUAAA 413 UUUAACUUAAGAAGCUCCU 182 GGUGACCCUUUAGUGAGCU 414 AGCUCACUAAAGGGUCACC 183 AGAGUAGGCGAGUAUCAGA 415 UCUGAUACUCGCCUACUCU 184 GCAGUGACAAUGGCAGUCU 416 AGACUGCCAUUGUCACUGC 185 AAACGAUGCCUUGUGUCAA 417 UUGACACAAGGCAUCGUUU 186 GGACUGAUGCCUGGCCUCA 418 UGAGGCCAGGCAUCAGUCC 187 UGAGAGAUAAAUGUUGAUC 419 GAUCAACAUUUAUCUCUCA 188 UGGUUUCUACACCAAAUAC 420 GUAUUUGGUGUAGAAACCA 189 UCUCUGUAAUAUGAUACAU 421 AUGUAUCAUAUUACAGAGA 190 GAGAGAUAAAUGUUGAUCU 422 AGAUCAACAUUUAUCUCUC 191 ACUCUAAUGAAGCAAUACA 423 UGUAUUGCUUCAUUAGAGU 192 UGAAGUGUUACCAACUAGC 424 GCUAGUUGGUAACACUUCA 193 AAUGAAGCAAUACAUUGAG 425 CUCAAUGUAUUGCUUCAUU 194 ACGAUGCCUUGUGUCAAGA 426 UCUUGACACAAGGCAUCGU 195 AGACCGCGAGGAGGAUCUU 427 AAGAUCCUCCUCGCGGUCU 196 UUGUUACCUAAAGUUAAUC 428 GAUUAACUUUAGGUAACAA 197 CAGAAGCCCGCUGUUUCUA 429 UAGAAACAGCGGGCUUCUG 198 UUUGACUUUAUGGAGAAUA 430 UAUUCUCCAUAAAGUCAAA 199 UACCUAAAGUUAAUCCAGA 431 UCUGGAUUAACUUUAGGUA 200 UUCAAACACCUGGUACACA 432 UGUGUACCAGGUGUUUGAA 201 UUGCACUCUAAUGAAGCAA 433 UUGCUUCAUUAGAGUGCAA 202 UGUUACCUAAAGUUAAUCC 434 GGAUUAACUUUAGGUAACA 203 CACUAAGUGACUAAAGUAA 435 UUACUUUAGUCACUUAGUG 204 UGCCAGAUAGAAGACAGGU 436 ACCUGUCUUCUAUCUGGCA 205 AAUGUAUAGUCUUCUUAUU 437 AAUAAGAAGACUAUACAUU 206 GACCACUAAUGGGAGCCAA 438 UUGGCUCCCAUUAGUGGUC 207 GUUACCUAAAGUUAAUCCA 439 UGGAUUAACUUUAGGUAAC 208 UGAUGCCUGGCCUCACAUU 440 AAUGUGAGGCCAGGCAUCA 209 CCAACUUUAAAGUCAGUCC 441 GGACUGACUUUAAAGUUGG 210 UAAACUUGUGUAGACUAAG 442 CUUAGUCUACACAAGUUUA 211 AGUAGGUUGUGUGAGUUAA 443 UUAACUCACACAACCUACU 212 GUUAAACUUGUGUAGACUA 444 UAGUCUACACAAGUUUAAC 213 CUGACCACUAAUGGGAGCC 445 GGCUCCCAUUAGUGGUCAG 214 UAUUCUUAAUAGGGCUACU 446 AGUAGCCCUAUUAAGAAUA 215 GUAGUGUCCUGGGAUUCUC 447 GAGAAUCCCAGGACACUAC 216 UAUCUGGCAGAUGUAUAAG 448 CUUAUACAUCUGCCAGAUA 217 AGGCUACCUAUGGUGAACG 449 CGUUCACCAUAGGUAGCCU 218 UCAGACCAUUUCCUAAUCA 450 UGAUUAGGAAAUGGUCUGA 219 UUACCUAAAGUUAAUCCAG 451 CUGGAUUAACUUUAGGUAA 220 GGUUUCUACACCAAAUACA 452 UGUAUUUGGUGUAGAAACC 221 GUUGGUGCCAGAUAGAAGA 453 UCUUCUAUCUGGCACCAAC 222 GCUACCUAUGGUGAACGUG 454 CACGUUCACCAUAGGUAGC 223 UCACUAAGUGACUAAAGUA 455 UACUUUAGUCACUUAGUGA 224 UUAUUGUUACCUAAAGUUA 456 UAACUUUAGGUAACAAUAA 225 UAGCUGAAUAAUGUGAGGA 457 UCCUCACAUUAUUCAGCUA 226 UGACCACUAAUGGGAGCCA 458 UGGCUCCCAUUAGUGGUCA 227 GUAGCUACCUCACAACCAG 459 CUGGUUGUGAGGUAGCUAC 228 UCCCGCUCGCGCCCAUCAC 460 GUGAUGGGCGCGAGCGGGA 229 CUUGGCUUUAAAGUGAGGG 461 CCCUCACUUUAAAGCCAAG 230 AGAAGCCCGCUGUUUCUAU 462 AUAGAAACAGCGGGCUUCU 231 ACUAAAGUAAGUUAAACUU 463 AAGUUUAACUUACUUUAGU 232 AGUAAGUUAAACUUGUGUA 464 UACACAAGUUUAACUUACU 233 AAUAAUUAUCAAUGCUGUU 465 AACAGCAUUGAUAAUUAUU

TABLE 2 Activity Activity testing with Activity testing with Activity 50 nM siRNA in testing with 50 nM siRNA in testing with HeLaS3 cells, 500 pM siRNA HeLaS3 cells, 30 pM siRNA SEQ SEQ transfection 1 in HeLaS3 cells transfection 2 in HeLaS3 cells ID sense strand sequence ID antisense strand sequence mRNA s.d. mRNA s.d. mRNA s.d. mRNA s.d. NO (5'-3') NO (5'-3') [%] [%] [%] [%] [%] [%] [%] [%] 526 agGAAAGAcuAAcuucuuudTsdT 967 AAAGAAGUuAGUCUUUCCUdTsdT n.d. n.d. n.d. n.d. 10  2  42  1 477 uucuGAAAuGuAuAGucuudTsdT 963 AAGACuAuAcAUUUcAGAAdTsdT n.d. n.d. n.d. n.d.  8  1  48  2 470 aguccAAcAGAGAAuucuudTsdT 962 AAGAAUUCUCUGUUGGACUdTsdT n.d. n.d. n.d. n.d.  7  0  49  2 476 gaAGGAAAGAcuAAcuucudTsdT 966 AGAAGUuAGUCUUUCCUUCdTsdT n.d. n.d. n.d. n.d.  8  2  50  2 507 ucuucuuAuuGAcAcuuAcdTsdT 964 GUAAGUGUcAAuAAGAAGAdTsdT n.d. n.d. n.d. n.d.  3  1  53  3 553 guAGGcGAGuAucAGAGGAdTsdT 968 UCCUCUGAuACUCGCCuACdTsdT n.d. n.d. n.d. n.d. 12  2  54  4 501 cuucuuAuuGAcAcuuAcAdTsdT 965 UGuAAGUGUcAAuAAGAAGdTsdT n.d. n.d. n.d. n.d.  9  1  58  7 497 ucccAuGuucuGGcuuucudTsdT 961 AGAAAGCcAGAAcAUGGGAdTsdT n.d. n.d. n.d. n.d.  5  1  70  7 508 ucuucuUAuuGAcAcuuAcdTsdT 972 GUAAGUGUcAAuAaGAAGAdTsdT n.d. n.d. n.d. n.d. 14  1  85  8 470 aguccAAcAGAGAAuucuudTsdT 970 AAGAAUUCUCUGUUGGACUdTsdT n.d. n.d. n.d. n.d. 15  1  89  2 477 uucuGAAAuGuAuAGucuudTsdT 971 AAGACuAuAcAUUucAGAAdTsdT n.d. n.d. n.d. n.d. 18  3  89  9 508 ucuucuuAuuGAcAcuuAcdTsdT 985 GuAAGUGUcAAuAAGAAGAdTsdT n.d. n.d. n.d. n.d. 11  2  91  5 507 ucuucuuAuuGAcAcuuAcdTsdT 972 GUAAGUGUcAAuAaGAAGAdTsdT n.d. n.d. n.d. n.d. 14  2  91 10 470 aguccAAcAGAGAAuucuudTsdT 978 AaGAAUUCUCUGUuGGACUdTsdT n.d. n.d. n.d. n.d. 24  3  92  7 501 cuucuuAuuGAcAcuuAcAdTsdT 973 UGuAAGUGUcAAuaAGAAGdTsdT n.d. n.d. n.d. n.d. 34  4  95  5 497 ucccAuGuucuGGcuuucudTsdT 969 AGAAAGCcAGAAcaUGGGAdTsdT n.d. n.d. n.d. n.d. 39  5  96  9 476 gaAGGAAAGAcuAAcuucudTsdT 974 AGAAGUuAGUCUUUCCUUCdTsdT n.d. n.d. n.d. n.d. 14  1  97  8 553 guAGGcGAGuAucAGAGGAdTsdT 984 UcCUCUGAuACUCgCCuACdTsdT n.d. n.d. n.d. n.d. 35  3  98  9 526 agGAAAGAcuAAcuucuuudTsdT 983 AaAGAAGUuAGUCuUUCCUdTsdT n.d. n.d. n.d. n.d. 26  3  98  8 553 guAGGcGAGuAucAGAGGAdTsdT 976 UCCUCUGAuACUCgCCuACdTsdT n.d. n.d. n.d. n.d. 23  1  99 11 526 agGAAAGAcuAAcuucuuudTsdT 975 AAAGAAGUuAGUCuUUCCUdTsdT n.d. n.d. n.d. n.d. 20  1 102  6 508 ucuucuUAuuGAcAcuuAcdTsdT 980 GuAAGUGUcAAuAaGAAGAdTsdT n.d. n.d. n.d. n.d. 21  1 102 13 477 uucuGAAAuGuAuAGucuudTsdT 979 AaGACuAuAcAUUucAGAAdTsdT n.d. n.d. n.d. n.d. 25  3 104 16 497 ucccAuGuucuGGcuuucudTsdT 977 AgAAAGCcAGAAcaUGGGAdTsdT n.d. n.d. n.d. n.d. 43  2 106  8 501 cuucuuAuuGAcAcuuAcAdTsdT 981 UguAAGUGUcAAuaAGAAGdTsdT n.d. n.d. n.d. n.d. 66 14 111 14 476 gaAGGAAAGAcuAAcuucudTSdT 982 AgAAGUuAGUCUUuCCUUCdTsdT n.d. n.d. n.d. n.d. 23  4 111 13 507 ucuucuuAuuGAcAcuuAcdTsdT 980 GuAAGUGUcAAuAaGAAGAdTsdT n.d. n.d. n.d. n.d. 21  5 115 15 507 ucuucuuAuuGAcAcuuAcdTsdT 841 pGUAAGUGUcAAuAAGAAGAdTsdT   7  2  11  2  2  0  45  2 477 uucuGAAAuGuAuAGucuudTsdT 839 pAAGACuAuAcAUUUcAGAAdTsdT  10  1  12  2  8  1  43  4 501 cuucuuAuuGAcAcuuAcAdTsdT 842 pUGuAAGUGUcAAuAAGAAGdTsdT  12  1  14  0  8  2  52  6 469 AguccAAcAGAGAAuucuudTsdT 742 pAAGAAUUCUCUGUUGGACUdTsdT  11  1  14  0  8  0  38  4 475 GaAGGAAAGAcuAAcuucudTsdT 884 pAGAAGUuAGUCUUUCCUUCdTsdT  10  1  14  0  7  1  48  5 522 cauuGAAAcGAuGccuuGudTsdT 845 pACAAGGcAUCGUUUcAAUGdTsdT  11  2  14  2 n.d. n.d. n.d. n.d. 525 AgGAAAGAcuAAcuucuuudTsdT 885 pAAAGAAGUuAGUCUUUCCUdTsdT  12  2  15  1  8  1  44  6 497 ucccAuGuucuGGcuuucudTsdT 711 pAGAAAGCcAGAAcAUGGGAdTsdT  12  1  15  2  6  1  71  5 471 uaGGcGAGuAucAGAGGAudTsdT 892 pAUCCUCUGAuACUCGCCuAdTsdT  14  1  16  1 n.d. n.d. n.d. n.d. 552 GuAGGcGAGuAucAGAGGAdTsdT 891 pUCCUCUGAuACUCGCCuACdTsdT  14  2  16  1 10  0  51  5 494 GgAuAGAAcAGGAGuuccudTsdT 866 pAGGAACUCCUGUUCuAUCCdTsdT  17  1  16  1 n.d. n.d. n.d. n.d. 473 uguucAAAcAccuGGuAcAdTsdT 863 pUGuACcAGGUGUUUGAAcAdTsdT  17  1  16  0 n.d. n.d. n.d. n.d. 560 cuuccAAAuuGccAuGGAAdTsdT 838 pUUCcAUGGcAAUUUGGAAGdTsdT  16  2  16  1 n.d. n.d. n.d. n.d. 544 GccAuuGAAAcGAuGccuudTsdT 718 pAAGGcAUCGUUUcAAUGGCdTsdT  13  2  17  1 n.d. n.d. n.d. n.d. 493 ugAuGuucAAAcAccuGGudTsdT 861 pACcAGGUGUUUGAAcAUcAdTsdT  21  1  17  1 n.d. n.d. n.d. n.d. 481 AaAuGuAuAGucuucuuAudTsdT 714 pAUAAGAAGACuAuAcAUUUdTsdT  14  1  17  1 n.d. n.d. n.d. n.d. 488 AuuGcAcucuAAuGAAGcAdTsdT 735 pUGCUUcAUuAGAGUGcAAUdTsdT  13  1  18  2 n.d. n.d. n.d. n.d. 532 GaGAAGAGAGuAGGcGAGudTsdT 887 pACUCGCCuACUCUCUUCUCdTsdT  18  2  18  1 n.d. n.d. n.d. n.d. 535 uuAuGcuGGAAcuGGGuuudTsdT 881 pAAACCcAGUUCcAGcAuAAdTsdT  19  2  18  1 n.d. n.d. n.d. n.d. 467 uuGuGGcAGAcAGAcuuAudTsdT 737 pAUAAGUCUGUCUGCcAcAAdTsdT  22  0  19  1 n.d. n.d. n.d. n.d. 489 uuAucAAuGcuGuucGGAudTsdT 728 pAUCCGAAcAGcAUUGAuAAdTsdT  15  1  19  1 n.d. n.d. n.d. n.d. 480 cccAuuuGAcuuuAuGGAGdTsdT 739 pCUCcAuAAAGUcAAAUGGGdTsdT  13  1  19  1 n.d. n.d. n.d. n.d. 533 AgAcuuAuGcuGGAAcuGGdTsdT 879 pCCAGUUCcAGcAuAAGUCUdTsdT  14  2  19  2 n.d. n.d. n.d. n.d. 582 AucuGGcAGAuGuAuAAGAdTsdT 825 pUCUuAuAcAUCUGCcAGAUdTsdT  19  3  19  1 n.d. n.d. n.d. n.d. 495 AauAuuucAcuGGAAGGAAdTsdT 741 pUUCCUUCcAGUGAAAuAUUdTsdT  16  1  19  2 n.d. n.d. n.d. n.d. 534 uuAcAGAAGcccGcuGuuudTsdT 831 pAAAcAGCGGGCUUCUGuAAdTsdT  23  2  20  3 n.d. n.d. n.d. n.d. 487 AuAGucuucuuAuuGAcAcdTsdT 715 pGUGUcAAuAAGAAGACuAUdTsdT  19  1  20  3 n.d. n.d. n.d. n.d. 521 GauuAcAGAAGcccGcuGudTsdT 712 pACAGCGGGCUUCUGuAAUCdTsdT  19  2  20  1 n.d. n.d. n.d. n.d. 663 ugAAGuGuuAccAAcuAGcdTsdT 743 pGCuAGUUGGuAAcACUUcAdTsdT  29  5  20  1 n.d. n.d. n.d. n.d. 578 uaucAAuGcuGuucGGAuAdTsdT 865 puAUCCGAAcAGcAUUGAuAdTsdT  19  3  20  2 n.d. n.d. n.d. n.d. 482 uacAuuGAGuuuGuGGcAGdTsdT 875 pCUGCcAcAAACUcAAUGuAdTsdT  15  1  20  2 n.d. n.d. n.d. n.d. 528 GacAAuGGcAGucuuGGcudTsdT 755 pAGCcAAGACUGCcAUUGUCdTsdT  20  2  21  3 n.d. n.d. n.d. n.d. 479 ugcAcucuAAuGAAGcAAudTsdT 871 pAUUGCUUcAUuAGAGUGcAdTsdT  15  1  21  1 n.d. n.d. n.d. n.d. 559 uaccAuGAuAucuGGcAGAdTsdT 821 pUCUGCcAGAuAUcAUGGuAdTsdT  23  2  21  2 n.d. n.d. n.d. n.d. 481 AaAuGuAuAGucuucuuAudTsdT 939 pAuAAGAAGACuAuAcAUUUdTsdT  18  2  21  1 n.d. n.d. n.d. n.d. 484 GaAcAGGAGuuccucAcuGdTsdT 868 pcAGUGAGGAACUCCUGUUCdTsdT  28  1  21  1 n.d. n.d. n.d. n.d. 498 uucGGAuAGAAcAGGAGuudTsdT 734 pAACUCCUGUUCuAUCCGAAdTsdT  18  1  21  1 n.d. n.d. n.d. n.d. 512 GaAAcGAGGAcuGAuGccudTsdT 852 pAGGcAUcAGUCCUCGUUUCdTsdT  17  2  21  2 n.d. n.d. n.d. n.d. 491 cauuGAGuuuGuGGcAGAcdTsdT 876 pGUCUGCcAcAAACUcAAUGdTsdT  17  1  21  2 n.d. n.d. n.d. n.d. 485 AucccAuGuucuGGcuuucdTsdT 710 pGAAAGCcAGAAcAUGGGAUdTsdT  12  1  22  2 n.d. n.d. n.d. n.d. 516 AgGcGAGuAucAGAGGAuGdTsdT 893 pcAUCCUCUGAuACUCGCCUdTsdT  21  2  22  2 n.d. n.d. n.d. n.d. 518 AacAuuGuuuGuAcucAcAdTsdT 913 pUGUGAGuAcAAAcAAUGUUdTsdT  27  2  22  2 n.d. n.d. n.d. n.d. 502 uacAGAAGcccGcuGuuucdTsdT 832 pGAAAcAGCGGGCUUCUGuAdTsdT  23  1  22  1 n.d. n.d. n.d. n.d. 504 AuAGAAcAGGAGuuccucAdTsdT 867 pUGAGGAACUCCUGUUCuAUdTsdT  23  1  22  2 n.d. n.d. n.d. n.d. 561 AccGcGAGGAGGAucuuccdTsdT 818 pGGAAGAUCCUCCUCGCGGUdTsdT  21  2  22  5 n.d. n.d. n.d. n.d. 529 AuGccuuGuGucAAGAAGAdTsdT 846 pUCUUCUUGAcAcAAGGcAUdTsdT  19  2  22  0 n.d. n.d. n.d. n.d. 568 uuGccuGAuGuucAAAcAcdTsdT 858 pGUGUUUGAAcAUcAGGcAAdTsdT  31  3  22  1 n.d. n.d. n.d. n.d. 597 AuuAcAGAAGcccGcuGuudTsdT 830 pAAcAGCGGGCUUCUGuAAUdTsdT  23  3  23  2 n.d. n.d. n.d. n.d. 510 AguAccAuGAuAucuGGcAdTsdT 820 pUGCcAGAuAUcAUGGuACUdTsdT  26  2  23  2 n.d. n.d. n.d. n.d. 633 uuAccAuAGcAGuGAcAAudTsdT 754 pAUUGUcACUGCuAUGGuAAdTsdT  20  4  23  1 n.d. n.d. n.d. n.d. 564 AgGGAAuuucucuucAAuGdTsdT 716 pcAUUGAAGAGAAAUUCCCUdTsdT  22  2  23  1 n.d. n.d. n.d. n.d. 515 AguAGAGAAcccAuuuGAcdTsdT 738 pGUcAAAUGGGUUCUCuACUdTsdT  20  2  23  3 n.d. n.d. n.d. n.d. 523 AcuuAuGcuGGAAcuGGGudTsdT 880 pACCcAGUUCcAGcAuAAGUdTsdT  20  2  23  2 n.d. n.d. n.d. n.d. 490 AgAAAcGAGGAcuGAuGccdTsdT 851 pGGcAUcAGUCCUCGUUUCUdTsdT  20  1  23  2 n.d. n.d. n.d. n.d. 545 AgccucAcuGcuucAAcGcdTsdT 758 pGCGUUGAAGcAGUGAGGCUdTsdT  23  2  23  1 n.d. n.d. n.d. n.d. 599 caGuGAcAAuGGcAGucuudTsdT 904 pAAGACUGCcAUUGUcACUGdTsdT  26  3  23  2 n.d. n.d. n.d. n.d. 539 caGccucAcuGcuucAAcGdTsdT 908 pCGUUGAAGcAGUGAGGCUGdTsdT  25  2  23  2 n.d. n.d. n.d. n.d. 521 GauuAcAGAAGcccGcuGudTsdT 938 pAcAGCGGGCUUCUGuAAUCdTsdT  22  1  23  1 n.d. n.d. n.d. n.d. 573 AauuAucAAuGcuGuucGGdTsdT 727 pCCGAAcAGcAUUGAuAAUUdTsdT  20  3  24  2 n.d. n.d. n.d. n.d. 505 CuGGcAcuuuAcAAAcAAAdTsdT 910 pUUUGUUUGuAAAGUGCcAGdTsdT  32  1  24  2 n.d. n.d. n.d. n.d. 585 ccAuGAuAucuGGcAGAuGdTsdT 823 pcAUCUGCcAGAuAUcAUGGdTsdT  23  3  25  1 n.d. n.d. n.d. n.d. 531 uaccucAcAAccAGuccuGdTsdT 745 pcAGGACUGGUUGUGAGGuAdTsdT  25  2  25  3 n.d. n.d. n.d. n.d. 574 GccuGAuGuucAAAcAccudTsdT 859 pAGGUGUUUGAAcAUcAGGCdTsdT  21  3  25  1 n.d. n.d. n.d. n.d. 492 AcAuucAGcAcuGGGAAucdTsdT 708 pGAUUCCcAGUGCUGAAUGUdTsdT  17  1  25  2 n.d. n.d. n.d. n.d. 513 AaGAGAGuAGGcGAGuAucdTsdT 888 pGAuACUCGCCuACUCUCUUdTsdT  21  2  25  4 n.d. n.d. n.d. n.d. 474 GgGuGAcccuuuAGuGAGcdTsdT 756 pGCUcACuAAAGGGUcACCCdTsdT  24  1  25  2 n.d. n.d. n.d. n.d. 598 GaGuAGGcGAGuAucAGAGdTsdT 890 pCUCUGAuACUCGCCuACUCdTsdT  23  3  25  1 n.d. n.d. n.d. n.d. 496 AauAAAcAuuGuuuGuAcudTsdT 911 pAGuAcAAAcAAUGUUuAUUdTsdT  25  1  25  2 n.d. n.d. n.d. n.d. 506 ucuAAuGAAGcAAuAcAuudTsdT 872 pAAUGuAUUGCUUcAUuAGAdTsdT  22  1  26  1 n.d. n.d. n.d. n.d. 500 uuAuAGuGcuGGuAGuAucdTsdT 746 pGAuACuACcAGcACuAuAAdTsdT  28  1  26  1 n.d. n.d. n.d. n.d. 583 uauAGuGcuGGuAGuAucAdTsdT 747 pUGAuACuACcAGcACuAuAdTsdT  26  3  26  1 n.d. n.d. n.d. n.d. 563 AuGuucAAAcAccuGGuAcdTsdT 862 pGUACcAGGUGUUUGAAcAUdTsdT  20  2  26  2 n.d. n.d. n.d. n.d. 468 ccuGAuGuucAAAcAccuGdTsdT 860 pcAGGUGUUUGAAcAUcAGGdTsdT  18  0  27  2 n.d. n.d. n.d. n.d. 587 uucAAuGccAuuGAAAcGAdTsdT 844 pUCGUUUcAAUGGcAUUGAAdTsdT  27  3  27  2 n.d. n.d. n.d. n.d. 550 uucAGAGuAGAGAAcccAudTsdT 882 pAUGGGUUCUCuACUCUGAAdTsdT  25  2  27  2 n.d. n.d. n.d. n.d. 575 cauAGcAGuGAcAAuGGcAdTsdT 902 pUGCcAUUGUcACUGCuAUGdTsdT  33  3  28  1 n.d. n.d. n.d. n.d. 624 AgcAAGAccGcGAGGAGGAdTsdT 814 pUCCUCCUCGCGGUCUUGCUdTsdT  29  4  28  4 n.d. n.d. n.d. n.d. 627 uuuAuAGuGcuGGuAGuAudTsdT 900 pAUACuACcAGcACuAuAAAdTsdT  30  4  28  3 n.d. n.d. n.d. n.d. 613 caGAuuAcAGAAGcccGcudTsdT 829 pAGCGGGCUUCUGuAAUCUGdTsdT  27  3  29  2 n.d. n.d. n.d. n.d. 507 ucuucuuAuuGAcAcuuAcdTsdT 949 pGuAAGUGUcAAuAAGAAGAdTsdT  18  2  29  2 n.d. n.d. n.d. n.d. 509 uguucGGAuAGAAcAGGAGdTsdT 733 pCUCCUGUUCuAUCCGAAcAdTsdT  18  2  30  4 n.d. n.d. n.d. n.d. 530 GccucAcuGcuucAAcGcAdTsdT 909 pUGCGUUGAAGcAGUGAGGCdTsdT  28  2  30  5 n.d. n.d. n.d. n.d. 483 caAuAcAuuGAGuuuGuGGdTsdT 874 pCCAcAAACUcAAUGuAUUGdTsdT  19  1  30  1 n.d. n.d. n.d. n.d. 519 GauGGGAGuGAuGucAAGudTsdT 896 pACUUGAcAUcACUCCcAUCdTsdT  26  2  30  2 n.d. n.d. n.d. n.d. 537 ucAAuGccAuuGAAAcGAudTsdT 717 pAUCGUUUcAAUGGcAUUGAdTsdT  31  2  30  2 n.d. n.d. n.d. n.d. 511 caGAGAuGAGGGuuuAcAcdTsdT 856 pGUGuAAACCCUcAUCUCUGdTsdT  23  2  30  3 n.d. n.d. n.d. n.d. 620 caGcAAGAccGcGAGGAGGdTsdT 707 pCCUCCUCGCGGUCUUGCUGdTsdT  30  4  31  4 n.d. n.d. n.d. n.d. 595 AccucAcAAccAGuccuGudTsdT 899 pACAGGACUGGUUGUGAGGUdTsdT  31  3  31  1 n.d. n.d. n.d. n.d. 668 caGAAGcccGcuGuuucuAdTsdT 833 puAGAAAcAGCGGGCUUCUGdTsdT  32  6  32  3 n.d. n.d. n.d. n.d. 577 AguGcuGGuAGuAucAccudTsdT 749 pAGGUGAuACuACcAGcACUdTsdT  28  3  32  2 n.d. n.d. n.d. n.d. 654 AgAGuAGGcGAGuAucAGAdTsdT 889 pUCUGAuACUCGCCuACUCUdTsdT  48  5  33  1 n.d. n.d. n.d. n.d. 546 GgcAGAcAGAcuuAuGcuGdTsdT 878 pcAGcAuAAGUCUGUCUGCCdTsdT  21  2  33  3 n.d. n.d. n.d. n.d. 622 uuAccuuGGAuGcuGAcuudTsdT 897 pAAGUcAGcAUCcAAGGuAAdTsdT  50  4  33  2 n.d. n.d. n.d. n.d. 541 GgcuGuGAcuuAccAuAGcdTsdT 751 pGCuAUGGuAAGUcAcAGCCdTsdT  21  2  33  2 n.d. n.d. n.d. n.d. 566 GauGAGGGuuuAcAcuGuGdTsdT 857 pcAcAGUGuAAACCCUcAUCdTsdT  33  2  34  2 n.d. n.d. n.d. n.d. 503 GuGAcccuuuAGuGAGcuudTsdT 907 pAAGCUcACuAAAGGGUcACdTsdT  25  1  34  2 n.d. n.d. n.d. n.d. 527 caAGAccGcGAGGAGGAucdTsdT 816 pGAUCCUCCUCGCGGUCUUGdTsdT  29  2  35  8 n.d. n.d. n.d. n.d. 589 cuAuGGcuuccAAAuuGccdTsdT 837 pGGcAAUUUGGAAGCcAuAGdTsdT  23  3  36  3 n.d. n.d. n.d. n.d. 643 GuGcuGGuAGuAucAccuudTsdT 750 pAAGGUGAuACuACcAGcACdTsdT  37  4  37  2 n.d. n.d. n.d. n.d. 600 GgccuuGcGcuGGAuuGGGdTsdT 849 pCCcAAUCcAGCGcAAGGCCdTsdT  27  3  38  2 n.d. n.d. n.d. n.d. 572 AuGcuGuucGGAuAGAAcAdTsdT 730 pUGUUCuAUCCGAAcAGcAUdTsdT  32  3  38  1 n.d. n.d. n.d. n.d. 517 uaGAcuAAGcAuGuAAuuudTsdT 784 pAAAUuAcAUGCUuAGUCuAdTsdT  32  2  39  3 n.d. n.d. n.d. n.d. 611 GgcuGGcuGuGAcuuAccAdTsdT 901 pUGGuAAGUcAcAGCcAGCCdTsdT  38  3  40  2 n.d. n.d. n.d. n.d. 540 ucuuGGcuuuAAAGuGAGGdTsdT 905 pCCUcACUUuAAAGCcAAGAdTsdT  23  2  40  2 n.d. n.d. n.d. n.d. 536 AuAAAcAuuGuuuGuAcucdTsdT 912 pGAGuAcAAAcAAUGUUuAUdTsdT  50  2  40  4 n.d. n.d. n.d. n.d. 524 GucGAcAAGGAGAAcAcGcdTsdT 705 pGCGUGUUCUCCUUGUCGACdTsdT  32  2  41  3 n.d. n.d. n.d. n.d. 551 AaAcGAGGAcuGAuGccuGdTsdT 724 pcAGGcAUcAGUCCUCGUUUdTsdT  26  2  42  4 n.d. n.d. n.d. n.d. 601 uucuuAuuGAcAcuuAcAudTsdT 843 pAUGuAAGUGUcAAuAAGAAdTsdT  31  3  43  3 n.d. n.d. n.d. n.d. 586 uuAAAcuuGuGuAGAcuAAdTsdT 777 pUUAGUCuAcAcAAGUUuAAdTsdT  37  3  43  4 n.d. n.d. n.d. n.d. 616 GuGAcuuAccAuAGcAGuGdTsdT 753 pcACUGCuAUGGuAAGUcACdTsdT  24  4  43  4 n.d. n.d. n.d. n.d. 472 GgcGAGuAucAGAGGAuGGdTsdT 894 pCCAUCCUCUGAuACUCGCCdTsdT  26  1  44  2 n.d. n.d. n.d. n.d. 570 uauAucccAuGuucuGGcudTsdT 828 pAGCcAGAAcAUGGGAuAuAdTsdT  28  3  44  8 n.d. n.d. n.d. n.d. 655 GcAGuGAcAAuGGcAGucudTsdT 903 pAGACUGCcAUUGUcACUGCdTsdT  34  5  44  2 n.d. n.d. n.d. n.d. 671 uucAAAcAccuGGuAcAcAdTsdT 864 pUGUGuACcAGGUGUUUGAAdTsdT  59  6  44  4 n.d. n.d. n.d. n.d. 580 AauGcuGuucGGAuAGAAcdTsdT 729 pGUUCuAUCCGAAcAGcAUUdTsdT  31  3  44  1 n.d. n.d. n.d. n.d. 618 ugGcAGAuGuAuAAGAAGGdTsdT 826 pCCUUCUuAuAcAUCUGCcAdTsdT  36  4  44  7 n.d. n.d. n.d. n.d. 478 cuGuGuAGcuAccucAcAAdTsdT 744 pUUGUGAGGuAGCuAcAcAGdTsdT  24  1  46  3 n.d. n.d. n.d. n.d. 533 AgAcuuAuGcuGGAAcuGGdTsdT 954 pCcAGUUCcAGcAuAAGUCUdTsdT  26  1  46  3 n.d. n.d. n.d. n.d. 605 GuAAGuuAAAcuuGuGuAGdTsdT 775 pCUAcAcAAGUUuAACUuACdTsdT  44  3  46  3 n.d. n.d. n.d. n.d. 571 uuGuGuAGAcuAAGcAuGudTsdT 781 pACAUGCUuAGUCuAcAcAAdTsdT  47  3  47  2 n.d. n.d. n.d. n.d. 557 uguGGcAGAcAGAcuuAuGdTsdT 877 pcAuAAGUCUGUCUGCcAcAdTsdT  31  2  47  7 n.d. n.d. n.d. n.d. 467 uuGuGGcAGAcAGAcuuAudTsdT 940 pAuAAGUCUGUCUGCcAcAAdTsdT  86 15  47  5 n.d. n.d. n.d. n.d. 579 GacuAAAGuAAGuuAAAcudTsdT 772 pAGUUuAACUuACUUuAGUCdTsdT  32  3  47  2 n.d. n.d. n.d. n.d. 543 cgcGAGGAGGAucuuccAGdTsdT 819 pCUGGAAGAUCCUCCUCGCGdTsdT  52  2  48  7 n.d. n.d. n.d. n.d. 547 GuGAcuAAAGuAAGuuAAAdTsdT 770 pUUuAACUuACUUuAGUcACdTsdT  39  2  48  2 n.d. n.d. n.d. n.d. 602 uucAcuAAGuGAcuAAAGudTsdT 765 pACUUuAGUcACUuAGUGAAdTsdT  39  3  49  4 n.d. n.d. n.d. n.d. 628 GcAAGAccGcGAGGAGGAudTsdT 815 pAUCCUCCUCGCGGUCUUGCdTsdT  36  4  49  3 n.d. n.d. n.d. n.d. 571 uuGuGuAGAcuAAGcAuGudTsdT 945 pAcAUGCUuAGUCuAcAcAAdTsdT  59  3  50  4 n.d. n.d. n.d. n.d. 562 GaAAuGuAuAGucuucuuAdTsdT 713 puAAGAAGACuAuAcAUUUCdTsdT  49  2  51  6 n.d. n.d. n.d. n.d. 593 GcGAGuAucAGAGGAuGGGdTsdT 895 pCCcAUCCUCUGAuACUCGCdTsdT  27  3  52  5 n.d. n.d. n.d. n.d. 538 AuAGuGcuGGuAGuAucAcdTsdT 748 pGUGAuACuACcAGcACuAUdTsdT  57  2  52  3 n.d. n.d. n.d. n.d. 666 AgAccGcGAGGAGGAucuudTsdT 817 pAAGAUCCUCCUCGCGGUCUdTsdT  52  6  52 15 n.d. n.d. n.d. n.d. 567 uguGuGAGuuAAuucAuuudTsdT 922 pAAAUGAAUuAACUcAcAcAdTsdT  48  2  53  4 n.d. n.d. n.d. n.d. 629 ucuAuGGcuuccAAAuuGcdTsdT 836 pGCAAUUUGGAAGCcAuAGAdTsdT  63  4  53  3 n.d. n.d. n.d. n.d. 590 AaGuGAcuAAAGuAAGuuAdTsdT 769 puAACUuACUUuAGUcACUUdTsdT  62  3  53  7 n.d. n.d. n.d. n.d. 681 uaAAcuuGuGuAGAcuAAGdTsdT 778 pCUuAGUCuAcAcAAGUUuAdTsdT  52  7  53  3 n.d. n.d. n.d. n.d. 703 AguAAGuuAAAcuuGuGuAdTsdT 774 puAcAcAAGUUuAACUuACUdTsdT  50 13  54  2 n.d. n.d. n.d. n.d. 603 GuGuGAGuuAAuucAuuuAdTsdT 791 puAAAUGAAUuAACUcAcACdTsdT  46  3  54  8 n.d. n.d. n.d. n.d. 642 uauuGuuAccuAAAGuuAAdTsdT 803 pUUAACUUuAGGuAAcAAuAdTsdT  44  4  55  6 n.d. n.d. n.d. n.d. 674 cacuAAGuGAcuAAAGuAAdTsdT 942 pUuACUUuAGUcACUuAGUGdTsdT  51  3  55  2 n.d. n.d. n.d. n.d. 569 AaAcuuGuGuAGAcuAAGcdTsdT 779 pGCUuAGUCuAcAcAAGUUUdTsdT  60  3  56  3 n.d. n.d. n.d. n.d. 636 uguuAAGuGGuGAAAucAAdTsdT 918 pUUGAUUUcACcACUuAAcAdTsdT  38  4  56  3 n.d. n.d. n.d. n.d. 659 ugGuuucuAcAccAAAuAcdTsdT 941 pGuAUUUGGUGuAGAAACcAdTsdT  51  4  56  8 n.d. n.d. n.d. n.d. 588 AgAAAGcuGAGAcAuuGcAdTsdT 925 pUGcAAUGUCUcAGCUUUCUdTsdT  43  3  57  1 n.d. n.d. n.d. n.d. 596 AcuAAGuGAcuAAAGuAAGdTsdT 768 pCUuACUUuAGUcACUuAGUdTsdT  52  3  57  5 n.d. n.d. n.d. n.d. 609 uguAGAcuAAGcAuGuAAudTsdT 783 pAUuAcAUGCUuAGUCuAcAdTsdT  60  3  58  5 n.d. n.d. n.d. n.d. 650 uguGuAGAcuAAGcAuGuAdTsdT 782 puAcAUGCUuAGUCuAcAcAdTsdT  54  5  58  4 n.d. n.d. n.d. n.d. 591 ugAcuAAAGuAAGuuAAAcdTsdT 771 pGUUuAACUuACUUuAGUcAdTsdT  54  3  58  1 n.d. n.d. n.d. n.d. 639 AacuuGuGuAGAcuAAGcAdTsdT 780 pUGCUuAGUCuAcAcAAGUUdTsdT  57  4  58  2 n.d. n.d. n.d. n.d. 683 GuuAAAcuuGuGuAGAcuAdTsdT 776 puAGUCuAcAcAAGUUuAACdTsdT  55  7  58  3 n.d. n.d. n.d. n.d. 586 uuAAAcuuGuGuAGAcuAAdTsdT 944 pUuAGUCuAcAcAAGUUuAAdTsdT  62  6  59  2 n.d. n.d. n.d. n.d. 653 GguGAcccuuuAGuGAGcudTsdT 757 pAGCUcACuAAAGGGUcACCdTsdT  60  5  60  7 n.d. n.d. n.d. n.d. 542 GgcuAccuAuGGuGAAcGudTsdT 722 pACGUUcACcAuAGGuAGCCdTsdT  30  2  60  6 n.d. n.d. n.d. n.d. 631 AccAuGAuAucuGGcAGAudTsdT 822 pAUCUGCcAGAuAUcAUGGUdTsdT  65  4  60  4 n.d. n.d. n.d. n.d. 605 GuAAGuuAAAcuuGuGuAGdTsdT 943 pCuAcAcAAGUUuAACUuACdTsdT  51  3  60  6 n.d. n.d. n.d. n.d. 676 AauGuAuAGucuucuuAuudTsdT 840 pAAuAAGAAGACuAuAcAUUdTsdT  62  6  60  8 n.d. n.d. n.d. n.d. 499 AaGuAGGuuGuGuGAGuuAdTsdT 790 puAACUcAcAcAACCuACUUdTsdT  56  1  60  2 n.d. n.d. n.d. n.d. 669 uuuGAcuuuAuGGAGAAuAdTsdT 883 puAUUCUCcAuAAAGUcAAAdTsdT  61  6  60  2 n.d. n.d. n.d. n.d. 677 GaccAcuAAuGGGAGccAAdTsdT 914 pUUGGCUCCcAUuAGUGGUCdTsdT  56  6  60  6 n.d. n.d. n.d. n.d. 627 uuuAuAGuGcuGGuAGuAudTsdT 957 pAuACuACcAGcACuAuAAAdTsdT  74  9  61  1 n.d. n.d. n.d. n.d. 656 AaAcGAuGccuuGuGucAAdTsdT 719 pUUGAcAcAAGGcAUCGUUUdTsdT  40  5  62  8 n.d. n.d. n.d. n.d. 647 GuuAuuGuuAccuAAAGuudTsdT 801 pAACUUuAGGuAAcAAuAACdTsdT  63  5  62 14 n.d. n.d. n.d. n.d. 644 cuGuGAcuuAccAuAGcAGdTsdT 752 pCUGCuAUGGuAAGUcAcAGdTsdT  30  4  62  6 n.d. n.d. n.d. n.d. 652 AgGAGcuucuuAAGuuAAAdTsdT 788 pUUuAACUuAAGAAGCUCCUdTsdT  61  5  62  4 n.d. n.d. n.d. n.d. 672 uuGcAcucuAAuGAAGcAAdTsdT 870 pUUGCUUcAUuAGAGUGcAAdTsdT  88  6  63  7 n.d. n.d. n.d. n.d. 682 AguAGGuuGuGuGAGuuAAdTsdT 920 pUUAACUcAcAcAACCuACUdTsdT  60  7  63  5 n.d. n.d. n.d. n.d. 594 GgGccuuGcGcuGGAuuGGdTsdT 848 pCCAAUCcAGCGcAAGGCCCdTsdT  32  3  63  5 n.d. n.d. n.d. n.d. 701 AgAAGcccGcuGuuucuAudTsdT 834 pAUAGAAAcAGCGGGCUUCUdTsdT  79 11  63  5 n.d. n.d. n.d. n.d. 697 ugAccAcuAAuGGGAGccAdTsdT 763 pUGGCUCCcAUuAGUGGUcAdTsdT  68  9  64  8 n.d. n.d. n.d. n.d. 664 AauGAAGcAAuAcAuuGAGdTsdT 873 pCUcAAUGuAUUGCUUcAUUdTsdT  63  5  64  4 n.d. n.d. n.d. n.d. 662 AcucuAAuGAAGcAAuAcAdTsdT 736 pUGuAUUGCUUcAUuAGAGUdTsdT  71  5  64  6 n.d. n.d. n.d. n.d. 659 ugGuuucuAcAccAAAuAcdTsdT 760 pGUAUUUGGUGuAGAAACcAdTsdT  54  5  64  3 n.d. n.d. n.d. n.d. 615 AuAAuuAucAAuGcuGuucdTsdT 726 pGAAcAGcAUUGAuAAUuAUdTsdT  45  4  65  4 n.d. n.d. n.d. n.d. 558 AgAGAuAAAuGuuGAucuudTsdT 798 pAAGAUcAAcAUUuAUCUCUdTsdT  67  2  65  7 n.d. n.d. n.d. n.d. 651 ugGGccuuGcGcuGGAuuGdTsdT 847 pcAAUCcAGCGcAAGGCCcAdTsdT  67  5  65  3 n.d. n.d. n.d. n.d. 698 GuAGcuAccucAcAAccAGdTsdT 898 pCUGGUUGUGAGGuAGCuACdTsdT  61  9  65  2 n.d. n.d. n.d. n.d. 680 ccAAcuuuAAAGucAGuccdTsdT 915 pGGACUGACUUuAAAGUUGGdTsdT  59  6  65  2 n.d. n.d. n.d. n.d. 645 GaGcuucuuAAGuuAAAucdTsdT 917 pGAUUuAACUuAAGAAGCUCdTsdT  59  5  65  2 n.d. n.d. n.d. n.d. 642 uauuGuuAccuAAAGuuAAdTsdT 947 pUuAACUUuAGGuAAcAAuAdTsdT  69  4  65  3 n.d. n.d. n.d. n.d. 486 GuAGGuuGuGuGAGuuAAudTsdT 921 pAUuAACUcAcAcAACCuACdTsdT  61  1  65  4 n.d. n.d. n.d. n.d. 692 GuuGGuGccAGAuAGAAGAdTsdT 785 pUCUUCuAUCUGGcACcAACdTsdT  65  8  65  4 n.d. n.d. n.d. n.d. 691 GguuucuAcAccAAAuAcAdTsdT 761 pUGuAUUUGGUGuAGAAACCdTsdT  63  7  66  6 n.d. n.d. n.d. n.d. 674 cacuAAGuGAcuAAAGuAAdTsdT 767 pUUACUUuAGUcACUuAGUGdTsdT  61  6  66  7 n.d. n.d. n.d. n.d. 623 AuucAGcAcuGGGAAucccdTsdT 709 pGGGAUUCCcAGUGCUGAAUdTsdT  68  4  66  9 n.d. n.d. n.d. n.d. 581 AgAAuAuuucAcuGGAAGGdTsdT 740 pCCUUCcAGUGAAAuAUUCUdTsdT  43  3  67  4 n.d. n.d. n.d. n.d. 673 uguuAccuAAAGuuAAuccdTsdT 805 pGGAUuAACUUuAGGuAAcAdTsdT  70  6  67  9 n.d. n.d. n.d. n.d. 607 AuGuGAGGAuuAAcuucuGdTsdT 810 pcAGAAGUuAAUCCUcAcAUdTsdT  69  3  67  6 n.d. n.d. n.d. n.d. 686 GuAGuGucouGGGAuucucdTsdT 787 pGAGAAUCCcAGGAcACuACdTsdT  72  7  68  4 n.d. n.d. n.d. n.d. 576 uguGAGuuAAuucAuuuAudTsdT 923 pAUAAAUGAAUuAACUcAcAdTsdT  64  3  68  5 n.d. n.d. n.d. n.d. 619 AuAGcuuGAuuuAuuuGGudTsdT 759 pACcAAAuAAAUcAAGCuAUdTsdT  59  4  68  5 n.d. n.d. n.d. n.d. 608 uuAAGuGGuGAAAucAAcudTsdT 919 pAGUUGAUUUcACcACUuAAdTsdT  62  3  68  9 n.d. n.d. n.d. n.d. 682 AguAGGuuGuGuGAGuuAAdTsdT 958 pUuAACUcAcAcAACCuACUdTsdT  75  5  69  5 n.d. n.d. n.d. n.d. 549 GccuuuAuGuuuGGGAGAAdTsdT 924 pUUCUCCcAAAcAuAAAGGCdTsdT  48  2  69  4 n.d. n.d. n.d. n.d. 520 caGAccAuuuccuAAucAGdTsdT 937 pCUGAUuAGGAAAUGGUCUGdTsdT  70  2  69  3 n.d. n.d. n.d. n.d. 556 GaAuAAuGuGAGGAuuAAcdTsdT 933 pGUuAAUCCUcAcAUuAUUCdTsdT  64  2  70  7 n.d. n.d. n.d. n.d. 679 ugAuGccuGGccucAcAuudTsdT 855 pAAUGUGAGGCcAGGcAUcAdTsdT  72  6  70  8 n.d. n.d. n.d. n.d. 660 ucucuGuAAuAuGAuAcAudTsdT 927 pAUGuAUcAuAUuAcAGAGAdTsdT  62  5  70  3 n.d. n.d. n.d. n.d. 694 ucAcuAAGuGAcuAAAGuAdTsdT 766 puACUUuAGUcACUuAGUGAdTsdT  68  8  70  5 n.d. n.d. n.d. n.d. 675 ugccAGAuAGAAGAcAGGudTsdT 786 pACCUGUCUUCuAUCUGGcAdTsdT  64  6  70  3 n.d. n.d. n.d. n.d. 658 ugAGAGAuAAAuGuuGAucdTsdT 797 pGAUcAAcAUUuAUCUCUcAdTsdT  70  5  71  9 n.d. n.d. n.d. n.d. 684 cuGAccAcuAAuGGGAGccdTsdT 762 pGGCUCCcAUuAGUGGUcAGdTsdT  68  7  72  9 n.d. n.d. n.d. n.d. 625 AgGGcuAcuuuGAAuuAAudTsdT 796 pAUuAAUUcAAAGuAGCCCUdTsdT  70  4  72  9 n.d. n.d. n.d. n.d. 649 AccAcuAAuGGGAGccAAudTsdT 764 pAUUGGCUCCcAUuAGUGGUdTsdT  61  5  72  4 n.d. n.d. n.d. n.d. 617 uaGGGcuAcuuuGAAuuAAdTsdT 946 pUuAAUUcAAAGuAGCCCuAdTsdT  73  3  72  6 n.d. n.d. n.d. n.d. 606 cgGAAGuuGGAAucAGGuudTsdT 931 pAACCUGAUUCcAACUUCCGdTsdT  57  3  73  2 n.d. n.d. n.d. n.d. 661 GaGAGAuAAAuGuuGAucudTsdT 926 pAGAUcAAcAUUuAUCUCUCdTsdT  60  5  73  6 n.d. n.d. n.d. n.d. 584 GgccAGcAAGAccGcGAGGdTsdT 706 pCCUCGCGGUCUUGCUGGCCdTsdT  49  3  74  5 n.d. n.d. n.d. n.d. 695 uuAuuGuuAccuAAAGuuAdTsdT 802 puAACUUuAGGuAAcAAuAAdTsdT  74  9  74 13 n.d. n.d. n.d. n.d. 576 uguGAGuuAAuucAuuuAudTsdT 959 pAuAAAUGAAUuAACUcAcAdTsdT  67  4  74  5 n.d. n.d. n.d. n.d. 617 uaGGGcuAcuuuGAAuuAAdTsdT 795 pUUAAUUcAAAGuAGCCCuAdTsdT  51  4  74 13 n.d. n.d. n.d. n.d. 635 uaGuGuccuGGGAuucucudTsdT 916 pAGAGAAUCCcAGGAcACuAdTsdT  72  4  74  6 n.d. n.d. n.d. n.d. 687 uaucuGGcAGAuGuAuAAGdTsdT 824 pCUuAuAcAUCUGCcAGAuAdTsdT  86  7  74  5 n.d. n.d. n.d. n.d. 632 GaccAuuuccuAAucAGuudTsdT 811 pAACUGAUuAGGAAAUGGUCdTsdT  61  4  75 10 n.d. n.d. n.d. n.d. 626 uaAGuuAuuGuuAccuAAAdTsdT 799 pUUuAGGuAAcAAuAACUuAdTsdT  84  4  75  9 n.d. n.d. n.d. n.d. 667 uuGuuAccuAAAGuuAAucdTsdT 804 pGAUuAACUUuAGGuAAcAAdTsdT  76  6  76  9 n.d. n.d. n.d. n.d. 630 AaAGAcuAAcuucuuuGAGdTsdT 886 pCUcAAAGAAGUuAGUCUUUdTsdT  49  4  76  3 n.d. n.d. n.d. n.d. 621 GacuGAuGccuGGccucAcdTsdT 854 pGUGAGGCcAGGcAUcAGUCdTsdT  67  4  76  4 n.d. n.d. n.d. n.d. 670 uaccuAAAGuuAAuccAGAdTsdT 807 pUCUGGAUuAACUUuAGGuAdTsdT  80  6  76 10 n.d. n.d. n.d. n.d. 634 AauGuGAGGAuuAAcuucudTsdT 809 pAGAAGUuAAUCCUcAcAUUdTsdT  69  4  77  2 n.d. n.d. n.d. n.d. 612 AaGAGGcuAccuAuGGuGAdTsdT 850 pUCACcAuAGGuAGCCUCUUdTsdT  65  3  78  2 n.d. n.d. n.d. n.d. 678 GuuAccuAAAGuuAAuccAdTsdT 928 pUGGAUuAACUUuAGGuAACdTsdT  73  6  79  5 n.d. n.d. n.d. n.d. 648 uaAuGuGAGGAuuAAcuucdTsdT 935 pGAAGUuAAUCCUcAcAUuAdTsdT  75  5  80  2 n.d. n.d. n.d. n.d. 689 ucAGAccAuuuccuAAucAdTsdT 936 pUGAUuAGGAAAUGGUCUGAdTsdT  75  7  81  6 n.d. n.d. n.d. n.d. 641 ccuAAAGuuAAuccAGAuudTsdT 929 pAAUCUGGAUuAACUUuAGGdTsdT  72  4  81  4 n.d. n.d. n.d. n.d. 555 ucAGcAcuGGGAAucccuGdTsdT 827 pcAGGGAUUCCcAGUGCUGAdTsdT  81  2  82 12 n.d. n.d. n.d. n.d. 565 cccuGuuAAGuGGuGAAAudTsdT 789 pAUUUcACcACUuAAcAGGGdTsdT  76  2  83  4 n.d. n.d. n.d. n.d. 554 AaGcccGcuGuuucuAuGGdTsdT 835 pCCAuAGAAAcAGCGGGCUUdTsdT  72  2  84  5 n.d. n.d. n.d. n.d. 696 uaGcuGAAuAAuGuGAGGAdTsdT 808 pUCCUcAcAUuAUUcAGCuAdTsdT  84  9  84 11 n.d. n.d. n.d. n.d. 483 caAuAcAuuGAGuuuGuGGdTsdT 953 pCcAcAAACUcAAUGuAUUGdTsdT  31  2  84  6 n.d. n.d. n.d. n.d. 638 GcGGAAGuuGGAAucAGGudTsdT 930 pACCUGAUUCcAACUUCCGCdTsdT  72  4  84  7 n.d. n.d. n.d. n.d. 514 cauuAGcuGAAuAAuGuGAdTsdT 932 pUCAcAUuAUUcAGCuAAUGdTsdT  72  2  85  6 n.d. n.d. n.d. n.d. 702 AcuAAAGuAAGuuAAAcuudTsdT 773 pAAGUUuAACUuACUUuAGUdTsdT  87 12  86  6 n.d. n.d. n.d. n.d. 595 AccucAcAAccAGuccuGudTsdT 956 pAcAGGACUGGUUGUGAGGUdTsdT  35  1  86  5 n.d. n.d. n.d. n.d. 472 GgcGAGuAucAGAGGAuGGdTsdT 955 pCcAUCCUCUGAuACUCGCCdTsdT  23  1  87  5 n.d. n.d. n.d. n.d. 690 uuAccuAAAGuuAAuccAGdTsdT 806 pCUGGAUuAACUUuAGGuAAdTsdT  89  7  88 12 n.d. n.d. n.d. n.d. 592 ugcuGuucGGAuAGAAcAGdTsdT 731 pCUGUUCuAUCCGAAcAGcAdTsdT  76  3  89  3 n.d. n.d. n.d. n.d. 693 GcuAccuAuGGuGAAcGuGdTsdT 723 pcACGUUcACcAuAGGuAGCdTsdT  77  8  89  7 n.d. n.d. n.d. n.d. 665 AcGAuGccuuGuGucAAGAdTsdT 720 pUCUUGAcAcAAGGcAUCGUdTsdT  76  6  90  4 n.d. n.d. n.d. n.d. 688 AgGcuAccuAuGGuGAAcGdTsdT 721 pCGUUcACcAuAGGuAGCCUdTsdT  90  7  90  8 n.d. n.d. n.d. n.d. 685 uauucuuAAuAGGGcuAcudTsdT 793 pAGuAGCCCuAUuAAGAAuAdTsdT  93  7  90 17 n.d. n.d. n.d. n.d. 701 AgAAGcccGcuGuuucuAudTsdT 948 pAuAGAAAcAGCGGGCUUCUdTsdT  79  3  90  4 n.d. n.d. n.d. n.d. 646 CuGuucGGAuAGAAcAGGAdTsdT 732 pUCCUGUUCuAUCCGAAcAGdTsdT  67  5  91  9 n.d. n.d. n.d. n.d. 640 AuucuuAAuAGGGcuAcuudTsdT 794 pAAGuAGCCCuAUuAAGAAUdTsdT 114  4  92 15 n.d. n.d. n.d. n.d. 548 AguuAuuGuuAccuAAAGudTsdT 800 pACUUuAGGuAAcAAuAACUdTsdT  67  2  92 10 n.d. n.d. n.d. n.d. 610 AuAAuGuGAGGAuuAAcuudTsdT 934 pAAGUuAAUCCUcAcAUuAUdTsdT  90  3  93  6 n.d. n.d. n.d. n.d. 637 AcAAAuAuucuuAAuAGGGdTsdT 792 pCCCuAUuAAGAAuAUUUGUdTsdT  79  4  94 18 n.d. n.d. n.d. n.d. 514 cauuAGcuGAAuAAuGuGAdTsdT 960 pUcAcAUuAUUcAGCuAAUGdTsdT  85  4  94  2 n.d. n.d. n.d. n.d. 614 ugAGGccuuGccuGuGAAGdTsdT 869 pCUUcAcAGGcAAGGCCUcAdTsdT 100  3  95  6 n.d. n.d. n.d. n.d. 563 AuGuucAAAcAccuGGuAcdTsdT 952 pGuACcAGGUGUUUGAAcAUdTsdT  96  9  95 14 n.d. n.d. n.d. n.d. 699 ucccGcucGcGcccAucAcdTsdT 812 pGUGAUGGGCGCGAGCGGGAdTsdT  94 10  95  8 n.d. n.d. n.d. n.d. 604 cccGcucGcGcccAucAcGdTsdT 813 pCGUGAUGGGCGCGAGCGGGdTsdT  90  3  96  4 n.d. n.d. n.d. n.d. 657 GgAcuGAuGccuGGccucAdTsdT 853 pUGAGGCcAGGcAUcAGUCCdTsdT  87  5  97  8 n.d. n.d. n.d. n.d. 612 AaGAGGcuAccuAuGGuGAdTsdT 951 pUcACcAuAGGuAGCCUCUUdTsdT  79  9  97  7 n.d. n.d. n.d. n.d. 522 cauuGAAAcGAuGccuuGudTsdT 950 pAcAAGGcAUCGUUUcAAUGdTsdT  93 11 100  6 n.d. n.d. n.d. n.d. 700 cuuGGcuuuAAAGuGAGGGdTsdT 906 pCCCUcACUUuAAAGCcAAGdTsdT  90 10 100  7 n.d. n.d. n.d. n.d. 704 AauAAuuAucAAuGcuGuudTsdT 725 pAAcAGcAUUGAuAAUuAUUdTsdT 134 14 101  2 n.d. n.d. n.d. n.d.

TABLE 3 Activity testing for dose Activity testing for Activity testing for response in HeLaS3 cells, dose response in HeLaS3 dose response in HeLaS3 means of two transfections cells, transfection 3 cells, transfection 4 mean mean mean mean mean mean max. mean mean mean max. mean mean mean max. SEQ ID NO IC50 IC80 IC20 inh IC50 IC80 IC20 inh IC50 IC80 IC20 inh pair [nM] [nM] [nM] [%] [nM] [nM] [nM] [%] [nM] [nM] [nM] [%] 469/742 0.004 0.059 0.001 91 0.013 0.124 0.002 95 0.014 0.158 0.002 91 525/885 0.004 0.074 0.001 90 0.01 0.10 0.00 92 n.d. n.d. n.d. n.d. 477/839 0.006 0.066 0.001 91 0.016 0.143 0.003 93 0.013 0.198 0.002 90 552/891 0.006 0.107 0.001 88 0.02 0.14 0.00 90 n.d. n.d. n.d. n.d. 475/884 0.006 0.073 0.001 91 0.02 0.16 0.00 93 n.d. n.d. n.d. n.d. 501/842 0.007 0.091 0.001 90 0.02 0.18 0.00 91 n.d. n.d. n.d. n.d. 473/863 0.009 0.330 0.002 84 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 507/841 0.010 0.081 0.002 97 0.03 0.21 0.01 97 n.d. n.d. n.d. n.d. 494/866 0.011 0.810 0.003 84 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 544/718 0.014 0.145 0.003 92 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 497/711 0.015 0.116 0.003 89 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 560/838 0.021 0.265 0.004 86 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 522/845 0.029 0.295 0.006 90 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 471/892 0.029 0.361 0.005 88 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 488/735 0.030 0.262 0.006 89 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 507/949 0.204 2.588 0.053 82 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 526/967 n.d. n.d. n.d. n.d. 0.015 0.120 0.0016 92 n.d. n.d. n.d. n.d. 470/962 n.d. n.d. n.d. n.d. 0.022 0.219 0.004 94 0.020 0.314 0.002 90 553/968 n.d. n.d. n.d. n.d. 0.024 0.152 0.0041 89 n.d. n.d. n.d. n.d. 477/963 n.d. n.d. n.d. n.d. 0.024 0.189 0.005 93 0.016 0.251 0.002 90 501/965 n.d. n.d. n.d. n.d. 0.036 0.281 0.0053 91 n.d. n.d. n.d. n.d. 476/966 n.d. n.d. n.d. n.d. 0.038 0.313 0.0062 93 n.d. n.d. n.d. n.d. 507/964 n.d. n.d. n.d. n.d. 0.045 0.310 0.0077 97 n.d. n.d. n.d. n.d. 477/971 n.d. n.d. n.d. n.d. 0.154 2.062 0.034 85 n.d. n.d. n.d. n.d. 470/970 n.d. n.d. n.d. n.d. 0.184 2.134 0.040 87 n.d. n.d. n.d. n.d. 470/978 n.d. n.d. n.d. n.d. 0.479 #N/A 0.073 72 n.d. n.d. n.d. n.d. 477/979 n.d. n.d. n.d. n.d. 0.906 #N/A 0.142 78 n.d. n.d. n.d. n.d.

TABLE 4 Stability Cyno Stability Human Stability Mouse Serum Serum Serum sense antisense sense antisense sense antisense Human PBMC SEQ ID NO t½ t½ t½ t½ t½ t½ assay pair [hr] [hr] [hr] [hr] [hr] [hr] IFN-a TNF-a 475/884 15.8 2.2 >48 0.9 15.5 9.2 0 0 507/841 16.2 0.7 >48 1.7 12.1 0.6 0 0 525/885 41.1 4.2 >48 2.0 13.1 7.7 0 0 469/742 36.4 4.7 >48 2.5 14.2 7.5 0 0 552/891 13.6 9.8 >48 7.1 10.3 11.6 0 0 501/842 17.4 2.2 >48 11.4 13.5 3.2 0 0 477/839 40.8 16.8 >48 >48 27.4 10.7 0 0 497/711 >48 11.8 >48 >48 >48 14.2 0 0

TABLE 5 sense antisense antisense SEQ ID strand sequence SEQ ID strand sequence SEQ ID sense strand sequence SEQ ID strand sequence NO (5′-3′) NO (5′-3′) NO (5′-3′) NO (5′-3′)   1 UUGUGGCAGACAGACUUAU 234 AUAAGUCUGUCUGCCACAA 467 uuGuGGcAGAcAGAcuuAudTsdT 737 pAUAAGUCUGUCUGCcAcAAdTsdT   1 UUGUGGCAGACAGACUUAU 234 AUAAGUCUGUCUGCCACAA 467 uuGuGGcAGAcAGAcuuAudTsdT 940 pAuAAGUCUGUCUGCcAcAAdTsdT   2 CCUGAUGUUCAAACACCUG 235 CAGGUGUUUGAACAUCAGG 468 ccuGAuGuucAAAcAccuGdTsdT 860 pcAGGUGUUUGAAcAUcAGGdTsdT   3 AGUCCAACAGAGAAUUCUU 236 AAGAAUUCUCUGUUGGACU 469 AguccAAcAGAGAAuucuudTsdT 742 pAAGAAUUCUCUGUUGGACUdTsdT   3 AGUCCAACAGAGAAUUCUU 236 AAGAAUUCUCUGUUGGACU 470 aguccAAcAGAGAAuucuudTsdT 962 AAGAAUUCUCUGUUGGACUdTsdT   3 AGUCCAACAGAGAAUUCUU 236 AAGAAUUCUCUGUUGGACU 470 aguccAAcAGAGAAuucuudTsdT 970 AAGAAUUCUCUGUuGGACUdTsdT   3 AGUCCAACAGAGAAUUCUU 236 AAGAAUUCUCUGUUGGACU 470 aguccAAcAGAGAAuucuudTsdT 978 AaGAAUUCUCUGUuGGACUdTsdT   4 UAGGCGAGUAUCAGAGGAU 237 AUCCUCUGAUACUCGCCUA 471 uaGGcGAGuAucAGAGGAudTsdT 892 pAUCCUCUGAuACUCGCCuAdTsdT   5 GGCGAGUAUCAGAGGAUGG 238 CCAUCCUCUGAUACUCGCC 472 GgcGAGuAucAGAGGAuGGdTsdT 894 pCCAUCCUCUGAuACUCGCCdTsdT   5 GGCGAGUAUCAGAGGAUGG 238 CCAUCCUCUGAUACUCGCC 472 GgcGAGuAucAGAGGAuGGdTsdT 955 pCcAUCCUCUGAuACUCGCCdTsdT   6 UGUUCAAACACCUGGUACA 239 UGUACCAGGUGUUUGAACA 473 uguucAAAcAccuGGuAcAdTsdT 863 pUGuACcAGGUGUUUGAAcAdTsdT   7 GGGUGACCCUUUAGUGAGC 240 GCUCACUAAAGGGUCACCC 474 GgGuGAcccuuuAGuGAGcdTsdT 756 pGCUcACuAAAGGGUcACCCdTsdT   8 GAAGGAAAGACUAACUUCU 241 AGAAGUUAGUCUUUCCUUC 475 GaAGGAAAGAcuAAcuucudTsdT 884 pAGAAGUuAGUCUUUCCUUCdTsdT   8 GAAGGAAAGACUAACUUCU 241 AGAAGUUAGUCUUUCCUUC 476 gaAGGAAAGAcuAAcuucudTsdT 966 AGAAGUuAGUCUUUCCUUCdTsdT   8 GAAGGAAAGACUAACUUCU 241 AGAAGUUAGUCUUUCCUUC 476 gaAGGAAAGAcuAAcuucudTsdT 974 AGAAGUuAGUCUUuCCUUCdTsdT   8 GAAGGAAAGACUAACUUCU 241 AGAAGUUAGUCUUUCCUUC 476 gaAGGAAAGAcuAAcuucudTsdT 982 AgAAGUuAGUCUUuCCUUCdTsdT   9 UUCUGAAAUGUAUAGUCUU 242 AAGACUAUACAUUUCAGAA 477 uucuGAAAuGuAuAGucuudTsdT 839 pAAGACuAuAcAUUUcAGAAdTsdT   9 UUCUGAAAUGUAUAGUCUU 242 AAGACUAUACAUUUCAGAA 477 uucuGAAAuGuAuAGucuudTsdT 963 AAGACuAuAcAUUUcAGAAdTsdT   9 UUCUGAAAUGUAUAGUCUU 242 AAGACUAUACAUUUCAGAA 477 uucuGAAAuGuAuAGucuudTsdT 971 AAGACuAuAcAUUucAGAAdTsdT   9 UUCUGAAAUGUAUAGUCUU 242 AAGACUAUACAUUUCAGAA 477 uucuGAAAuGuAuAGucuudTsdT 979 AaGACuAuAcAUUucAGAAdTsdT  10 CUGUGUAGCUACCUCACAA 243 UUGUGAGGUAGCUACACAG 478 cuGuGuAGcuAccucAcAAdTsdT 744 pUUGUGAGGuAGCuAcAcAGdTsdT  11 UGCACUCUAAUGAAGCAAU 244 AUUGCUUCAUUAGAGUGCA 479 ugcAcucuAAuGAAGcAAudTsdT 871 pAUUGCUUcAUuAGAGUGcAdTsdT  12 CCCAUUUGACUUUAUGGAG 245 CUCCAUAAAGUCAAAUGGG 480 cccAuuuGAcuuuAuGGAGdTsdT 739 pCUCcAuAAAGUcAAAUGGGdTsdT  13 AAAUGUAUAGUCUUCUUAU 246 AUAAGAAGACUAUACAUUU 481 AaAuGuAuAGucuucuuAudTsdT 714 pAUAAGAAGACuAuAcAUUUdTsdT  13 AAAUGUAUAGUCUUCUUAU 246 AUAAGAAGACUAUACAUUU 481 AaAuGuAuAGucuucuuAudTsdT 939 pAuAAGAAGACuAuAcAUUUdTsdT  14 UACAUUGAGUUUGUGGCAG 247 CUGCCACAAACUCAAUGUA 482 uacAuuGAGuuuGuGGcAGdTsdT 875 pCUGCcAcAAACUcAAUGuAdTsdT  15 CAAUACAUUGAGUUUGUGG 248 CCACAAACUCAAUGUAUUG 483 caAuAcAuuGAGuuuGuGGdTsdT 874 pCCAcAAACUcAAUGuAUUGdTsdT  15 CAAUACAUUGAGUUUGUGG 248 CCACAAACUCAAUGUAUUG 483 caAuAcAuuGAGuuuGuGGdTsdT 953 pCcAcAAACUcAAUGuAUUGdTsdT  16 GAACAGGAGUUCCUCACUG 249 CAGUGAGGAACUCCUGUUC 484 GaAcAGGAGuuccucAcuGdTsdT 868 pcAGUGAGGAACUCCUGUUCdTsdT  17 AUCCCAUGUUCUGGCUUUC 250 GAAAGCCAGAACAUGGGAU 485 AucccAuGuucuGGcuuucdTsdT 710 pGAAAGCcAGAAcAUGGGAUdTsdT  18 GUAGGUUGUGUGAGUUAAU 251 AUUAACUCACACAACCUAC 486 GuAGGuuGuGuGAGuuAAudTsdT 921 pAUuAACUcAcAcAACCuACdTsdT  19 AUAGUCUUCUUAUUGACAC 252 GUGUCAAUAAGAAGACUAU 487 AuAGucuucuuAuuGAcAcdTsdT 715 pGUGUcAAuAAGAAGACuAUdTsdT  20 AUUGCACUCUAAUGAAGCA 253 UGCUUCAUUAGAGUGCAAU 488 AuuGcAcucuAAuGAAGcAdTsdT 735 pUGCUUcAUuAGAGUGcAAUdTsdT  21 UUAUCAAUGCUGUUCGGAU 254 AUCCGAACAGCAUUGAUAA 489 uuAucAAuGcuGuucGGAudTsdT 728 pAUCCGAAcAGcAUUGAuAAdTsdT  22 AGAAACGAGGACUGAUGCC 255 GGCAUCAGUCCUCGUUUCU 490 AgAAAcGAGGAcuGAuGccdTsdT 851 pGGcAUcAGUCCUCGUUUCUdTsdT  23 CAUUGAGUUUGUGGCAGAC 256 GUCUGCCACAAACUCAAUG 491 cauuGAGuuuGuGGcAGAcdTsdT 876 pGUCUGCcAcAAACUcAAUGdTsdT  24 ACAUUCAGCACUGGGAAUC 257 GAUUCCCAGUGCUGAAUGU 492 AcAuucAGcAcuGGGAAucdTsdT 708 pGAUUCCcAGUGCUGAAUGUdTsdT  25 UGAUGUUCAAACACCUGGU 258 ACCAGGUGUUUGAACAUCA 493 ugAuGuucAAAcAccuGGudTsdT 861 pACcAGGUGUUUGAAcAUcAdTsdT  26 GGAUAGAACAGGAGUUCCU 259 AGGAACUCCUGUUCUAUCC 494 GgAuAGAAcAGGAGuuccudTsdT 866 pAGGAACUCCUGUUCuAUCCdTsdT  27 AAUAUUUCACUGGAAGGAA 260 UUCCUUCCAGUGAAAUAUU 495 AauAuuucAcuGGAAGGAAdTsdT 741 pUUCCUUCcAGUGAAAuAUUdTsdT  28 AAUAAACAUUGUUUGUACU 261 AGUACAAACAAUGUUUAUU 496 AauAAAcAuuGuuuGuAcudTsdT 911 pAGuAcAAAcAAUGUUuAUUdTsdT  29 UCCCAUGUUCUGGCUUUCU 262 AGAAAGCCAGAACAUGGGA 497 ucccAuGuucuGGcuuucudTsdT 711 pAGAAAGCcAGAAcAUGGGAdTsdT  29 UCCCAUGUUCUGGCUUUCU 262 AGAAAGCCAGAACAUGGGA 497 ucccAuGuucuGGcuuucudTsdT 961 AGAAAGCcAGAAcAUGGGAdTsdT  29 UCCCAUGUUCUGGCUUUCU 262 AGAAAGCCAGAACAUGGGA 497 ucccAuGuucuGGcuuucudTsdT 969 AGAAAGCcAGAAcaUGGGAdTsdT  29 UCCCAUGUUCUGGCUUUCU 262 AGAAAGCCAGAACAUGGGA 497 ucccAuGuucuGGcuuucudTsdT 977 AgAAAGCcAGAAcaUGGGAdTsdT  30 UUCGGAUAGAACAGGAGUU 263 AACUCCUGUUCUAUCCGAA 498 uucGGAuAGAAcAGGAGuudTsdT 734 pAACUCCUGUUCuAUCCGAAdTsdT  31 AAGUAGGUUGUGUGAGUUA 264 UAACUCACACAACCUACUU 499 AaGuAGGuuGuGuGAGuuAdTsdT 790 puAACUcAcAcAACCuACUUdTsdT  32 UUAUAGUGCUGGUAGUAUC 265 GAUACUACCAGCACUAUAA 500 uuAuAGuGcuGGuAGuAucdTsdT 746 pGAuACuACcAGcACuAuAAdTsdT  33 CUUCUUAUUGACACUUACA 266 UGUAAGUGUCAAUAAGAAG 501 cuucuuAuuGAcAcuuAcAdTsdT 842 pUGuAAGUGUcAAuAAGAAGdTsdT  33 CUUCUUAUUGACACUUACA 266 UGUAAGUGUCAAUAAGAAG 501 cuucuuAuuGAcAcuuAcAdTsdT 965 UGuAAGUGUcAAuAAGAAGdTsdT  33 CUUCUUAUUGACACUUACA 266 UGUAAGUGUCAAUAAGAAG 501 cuucuuAuuGAcAcuuAcAdTsdT 973 UGuAAGUGUcAAuaAGAAGdTsdT  33 CUUCUUAUUGACACUUACA 266 UGUAAGUGUCAAUAAGAAG 501 cuucuuAuuGAcAcuuAcAdTsdT 981 UguAAGUGUcAAuaAGAAGdTsdT  34 UACAGAAGCCCGCUGUUUC 267 GAAACAGCGGGCUUCUGUA 502 uacAGAAGcccGcuGuuucdTsdT 832 pGAAAcAGCGGGCUUCUGuAdTsdT  35 GUGACCCUUUAGUGAGCUU 268 AAGCUCACUAAAGGGUCAC 503 GuGAcccuuuAGuGAGcuudTsdT 907 pAAGCUcACuAAAGGGUcACdTsdT  36 AUAGAACAGGAGUUCCUCA 269 UGAGGAACUCCUGUUCUAU 504 AuAGAAcAGGAGuuccucAdTsdT 867 pUGAGGAACUCCUGUUCuAUdTsdT  37 CUGGCACUUUACAAACAAA 270 UUUGUUUGUAAAGUGCCAG 505 cuGGcAcuuuAcAAAcAAAdTsdT 910 pUUUGUUUGuAAAGUGCcAGdTsdT  38 UCUAAUGAAGCAAUACAUU 271 AAUGUAUUGCUUCAUUAGA 506 ucuAAuGAAGcAAuAcAuudTsdT 872 pAAUGuAUUGCUUcAUuAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 507 ucuucuuAuuGAcAcuuAcdTsdT 841 pGUAAGUGUcAAuAAGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 507 ucuucuuAuuGAcAcuuAcdTsdT 949 pGuAAGUGUcAAuAAGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 507 ucuucuuAuuGAcAcuuAcdTsdT 964 GUAAGUGUcAAuAAGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 507 ucuucuuAuuGAcAcuuAcdTsdT 972 GUAAGUGUcAAuAaGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 508 ucuucuUAuuGAcAcuuAcdTsdT 972 GUAAGUGUcAAuAaGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 507 ucuucuuAuuGAcAcuuAcdTsdT 980 GuAAGUGUcAAuAaGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 508 ucuucuUAuuGAcAcuuAcdTsdT 980 GuAAGUGUcAAuAaGAAGAdTsdT  39 UCUUCUUAUUGACACUUAC 272 GUAAGUGUCAAUAAGAAGA 508 ucuucuUAuuGAcAcuuAcdTsdT 985 GuAAGUGUcAAuAAGAAGAdTsdT  40 UGUUCGGAUAGAACAGGAG 273 CUCCUGUUCUAUCCGAACA 509 uguucGGAuAGAAcAGGAGdTsdT 733 pCUCCUGUUCuAUCCGAAcAdTsdT  41 AGUACCAUGAUAUCUGGCA 274 UGCCAGAUAUCAUGGUACU 510 AguAccAuGAuAucuGGcAdTsdT 820 pUGCcAGAuAUcAUGGuACUdTsdT  42 CAGAGAUGAGGGUUUACAC 275 GUGUAAACCCUCAUCUCUG 511 caGAGAuGAGGGuuuAcAcdTsdT 856 pGUGuAAACCCUcAUCUCUGdTsdT  43 GAAACGAGGACUGAUGCCU 276 AGGCAUCAGUCCUCGUUUC 512 GaAAcGAGGAcuGAuGccudTsdT 852 pAGGcAUcAGUCCUCGUUUCdTsdT  44 AAGAGAGUAGGCGAGUAUC 277 GAUACUCGCCUACUCUCUU 513 AaGAGAGuAGGcGAGuAucdTsdT 888 pGAuACUCGCCuACUCUCUUdTsdT  45 CAUUAGCUGAAUAAUGUGA 278 UCACAUUAUUCAGCUAAUG 514 cauuAGcuGAAuAAuGuGAdTsdT 932 pUCAcAUuAUUcAGCuAAUGdTsdT  45 CAUUAGCUGAAUAAUGUGA 278 UCACAUUAUUCAGCUAAUG 514 cauuAGcuGAAuAAuGuGAdTsdT 960 pUcAcAUuAUUcAGCuAAUGdTsdT  46 AGUAGAGAACCCAUUUGAC 279 GUCAAAUGGGUUCUCUACU 515 AguAGAGAAcccAuuuGAcdTsdT 738 pGUcAAAUGGGUUCUCuACUdTsdT  47 AGGCGAGUAUCAGAGGAUG 280 CAUCCUCUGAUACUCGCCU 516 AgGcGAGuAucAGAGGAuGdTsdT 893 pcAUCCUCUGAuACUCGCCUdTsdT  48 UAGACUAAGCAUGUAAUUU 281 AAAUUACAUGCUUAGUCUA 517 uaGAcuAAGcAuGuAAuuudTsdT 784 pAAAUuAcAUGCUuAGUCuAdTsdT  49 AACAUUGUUUGUACUCACA 282 UGUGAGUACAAACAAUGUU 518 AacAuuGuuuGuAcucAcAdTsdT 913 pUGUGAGuAcAAAcAAUGUUdTsdT  50 GAUGGGAGUGAUGUCAAGU 283 ACUUGACAUCACUCCCAUC 519 GauGGGAGuGAuGucAAGudTsdT 896 pACUUGAcAUcACUCCcAUCdTsdT  51 CAGACCAUUUCCUAAUCAG 284 CUGAUUAGGAAAUGGUCUG 520 caGAccAuuuccuAAucAGdTsdT 937 pCUGAUuAGGAAAUGGUCUGdTsdT  52 GAUUACAGAAGCCCGCUGU 285 ACAGCGGGCUUCUGUAAUC 521 GauuAcAGAAGcccGcuGudTsdT 712 pACAGCGGGCUUCUGuAAUCdTsdT  52 GAUUACAGAAGCCCGCUGU 285 ACAGCGGGCUUCUGUAAUC 521 GauuAcAGAAGcccGcuGudTsdT 938 pAcAGCGGGCUUCUGuAAUCdTsdT  53 CAUUGAAACGAUGCCUUGU 286 ACAAGGCAUCGUUUCAAUG 522 cauuGAAAcGAuGccuuGudTsdT 845 pACAAGGcAUCGUUUcAAUGdTsdT  53 CAUUGAAACGAUGCCUUGU 286 ACAAGGCAUCGUUUCAAUG 522 cauuGAAAcGAuGccuuGudTsdT 950 pAcAAGGcAUCGUUUcAAUGdTsdT  54 ACUUAUGCUGGAACUGGGU 287 ACCCAGUUCCAGCAUAAGU 523 AcuuAuGcuGGAAcuGGGudTsdT 880 pACCcAGUUCcAGcAuAAGUdTsdT  55 GUCGACAAGGAGAACACGC 288 GCGUGUUCUCCUUGUCGAC 524 GucGAcAAGGAGAAcAcGcdTsdT 705 pGCGUGUUCUCCUUGUCGACdTsdT  56 AGGAAAGACUAACUUCUUU 289 AAAGAAGUUAGUCUUUCCU 525 AgGAAAGAcuAAcuucuuudTsdT 885 pAAAGAAGUuAGUCUUUCCUdTsdT  56 AGGAAAGACUAACUUCUUU 289 AAAGAAGUUAGUCUUUCCU 526 agGAAAGAcuAAcuucuuudTsdT 967 AAAGAAGUuAGUCUUUCCUdTsdT  56 AGGAAAGACUAACUUCUUU 289 AAAGAAGUUAGUCUUUCCU 526 agGAAAGAcuAAcuucuuudTsdT 975 AAAGAAGUuAGUCuUUCCUdTsdT  56 AGGAAAGACUAACUUCUUU 289 AAAGAAGUUAGUCUUUCCU 526 agGAAAGAcuAAcuucuuudTsdT 983 AaAGAAGUuAGUCuUUCCUdTsdT  57 CAAGACCGCGAGGAGGAUC 290 GAUCCUCCUCGCGGUCUUG 527 caAGAccGcGAGGAGGAucdTsdT 816 pGAUCCUCCUCGCGGUCUUGdTsdT  58 GACAAUGGCAGUCUUGGCU 291 AGCCAAGACUGCCAUUGUC 528 GacAAuGGcAGucuuGGcudTsdT 755 pAGCcAAGACUGCcAUUGUCdTsdT  59 AUGCCUUGUGUCAAGAAGA 292 UCUUCUUGACACAAGGCAU 529 AuGccuuGuGucAAGAAGAdTsdT 846 pUCUUCUUGAcAcAAGGcAUdTsdT  60 GCCUCACUGCUUCAACGCA 293 UGCGUUGAAGCAGUGAGGC 530 GccucAcuGcuucAAcGcAdTsdT 909 pUGCGUUGAAGcAGUGAGGCdTsdT  61 UACCUCACAACCAGUCCUG 294 CAGGACUGGUUGUGAGGUA 531 uaccucAcAAccAGuccuGdTsdT 745 pcAGGACUGGUUGUGAGGuAdTsdT  62 GAGAAGAGAGUAGGCGAGU 295 ACUCGCCUACUCUCUUCUC 532 GaGAAGAGAGuAGGcGAGudTsdT 887 pACUCGCCuACUCUCUUCUCdTsdT  63 AGACUUAUGCUGGAACUGG 296 CCAGUUCCAGCAUAAGUCU 533 AgAcuuAuGcuGGAAcuGGdTsdT 879 pCCAGUUCcAGcAuAAGUCUdTsdT  63 AGACUUAUGCUGGAACUGG 296 CCAGUUCCAGCAUAAGUCU 533 AgAcuuAuGcuGGAAcuGGdTsdT 954 pCcAGUUCcAGcAuAAGUCUdTsdT  64 UUACAGAAGCCCGCUGUUU 297 AAACAGCGGGCUUCUGUAA 534 uuAcAGAAGcccGcuGuuudTsdT 831 pAAAcAGCGGGCUUCUGuAAdTsdT  65 UUAUGCUGGAACUGGGUUU 298 AAACCCAGUUCCAGCAUAA 535 uuAuGcuGGAAcuGGGuuudTsdT 881 pAAACCcAGUUCcAGcAuAAdTsdT  66 AUAAACAUUGUUUGUACUC 299 GAGUACAAACAAUGUUUAU 536 AuAAAcAuuGuuuGuAcucdTsdT 912 pGAGuAcAAAcAAUGUUuAUdTsdT  67 UCAAUGCCAUUGAAACGAU 300 AUCGUUUCAAUGGCAUUGA 537 ucAAuGccAuuGAAAcGAudTsdT 717 pAUCGUUUcAAUGGcAUUGAdTsdT  68 AUAGUGCUGGUAGUAUCAC 301 GUGAUACUACCAGCACUAU 538 AuAGuGcuGGuAGuAucAcdTsdT 748 pGUGAuACuACcAGcACuAUdTsdT  69 CAGCCUCACUGCUUCAACG 302 CGUUGAAGCAGUGAGGCUG 539 caGccucAcuGcuucAAcGdTsdT 908 pCGUUGAAGcAGUGAGGCUGdTsdT  70 UCUUGGCUUUAAAGUGAGG 303 CCUCACUUUAAAGCCAAGA 540 ucuuGGcuuuAAAGuGAGGdTsdT 905 pCCUcACUUuAAAGCcAAGAdTsdT  71 GGCUGUGACUUACCAUAGC 304 GCUAUGGUAAGUCACAGCC 541 GgcuGuGAcuuAccAuAGcdTsdT 751 pGCuAUGGuAAGUcAcAGCCdTsdT  72 GGCUACCUAUGGUGAACGU 305 ACGUUCACCAUAGGUAGCC 542 GgcuAccuAuGGuGAAcGudTsdT 722 pACGUUcACcAuAGGuAGCCdTsdT  73 CGCGAGGAGGAUCUUCCAG 306 CUGGAAGAUCCUCCUCGCG 543 cgcGAGGAGGAucuuccAGdTsdT 819 pCUGGAAGAUCCUCCUCGCGdTsdT  74 GCCAUUGAAACGAUGCCUU 307 AAGGCAUCGUUUCAAUGGC 544 GccAuuGAAAcGAuGccuudTsdT 718 pAAGGcAUCGUUUcAAUGGCdTsdT  75 AGCCUCACUGCUUCAACGC 308 GCGUUGAAGCAGUGAGGCU 545 AgccucAcuGcuucAAcGcdTsdT 758 pGCGUUGAAGcAGUGAGGCUdTsdT  76 GGCAGACAGACUUAUGCUG 309 CAGCAUAAGUCUGUCUGCC 546 GgcAGAcAGAcuuAuGcuGdTsdT 878 pcAGcAuAAGUCUGUCUGCCdTsdT  77 GUGACUAAAGUAAGUUAAA 310 UUUAACUUACUUUAGUCAC 547 GuGAcuAAAGuAAGuuAAAdTsdT 770 pUUuAACUuACUUuAGUcACdTsdT  78 AGUUAUUGUUACCUAAAGU 311 ACUUUAGGUAACAAUAACU 548 AguuAuuGuuAccuAAAGudTsdT 800 pACUUuAGGuAAcAAuAACUdTsdT  79 GCCUUUAUGUUUGGGAGAA 312 UUCUCCCAAACAUAAAGGC 549 GccuuuAuGuuuGGGAGAAdTsdT 924 pUUCUCCcAAAcAuAAAGGCdTsdT  80 UUCAGAGUAGAGAACCCAU 313 AUGGGUUCUCUACUCUGAA 550 uucAGAGuAGAGAAcccAudTsdT 882 pAUGGGUUCUCuACUCUGAAdTsdT  81 AAACGAGGACUGAUGCCUG 314 CAGGCAUCAGUCCUCGUUU 551 AaAcGAGGAcuGAuGccuGdTsdT 724 pcAGGcAUcAGUCCUCGUUUdTsdT  82 GUAGGCGAGUAUCAGAGGA 315 UCCUCUGAUACUCGCCUAC 552 GuAGGcGAGuAucAGAGGAdTsdT 891 pUCCUCUGAuACUCGCCuACdTsdT  82 GUAGGCGAGUAUCAGAGGA 315 UCCUCUGAUACUCGCCUAC 553 guAGGcGAGuAucAGAGGAdTsdT 968 UCCUCUGAuACUCGCCuACdTsdT  82 GUAGGCGAGUAUCAGAGGA 315 UCCUCUGAUACUCGCCUAC 553 guAGGcGAGuAucAGAGGAdTsdT 976 UCCUCUGAuACUCgCCuACdTsdT  82 GUAGGCGAGUAUCAGAGGA 315 UCCUCUGAUACUCGCCUAC 553 guAGGcGAGuAucAGAGGAdTsdT 984 UcCUCUGAuACUCgCCuACdTsdT  83 AAGCCCGCUGUUUCUAUGG 316 CCAUAGAAACAGCGGGCUU 554 AaGcccGcuGuuucuAuGGdTsdT 835 pCCAuAGAAAcAGCGGGCUUdTsdT  84 UCAGCACUGGGAAUCCCUG 317 CAGGGAUUCCCAGUGCUGA 555 ucAGcAcuGGGAAucccuGdTsdT 827 pcAGGGAUUCCcAGUGCUGAdTsdT  85 GAAUAAUGUGAGGAUUAAC 318 GUUAAUCCUCACAUUAUUC 556 GaAuAAuGuGAGGAuuAAcdTsdT 933 pGUuAAUCCUcAcAUuAUUCdTsdT  86 UGUGGCAGACAGACUUAUG 319 CAUAAGUCUGUCUGCCACA 557 uguGGcAGAcAGAcuuAuGdTsdT 877 pcAuAAGUCUGUCUGCcAcAdTsdT  87 AGAGAUAAAUGUUGAUCUU 320 AAGAUCAACAUUUAUCUCU 558 AgAGAuAAAuGuuGAucuudTsdT 798 pAAGAUcAAcAUUuAUCUCUdTsdT  88 UACCAUGAUAUCUGGCAGA 321 UCUGCCAGAUAUCAUGGUA 559 uaccAuGAuAucuGGcAGAdTsdT 821 pUCUGCcAGAuAUcAUGGuAdTsdT  89 CUUCCAAAUUGCCAUGGAA 322 UUCCAUGGCAAUUUGGAAG 560 cuuccAAAuuGccAuGGAAdTsdT 838 pUUCcAUGGcAAUUUGGAAGdTsdT  90 ACCGCGAGGAGGAUCUUCC 323 GGAAGAUCCUCCUCGCGGU 561 AccGcGAGGAGGAucuuccdTsdT 818 pGGAAGAUCCUCCUCGCGGUdTsdT  91 GAAAUGUAUAGUCUUCUUA 324 UAAGAAGACUAUACAUUUC 562 GaAAuGuAuAGucuucuuAdTsdT 713 puAAGAAGACuAuAcAUUUCdTsdT  92 AUGUUCAAACACCUGGUAC 325 GUACCAGGUGUUUGAACAU 563 AuGuucAAAcAccuGGuAcdTsdT 862 pGUACcAGGUGUUUGAAcAUdTsdT  92 AUGUUCAAACACCUGGUAC 325 GUACCAGGUGUUUGAACAU 563 AuGuucAAAcAccuGGuAcdTsdT 952 pGuACcAGGUGUUUGAAcAUdTsdT  93 AGGGAAUUUCUCUUCAAUG 326 CAUUGAAGAGAAAUUCCCU 564 AgGGAAuuucucuucAAuGdTsdT 716 pcAUUGAAGAGAAAUUCCCUdTsdT  94 CCCUGUUAAGUGGUGAAAU 327 AUUUCACCACUUAACAGGG 565 cccuGuuAAGuGGuGAAAudTsdT 789 pAUUUcACcACUuAAcAGGGdTsdT  95 GAUGAGGGUUUACACUGUG 328 CACAGUGUAAACCCUCAUC 566 GauGAGGGuuuAcAcuGuGdTsdT 857 pcAcAGUGuAAACCCUcAUCdTsdT  96 UGUGUGAGUUAAUUCAUUU 329 AAAUGAAUUAACUCACACA 567 uguGuGAGuuAAuucAuuudTsdT 922 pAAAUGAAUuAACUcAcAcAdTsdT  97 UUGCCUGAUGUUCAAACAC 330 GUGUUUGAACAUCAGGCAA 568 uuGccuGAuGuucAAAcAcdTsdT 858 pGUGUUUGAAcAUcAGGcAAdTsdT  98 AAACUUGUGUAGACUAAGC 331 GCUUAGUCUACACAAGUUU 569 AaAcuuGuGuAGAcuAAGcdTsdT 779 pGCUuAGUCuAcAcAAGUUUdTsdT  99 UAUAUCCCAUGUUCUGGCU 332 AGCCAGAACAUGGGAUAUA 570 uauAucccAuGuucuGGcudTsdT 828 pAGCcAGAAcAUGGGAuAuAdTsdT 100 UUGUGUAGACUAAGCAUGU 333 ACAUGCUUAGUCUACACAA 571 uuGuGuAGAcuAAGcAuGudTsdT 781 pACAUGCUuAGUCuAcAcAAdTsdT 100 UUGUGUAGACUAAGCAUGU 333 ACAUGCUUAGUCUACACAA 571 uuGuGuAGAcuAAGcAuGudTsdT 945 pAcAUGCUuAGUCuAcAcAAdTsdT 101 AUGCUGUUCGGAUAGAACA 334 UGUUCUAUCCGAACAGCAU 572 AuGcuGuucGGAuAGAAcAdTsdT 730 pUGUUCuAUCCGAAcAGcAUdTsdT 102 AAUUAUCAAUGCUGUUCGG 335 CCGAACAGCAUUGAUAAUU 573 AauuAucAAuGcuGuucGGdTsdT 727 pCCGAAcAGcAUUGAuAAUUdTsdT 103 GCCUGAUGUUCAAACACCU 336 AGGUGUUUGAACAUCAGGC 574 GccuGAuGuucAAAcAccudTsdT 859 pAGGUGUUUGAAcAUcAGGCdTsdT 104 CAUAGCAGUGACAAUGGCA 337 UGCCAUUGUCACUGCUAUG 575 cauAGcAGuGAcAAuGGcAdTsdT 902 pUGCcAUUGUcACUGCuAUGdTsdT 105 UGUGAGUUAAUUCAUUUAU 338 AUAAAUGAAUUAACUCACA 576 uguGAGuuAAuucAuuuAudTsdT 923 pAUAAAUGAAUuAACUcAcAdTsdT 105 UGUGAGUUAAUUCAUUUAU 338 AUAAAUGAAUUAACUCACA 576 uguGAGuuAAuucAuuuAudTsdT 959 pAuAAAUGAAUuAACUcAcAdTsdT 106 AGUGCUGGUAGUAUCACCU 339 AGGUGAUACUACCAGCACU 577 AguGcuGGuAGuAucAccudTsdT 749 pAGGUGAuACuACcAGcACUdTsdT 107 UAUCAAUGCUGUUCGGAUA 340 UAUCCGAACAGCAUUGAUA 578 uaucAAuGcuGuucGGAuAdTsdT 865 puAUCCGAAcAGcAUUGAuAdTsdT 108 GACUAAAGUAAGUUAAACU 341 AGUUUAACUUACUUUAGUC 579 GacuAAAGuAAGuuAAAcudTsdT 772 pAGUUuAACUuACUUuAGUCdTsdT 109 AAUGCUGUUCGGAUAGAAC 342 GUUCUAUCCGAACAGCAUU 580 AauGcuGuucGGAuAGAAcdTsdT 729 pGUUCuAUCCGAAcAGcAUUdTsdT 110 AGAAUAUUUCACUGGAAGG 343 CCUUCCAGUGAAAUAUUCU 581 AgAAuAuuucAcuGGAAGGdTsdT 740 pCCUUCcAGUGAAAuAUUCUdTsdT 111 AUCUGGCAGAUGUAUAAGA 344 UCUUAUACAUCUGCCAGAU 582 AucuGGcAGAuGuAuAAGAdTsdT 825 pUCUuAuAcAUCUGCcAGAUdTsdT 112 UAUAGUGCUGGUAGUAUCA 345 UGAUACUACCAGCACUAUA 583 uauAGuGcuGGuAGuAucAdTsdT 747 pUGAuACuACcAGcACuAuAdTsdT 113 GGCCAGCAAGACCGCGAGG 346 CCUCGCGGUCUUGCUGGCC 584 GgccAGcAAGAccGcGAGGdTsdT 706 pCCUCGCGGUCUUGCUGGCCdTsdT 114 CCAUGAUAUCUGGCAGAUG 347 CAUCUGCCAGAUAUCAUGG 585 ccAuGAuAucuGGcAGAuGdTsdT 823 pcAUCUGCcAGAuAUcAUGGdTsdT 115 UUAAACUUGUGUAGACUAA 348 UUAGUCUACACAAGUUUAA 586 uuAAAcuuGuGuAGAcuAAdTsdT 777 pUUAGUCuAcAcAAGUUuAAdTsdT 115 UUAAACUUGUGUAGACUAA 348 UUAGUCUACACAAGUUUAA 586 uuAAAcuuGuGuAGAcuAAdTsdT 944 pUuAGUCuAcAcAAGUUuAAdTsdT 116 UUCAAUGCCAUUGAAACGA 349 UCGUUUCAAUGGCAUUGAA 587 uucAAuGccAuuGAAAcGAdTsdT 844 pUCGUUUcAAUGGcAUUGAAdTsdT 117 AGAAAGCUGAGACAUUGCA 350 UGCAAUGUCUCAGCUUUCU 588 AgAAAGcuGAGAcAuuGcAdTsdT 925 pUGcAAUGUCUcAGCUUUCUdTsdT 118 CUAUGGCUUCCAAAUUGCC 351 GGCAAUUUGGAAGCCAUAG 589 cuAuGGcuuccAAAuuGccdTsdT 837 pGGcAAUUUGGAAGCcAuAGdTsdT 119 AAGUGACUAAAGUAAGUUA 352 UAACUUACUUUAGUCACUU 590 AaGuGAcuAAAGuAAGuuAdTsdT 769 puAACUuACUUuAGUcACUUdTsdT 120 UGACUAAAGUAAGUUAAAC 353 GUUUAACUUACUUUAGUCA 591 ugAcuAAAGuAAGuuAAAcdTsdT 771 pGUUuAACUuACUUuAGUcAdTsdT 121 UGCUGUUCGGAUAGAACAG 354 CUGUUCUAUCCGAACAGCA 592 ugcuGuucGGAuAGAAcAGdTsdT 731 pCUGUUCuAUCCGAAcAGcAdTsdT 122 GCGAGUAUCAGAGGAUGGG 355 CCCAUCCUCUGAUACUCGC 593 GcGAGuAucAGAGGAuGGGdTsdT 895 pCCcAUCCUCUGAuACUCGCdTsdT 123 GGGCCUUGCGCUGGAUUGG 356 CCAAUCCAGCGCAAGGCCC 594 GgGccuuGcGcuGGAuuGGdTsdT 848 pCCAAUCcAGCGcAAGGCCCdTsdT 124 ACCUCACAACCAGUCCUGU 357 ACAGGACUGGUUGUGAGGU 595 AccucAcAAccAGuccuGudTsdT 899 pACAGGACUGGUUGUGAGGUdTsdT 124 ACCUCACAACCAGUCCUGU 357 ACAGGACUGGUUGUGAGGU 595 AccucAcAAccAGuccuGudTsdT 956 pAcAGGACUGGUUGUGAGGUdTsdT 125 ACUAAGUGACUAAAGUAAG 358 CUUACUUUAGUCACUUAGU 596 AcuAAGuGAcuAAAGuAAGdTsdT 768 pCUuACUUuAGUcACUuAGUdTsdT 126 AUUACAGAAGCCCGCUGUU 359 AACAGCGGGCUUCUGUAAU 597 AuuAcAGAAGcccGcuGuudTsdT 830 pAAcAGCGGGCUUCUGuAAUdTsdT 127 GAGUAGGCGAGUAUCAGAG 360 CUCUGAUACUCGCCUACUC 598 GaGuAGGcGAGuAucAGAGdTsdT 890 pCUCUGAuACUCGCCuACUCdTsdT 128 CAGUGACAAUGGCAGUCUU 361 AAGACUGCCAUUGUCACUG 599 caGuGAcAAuGGcAGucuudTsdT 904 pAAGACUGCcAUUGUcACUGdTsdT 129 GGCCUUGCGCUGGAUUGGG 362 CCCAAUCCAGCGCAAGGCC 600 GgccuuGcGcuGGAuuGGGdTsdT 849 pCCcAAUCcAGCGcAAGGCCdTsdT 130 UUCUUAUUGACACUUACAU 363 AUGUAAGUGUCAAUAAGAA 601 uucuuAuuGAcAcuuAcAudTsdT 843 pAUGuAAGUGUcAAuAAGAAdTsdT 131 UUCACUAAGUGACUAAAGU 364 ACUUUAGUCACUUAGUGAA 602 uucAcuAAGuGAcuAAAGudTsdT 765 pACUUuAGUcACUuAGUGAAdTsdT 132 GUGUGAGUUAAUUCAUUUA 365 UAAAUGAAUUAACUCACAC 603 GuGuGAGuuAAuucAuuuAdTsdT 791 puAAAUGAAUuAACUcAcACdTsdT 133 CCCGCUCGCGCCCAUCACG 366 CGUGAUGGGCGCGAGCGGG 604 cccGcucGcGcccAucAcGdTsdT 813 pCGUGAUGGGCGCGAGCGGGdTsdT 134 GUAAGUUAAACUUGUGUAG 367 CUACACAAGUUUAACUUAC 605 GuAAGuuAAAcuuGuGuAGdTsdT 775 pCUAcAcAAGUUuAACUuACdTsdT 134 GUAAGUUAAACUUGUGUAG 367 CUACACAAGUUUAACUUAC 605 GuAAGuuAAAcuuGuGuAGdTsdT 943 pCuAcAcAAGUUuAACUuACdTsdT 135 CGGAAGUUGGAAUCAGGUU 368 AACCUGAUUCCAACUUCCG 606 cgGAAGuuGGAAucAGGuudTsdT 931 pAACCUGAUUCcAACUUCCGdTsdT 136 AUGUGAGGAUUAACUUCUG 369 CAGAAGUUAAUCCUCACAU 607 AuGuGAGGAuuAAcuucuGdTsdT 810 pcAGAAGUuAAUCCUcAcAUdTsdT 137 UUAAGUGGUGAAAUCAACU 370 AGUUGAUUUCACCACUUAA 608 uuAAGuGGuGAAAucAAcudTsdT 919 pAGUUGAUUUcACcACUuAAdTsdT 138 UGUAGACUAAGCAUGUAAU 371 AUUACAUGCUUAGUCUACA 609 uguAGAcuAAGcAuGuAAudTsdT 783 pAUuAcAUGCUuAGUCuAcAdTsdT 139 AUAAUGUGAGGAUUAACUU 372 AAGUUAAUCCUCACAUUAU 610 AuAAuGuGAGGAuuAAcuudTsdT 934 pAAGUuAAUCCUcAcAUuAUdTsdT 140 GGCUGGCUGUGACUUACCA 373 UGGUAAGUCACAGCCAGCC 611 GgcuGGcuGuGAcuuAccAdTsdT 901 pUGGuAAGUcAcAGCcAGCCdTsdT 141 AAGAGGCUACCUAUGGUGA 374 UCACCAUAGGUAGCCUCUU 612 AaGAGGcuAccuAuGGuGAdTsdT 850 pUCACcAuAGGuAGCCUCUUdTsdT 141 AAGAGGCUACCUAUGGUGA 374 UCACCAUAGGUAGCCUCUU 612 AaGAGGcuAccuAuGGuGAdTsdT 951 pUcACcAuAGGuAGCCUCUUdTsdT 142 CAGAUUACAGAAGCCCGCU 375 AGCGGGCUUCUGUAAUCUG 613 caGAuuAcAGAAGcccGcudTsdT 829 pAGCGGGCUUCUGuAAUCUGdTsdT 143 UGAGGCCUUGCCUGUGAAG 376 CUUCACAGGCAAGGCCUCA 614 ugAGGccuuGccuGuGAAGdTsdT 869 pCUUcAcAGGcAAGGCCUcAdTsdT 144 AUAAUUAUCAAUGCUGUUC 377 GAACAGCAUUGAUAAUUAU 615 AuAAuuAucAAuGcuGuucdTsdT 726 pGAAcAGcAUUGAuAAUuAUdTsdT 145 GUGACUUACCAUAGCAGUG 466 CACUGCUAUGGUAAGUCAC 616 GuGAcuuAccAuAGcAGuGdTsdT 753 pcACUGCuAUGGuAAGUcACdTsdT 146 UAGGGCUACUUUGAAUUAA 378 UUAAUUCAAAGUAGCCCUA 617 uaGGGcuAcuuuGAAuuAAdTsdT 795 pUUAAUUcAAAGuAGCCCuAdTsdT 146 UAGGGCUACUUUGAAUUAA 378 UUAAUUCAAAGUAGCCCUA 617 uaGGGcuAcuuuGAAuuAAdTsdT 946 pUuAAUUcAAAGuAGCCCuAdTsdT 147 UGGCAGAUGUAUAAGAAGG 379 CCUUCUUAUACAUCUGCCA 618 ugGcAGAuGuAuAAGAAGGdTsdT 826 pCCUUCUuAuAcAUCUGCcAdTsdT 148 AUAGCUUGAUUUAUUUGGU 380 ACCAAAUAAAUCAAGCUAU 619 AuAGcuuGAuuuAuuuGGudTsdT 759 pACcAAAuAAAUcAAGCuAUdTsdT 149 CAGCAAGACCGCGAGGAGG 381 CCUCCUCGCGGUCUUGCUG 620 caGcAAGAccGcGAGGAGGdTsdT 707 pCCUCCUCGCGGUCUUGCUGdTsdT 150 GACUGAUGCCUGGCCUCAC 382 GUGAGGCCAGGCAUCAGUC 621 GacuGAuGccuGGccucAcdTsdT 854 pGUGAGGCcAGGcAUcAGUCdTsdT 151 UUACCUUGGAUGCUGACUU 383 AAGUCAGCAUCCAAGGUAA 622 uuAccuuGGAuGcuGAcuudTsdT 897 pAAGUcAGcAUCcAAGGuAAdTsdT 152 AUUCAGCACUGGGAAUCCC 384 GGGAUUCCCAGUGCUGAAU 623 AuucAGcAcuGGGAAucccdTsdT 709 pGGGAUUCCcAGUGCUGAAUdTsdT 153 AGCAAGACCGCGAGGAGGA 385 UCCUCCUCGCGGUCUUGCU 624 AgcAAGAccGcGAGGAGGAdTsdT 814 pUCCUCCUCGCGGUCUUGCUdTsdT 154 AGGGCUACUUUGAAUUAAU 386 AUUAAUUCAAAGUAGCCCU 625 AgGGcuAcuuuGAAuuAAudTsdT 796 pAUuAAUUcAAAGuAGCCCUdTsdT 155 UAAGUUAUUGUUACCUAAA 387 UUUAGGUAACAAUAACUUA 626 uaAGuuAuuGuuAccuAAAdTsdT 799 pUUuAGGuAAcAAuAACUuAdTsdT 156 UUUAUAGUGCUGGUAGUAU 388 AUACUACCAGCACUAUAAA 627 uuuAuAGuGcuGGuAGuAudTsdT 900 pAUACuACcAGcACuAuAAAdTsdT 156 UUUAUAGUGCUGGUAGUAU 388 AUACUACCAGCACUAUAAA 627 uuuAuAGuGcuGGuAGuAudTsdT 957 pAuACuACcAGcACuAuAAAdTsdT 157 GCAAGACCGCGAGGAGGAU 389 AUCCUCCUCGCGGUCUUGC 628 GcAAGAccGcGAGGAGGAudTsdT 815 pAUCCUCCUCGCGGUCUUGCdTsdT 158 UCUAUGGCUUCCAAAUUGC 390 GCAAUUUGGAAGCCAUAGA 629 ucuAuGGcuuccAAAuuGcdTsdT 836 pGCAAUUUGGAAGCcAuAGAdTsdT 159 AAAGACUAACUUCUUUGAG 391 CUCAAAGAAGUUAGUCUUU 630 AaAGAcuAAcuucuuuGAGdTsdT 886 pCUcAAAGAAGUuAGUCUUUdTsdT 160 ACCAUGAUAUCUGGCAGAU 392 AUCUGCCAGAUAUCAUGGU 631 AccAuGAuAucuGGcAGAudTsdT 822 pAUCUGCcAGAuAUcAUGGUdTsdT 161 GACCAUUUCCUAAUCAGUU 393 AACUGAUUAGGAAAUGGUC 632 GaccAuuuccuAAucAGuudTsdT 811 pAACUGAUuAGGAAAUGGUCdTsdT 162 UUACCAUAGCAGUGACAAU 394 AUUGUCACUGCUAUGGUAA 633 uuAccAuAGcAGuGAcAAudTsdT 754 pAUUGUcACUGCuAUGGuAAdTsdT 163 AAUGUGAGGAUUAACUUCU 395 AGAAGUUAAUCCUCACAUU 634 AauGuGAGGAuuAAcuucudTsdT 809 pAGAAGUuAAUCCUcAcAUUdTsdT 164 UAGUGUCCUGGGAUUCUCU 396 AGAGAAUCCCAGGACACUA 635 uaGuGuccuGGGAuucucudTsdT 916 pAGAGAAUCCcAGGAcACuAdTsdT 165 UGUUAAGUGGUGAAAUCAA 397 UUGAUUUCACCACUUAACA 636 uguuAAGuGGuGAAAucAAdTsdT 918 pUUGAUUUcACcACUuAAcAdTsdT 166 ACAAAUAUUCUUAAUAGGG 398 CCCUAUUAAGAAUAUUUGU 637 AcAAAuAuucuuAAuAGGGdTsdT 792 pCCCuAUuAAGAAuAUUUGUdTsdT 167 GCGGAAGUUGGAAUCAGGU 399 ACCUGAUUCCAACUUCCGC 638 GcGGAAGuuGGAAucAGGudTsdT 930 pACCUGAUUCcAACUUCCGCdTsdT 168 AACUUGUGUAGACUAAGCA 400 UGCUUAGUCUACACAAGUU 639 AacuuGuGuAGAcuAAGcAdTsdT 780 pUGCUuAGUCuAcAcAAGUUdTsdT 169 AUUCUUAAUAGGGCUACUU 401 AAGUAGCCCUAUUAAGAAU 640 AuucuuAAuAGGGcuAcuudTsdT 794 pAAGuAGCCCuAUuAAGAAUdTsdT 170 CCUAAAGUUAAUCCAGAUU 402 AAUCUGGAUUAACUUUAGG 641 ccuAAAGuuAAuccAGAuudTsdT 929 pAAUCUGGAUuAACUUuAGGdTsdT 171 UAUUGUUACCUAAAGUUAA 403 UUAACUUUAGGUAACAAUA 642 uauuGuuAccuAAAGuuAAdTsdT 803 pUUAACUUuAGGuAAcAAuAdTsdT 171 UAUUGUUACCUAAAGUUAA 403 UUAACUUUAGGUAACAAUA 642 uauuGuuAccuAAAGuuAAdTsdT 947 pUuAACUUuAGGuAAcAAuAdTsdT 172 GUGCUGGUAGUAUCACCUU 404 AAGGUGAUACUACCAGCAC 643 GuGcuGGuAGuAucAccuudTsdT 750 pAAGGUGAuACuACcAGcACdTsdT 173 CUGUGACUUACCAUAGCAG 405 CUGCUAUGGUAAGUCACAG 644 cuGuGAcuuAccAuAGcAGdTsdT 752 pCUGCuAUGGuAAGUcAcAGdTsdT 174 GAGCUUCUUAAGUUAAAUC 406 GAUUUAACUUAAGAAGCUC 645 GaGcuucuuAAGuuAAAucdTsdT 917 pGAUUuAACUuAAGAAGCUCdTsdT 175 CUGUUCGGAUAGAACAGGA 407 UCCUGUUCUAUCCGAACAG 646 cuGuucGGAuAGAAcAGGAdTsdT 732 pUCCUGUUCuAUCCGAAcAGdTsdT 176 GUUAUUGUUACCUAAAGUU 408 AACUUUAGGUAACAAUAAC 647 GuuAuuGuuAccuAAAGuudTsdT 801 pAACUUuAGGuAAcAAuAACdTsdT 177 UAAUGUGAGGAUUAACUUC 409 GAAGUUAAUCCUCACAUUA 648 uaAuGuGAGGAuuAAcuucdTsdT 935 pGAAGUuAAUCCUcAcAUuAdTsdT 178 ACCACUAAUGGGAGCCAAU 410 AUUGGCUCCCAUUAGUGGU 649 AccAcuAAuGGGAGccAAudTsdT 764 pAUUGGCUCCcAUuAGUGGUdTsdT 179 UGUGUAGACUAAGCAUGUA 411 UACAUGCUUAGUCUACACA 650 uguGuAGAcuAAGcAuGuAdTsdT 782 puAcAUGCUuAGUCuAcAcAdTsdT 180 UGGGCCUUGCGCUGGAUUG 412 CAAUCCAGCGCAAGGCCCA 651 ugGGccuuGcGcuGGAuuGdTsdT 847 pcAAUCcAGCGcAAGGCCcAdTsdT 181 AGGAGCUUCUUAAGUUAAA 413 UUUAACUUAAGAAGCUCCU 652 AgGAGcuucuuAAGuuAAAdTsdT 788 pUUuAACUuAAGAAGCUCCUdTsdT 182 GGUGACCCUUUAGUGAGCU 414 AGCUCACUAAAGGGUCACC 653 GguGAcccuuuAGuGAGcudTsdT 757 pAGCUcACuAAAGGGUcACCdTsdT 183 AGAGUAGGCGAGUAUCAGA 415 UCUGAUACUCGCCUACUCU 654 AgAGuAGGcGAGuAucAGAdTsdT 889 pUCUGAuACUCGCCuACUCUdTsdT 184 GCAGUGACAAUGGCAGUCU 416 AGACUGCCAUUGUCACUGC 655 GcAGuGAcAAuGGcAGucudTsdT 903 pAGACUGCcAUUGUcACUGCdTsdT 185 AAACGAUGCCUUGUGUCAA 417 UUGACACAAGGCAUCGUUU 656 AaAcGAuGccuuGuGucAAdTsdT 719 pUUGAcAcAAGGcAUCGUUUdTsdT 186 GGACUGAUGCCUGGCCUCA 418 UGAGGCCAGGCAUCAGUCC 657 GgAcuGAuGccuGGccucAdTsdT 853 pUGAGGCcAGGcAUcAGUCCdTsdT 187 UGAGAGAUAAAUGUUGAUC 419 GAUCAACAUUUAUCUCUCA 658 ugAGAGAuAAAuGuuGAucdTsdT 797 pGAUcAAcAUUuAUCUCUcAdTsdT 188 UGGUUUCUACACCAAAUAC 420 GUAUUUGGUGUAGAAACCA 659 ugGuuucuAcAccAAAuAcdTsdT 760 pGUAUUUGGUGuAGAAACcAdTsdT 188 UGGUUUCUACACCAAAUAC 420 GUAUUUGGUGUAGAAACCA 659 ugGuuucuAcAccAAAuAcdTsdT 941 pGuAUUUGGUGuAGAAACcAdTsdT 189 UCUCUGUAAUAUGAUACAU 421 AUGUAUCAUAUUACAGAGA 660 ucucuGuAAuAuGAuAcAudTsdT 927 pAUGuAUcAuAUuAcAGAGAdTsdT 190 GAGAGAUAAAUGUUGAUCU 422 AGAUCAACAUUUAUCUCUC 661 GaGAGAuAAAuGuuGAucudTsdT 926 pAGAUcAAcAUUuAUCUCUCdTsdT 191 ACUCUAAUGAAGCAAUACA 423 UGUAUUGCUUCAUUAGAGU 662 AcucuAAuGAAGcAAuAcAdTsdT 736 pUGuAUUGCUUcAUuAGAGUdTsdT 192 UGAAGUGUUACCAACUAGC 424 GCUAGUUGGUAACACUUCA 663 ugAAGuGuuAccAAcuAGcdTsdT 743 pGCuAGUUGGuAAcACUUcAdTsdT 193 AAUGAAGCAAUACAUUGAG 425 CUCAAUGUAUUGCUUCAUU 664 AauGAAGcAAuAcAuuGAGdTsdT 873 pCUcAAUGuAUUGCUUcAUUdTsdT 194 ACGAUGCCUUGUGUCAAGA 426 UCUUGACACAAGGCAUCGU 665 AcGAuGccuuGuGucAAGAdTsdT 720 pUCUUGAcAcAAGGcAUCGUdTsdT 195 AGACCGCGAGGAGGAUCUU 427 AAGAUCCUCCUCGCGGUCU 666 AgAccGcGAGGAGGAucuudTsdT 817 pAAGAUCCUCCUCGCGGUCUdTsdT 196 UUGUUACCUAAAGUUAAUC 428 GAUUAACUUUAGGUAACAA 667 uuGuuAccuAAAGuuAAucdTsdT 804 pGAUuAACUUuAGGuAAcAAdTsdT 197 CAGAAGCCCGCUGUUUCUA 429 UAGAAACAGCGGGCUUCUG 668 caGAAGcccGcuGuuucuAdTsdT 833 puAGAAAcAGCGGGCUUCUGdTsdT 198 UUUGACUUUAUGGAGAAUA 430 UAUUCUCCAUAAAGUCAAA 669 uuuGAcuuuAuGGAGAAuAdTsdT 883 puAUUCUCcAuAAAGUcAAAdTsdT 199 UACCUAAAGUUAAUCCAGA 431 UCUGGAUUAACUUUAGGUA 670 uaccuAAAGuuAAuccAGAdTsdT 807 pUCUGGAUuAACUUuAGGuAdTsdT 200 UUCAAACACCUGGUACACA 432 UGUGUACCAGGUGUUUGAA 671 uucAAAcAccuGGuAcAcAdTsdT 864 pUGUGuACcAGGUGUUUGAAdTsdT 201 UUGCACUCUAAUGAAGCAA 433 UUGCUUCAUUAGAGUGCAA 672 uuGcAcucuAAuGAAGcAAdTsdT 870 pUUGCUUcAUuAGAGUGcAAdTsdT 202 UGUUACCUAAAGUUAAUCC 434 GGAUUAACUUUAGGUAACA 673 uguuAccuAAAGuuAAuccdTsdT 805 pGGAUuAACUUuAGGuAAcAdTsdT 203 CACUAAGUGACUAAAGUAA 435 UUACUUUAGUCACUUAGUG 674 cacuAAGuGAcuAAAGuAAdTsdT 767 pUUACUUuAGUcACUuAGUGdTsdT 203 CACUAAGUGACUAAAGUAA 435 UUACUUUAGUCACUUAGUG 674 cacuAAGuGAcuAAAGuAAdTsdT 942 pUuACUUuAGUcACUuAGUGdTsdT 204 UGCCAGAUAGAAGACAGGU 436 ACCUGUCUUCUAUCUGGCA 675 ugccAGAuAGAAGAcAGGudTsdT 786 pACCUGUCUUCuAUCUGGcAdTsdT 205 AAUGUAUAGUCUUCUUAUU 437 AAUAAGAAGACUAUACAUU 676 AauGuAuAGucuucuuAuudTsdT 840 pAAuAAGAAGACuAuAcAUUdTsdT 206 GACCACUAAUGGGAGCCAA 438 UUGGCUCCCAUUAGUGGUC 677 GaccAcuAAuGGGAGccAAdTsdT 914 pUUGGCUCCcAUuAGUGGUCdTsdT 207 GUUACCUAAAGUUAAUCCA 439 UGGAUUAACUUUAGGUAAC 678 GuuAccuAAAGuuAAuccAdTsdT 928 pUGGAUuAACUUuAGGuAACdTsdT 208 UGAUGCCUGGCCUCACAUU 440 AAUGUGAGGCCAGGCAUCA 679 ugAuGccuGGccucAcAuudTsdT 855 pAAUGUGAGGCcAGGcAUcAdTsdT 209 CCAACUUUAAAGUCAGUCC 441 GGACUGACUUUAAAGUUGG 680 ccAAcuuuAAAGucAGuccdTsdT 915 pGGACUGACUUuAAAGUUGGdTsdT 210 UAAACUUGUGUAGACUAAG 442 CUUAGUCUACACAAGUUUA 681 uaAAcuuGuGuAGAcuAAGdTsdT 778 pCUuAGUCuAcAcAAGUUuAdTsdT 211 AGUAGGUUGUGUGAGUUAA 443 UUAACUCACACAACCUACU 682 AguAGGuuGuGuGAGuuAAdTsdT 920 pUUAACUcAcAcAACCuACUdTsdT 211 AGUAGGUUGUGUGAGUUAA 443 UUAACUCACACAACCUACU 682 AguAGGuuGuGuGAGuuAAdTsdT 958 pUuAACUcAcAcAACCuACUdTsdT 212 GUUAAACUUGUGUAGACUA 444 UAGUCUACACAAGUUUAAC 683 GuuAAAcuuGuGuAGAcuAdTsdT 776 puAGUCuAcAcAAGUUuAACdTsdT 213 CUGACCACUAAUGGGAGCC 445 GGCUCCCAUUAGUGGUCAG 684 cuGAccAcuAAuGGGAGccdTsdT 762 pGGCUCCcAUuAGUGGUcAGdTsdT 214 UAUUCUUAAUAGGGCUACU 446 AGUAGCCCUAUUAAGAAUA 685 uauucuuAAuAGGGcuAcudTsdT 793 pAGuAGCCCuAUuAAGAAuAdTsdT 215 GUAGUGUCCUGGGAUUCUC 447 GAGAAUCCCAGGACACUAC 686 GuAGuGuccuGGGAuucucdTsdT 787 pGAGAAUCCcAGGAcACuACdTsdT 216 UAUCUGGCAGAUGUAUAAG 448 CUUAUACAUCUGCCAGAUA 687 uaucuGGcAGAuGuAuAAGdTsdT 824 pCUuAuAcAUCUGCcAGAuAdTsdT 217 AGGCUACCUAUGGUGAACG 449 CGUUCACCAUAGGUAGCCU 688 AgGcuAccuAuGGuGAAcGdTsdT 721 pCGUUcACcAuAGGuAGCCUdTsdT 218 UCAGACCAUUUCCUAAUCA 450 UGAUUAGGAAAUGGUCUGA 689 ucAGAccAuuuccuAAucAdTsdT 936 pUGAUuAGGAAAUGGUCUGAdTsdT 219 UUACCUAAAGUUAAUCCAG 451 CUGGAUUAACUUUAGGUAA 690 uuAccuAAAGuuAAuccAGdTsdT 806 pCUGGAUuAACUUuAGGuAAdTsdT 220 GGUUUCUACACCAAAUACA 452 UGUAUUUGGUGUAGAAACC 691 GguuucuAcAccAAAuAcAdTsdT 761 pUGuAUUUGGUGuAGAAACCdTsdT 221 GUUGGUGCCAGAUAGAAGA 453 UCUUCUAUCUGGCACCAAC 692 GuuGGuGccAGAuAGAAGAdTsdT 785 pUCUUCuAUCUGGcACcAACdTsdT 222 GCUACCUAUGGUGAACGUG 454 CACGUUCACCAUAGGUAGC 693 GcuAccuAuGGuGAAcGuGdTsdT 723 pcACGUUcACcAuAGGuAGCdTsdT 223 UCACUAAGUGACUAAAGUA 455 UACUUUAGUCACUUAGUGA 694 ucAcuAAGuGAcuAAAGuAdTsdT 766 puACUUuAGUcACUuAGUGAdTsdT 224 UUAUUGUUACCUAAAGUUA 456 UAACUUUAGGUAACAAUAA 695 uuAuuGuuAccuAAAGuuAdTsdT 802 puAACUUuAGGuAAcAAuAAdTsdT 225 UAGCUGAAUAAUGUGAGGA 457 UCCUCACAUUAUUCAGCUA 696 uaGcuGAAuAAuGuGAGGAdTsdT 808 pUCCUcAcAUuAUUcAGCuAdTsdT 226 UGACCACUAAUGGGAGCCA 458 UGGCUCCCAUUAGUGGUCA 697 ugAccAcuAAuGGGAGccAdTsdT 763 pUGGCUCCcAUuAGUGGUcAdTsdT 227 GUAGCUACCUCACAACCAG 459 CUGGUUGUGAGGUAGCUAC 698 GuAGcuAccucAcAAccAGdTsdT 898 pCUGGUUGUGAGGuAGCuACdTsdT 228 UCCCGCUCGCGCCCAUCAC 460 GUGAUGGGCGCGAGCGGGA 699 ucccGcucGcGcccAucAcdTsdT 812 pGUGAUGGGCGCGAGCGGGAdTsdT 229 CUUGGCUUUAAAGUGAGGG 461 CCCUCACUUUAAAGCCAAG 700 cuuGGcuuuAAAGuGAGGGdTsdT 906 pCCCUcACUUuAAAGCcAAGdTsdT 230 AGAAGCCCGCUGUUUCUAU 462 AUAGAAACAGCGGGCUUCU 701 AgAAGcccGcuGuuucuAudTsdT 834 pAUAGAAAcAGCGGGCUUCUdTsdT 230 AGAAGCCCGCUGUUUCUAU 462 AUAGAAACAGCGGGCUUCU 701 AgAAGcccGcuGuuucuAudTsdT 948 pAuAGAAAcAGCGGGCUUCUdTsdT 231 ACUAAAGUAAGUUAAACUU 463 AAGUUUAACUUACUUUAGU 702 AcuAAAGuAAGuuAAAcuudTsdT 773 pAAGUUuAACUuACUUuAGUdTsdT 232 AGUAAGUUAAACUUGUGUA 464 UACACAAGUUUAACUUACU 703 AguAAGuuAAAcuuGuGuAdTsdT 774 puAcAcAAGUUuAACUuACUdTsdT 233 AAUAAUUAUCAAUGCUGUU 465 AACAGCAUUGAUAAUUAUU 704 AauAAuuAucAAuGcuGuudTsdT 725 pAAcAGcAUUGAuAAUuAUUdTsdT

TABLE 6 SEQ ID FPL Name Function Sequence No. hsRRM001 CE cgggtttcagggattcccagTTTTTctcttggaaagaaagt  997 hsRRM002 CE gcttgctgcaaagaaagccaTTTTTctcttggaaagaaagt  998 hsRRM003 CE cttcttggctaaatcgctccaTTTTTctcttggaaagaaagt  999 hsRRM004 CE agcgggcttctgtaatctgaaTTTTTctcttggaaagaaagt 1000 hsRRM005 CE gagaaattccctttctttgggaTTTTTctcttggaaagaaagt 1001 hsRRM006 CE ggtagcctctttgtccccaatTTTTTctcttggaaagaaagt 1002 hsRRM007 LE gaacatgggatataaaatatctctcctTTTTTaggcataggacccgtgtct 1003 hsRRM008 LE ccaagttttcatttactatgccatcTTTTTaggcataggacccgtgtct 1004 hsRRM009 LE catttcagaatgtatgttttccatgTTTTTaggcataggacccgtgtct 1005 hsRRM010 LE catcgtttcaatggcattgaaTTTTTaggcataggacccgtgtct 1006 hsRRM011 LE ccagcgcaaggcccagtTTTTTaggcataggacccgtgtct 1007 hsRRM012 LE aaggctacaacacgttcaccataTTTTTaggcataggacccgtgtct 1008 hsRRM013 LE aatgccttccactgcagcaTTTTTaggcataggacccgtgtct 1009 hsRRM014 BL gcaatttggaagccatagaaac 1010 hsRRM015 BL tcttttatgtaagtgtcaataagaagactata 1011 hsRRM016 BL ctgccttcttcttgacacaagg 1012

TABLE 7 SEQ ID FPL Name Function Sequence No. hGAP001 CE gaatttgccatgggtggaatTTTTTctcttggaaagaaagt 986 hGAP002 CE ggagggatctcgctcctggaTTTTTctcttggaaagaaagt 987 hGAP003 CE ccccagccttctccatggtTTTTTctcttggaaagaaagt 988 hGAP004 CE gctcccccctgcaaatgagTTTTTctcttggaaagaaagt 989 hGAP005 LE agccttgacggtgccatgTTTTTaggcataggacccgtgtct 990 hGAP006 LE gatgacaagatcccgttctcTTTTTaggcataggacccgtgtct 991 hGAP007 LE agatggtgatgggatttccattTTTTTaggcataggacccgtgtct 992 hGAP008 LE gcatcgccccacttgattttTTTTTaggcataggacccgtgtct 993 hGAP009 LE cacgacgtactcagcgccaTTTTTaggcataggacccgtgtct 994 hGAP010 LE ggcagagatgatgacccttttgTTTTTaggcataggacccgtgtct 995 hGAP011 BL ggtgaagacgccagtggactc 996

TABLE 8 Cell- p53 bDNA Titer status expt. 1 expt. 2 Glo xCELLigence SEQ ID 497/711 HepG2 wt 10.1 33 540 210 HLF mutant 4.7 37 180 80 A549 wt 5.2 165 520 140 SEQ ID 477/839 HepG2 wt 3.6 28 380 130 HLF mutant 0.73 21 120 69 A549 wt 0.73 21 190 160

TABLE 9 24 hr 48 hr 72 hr SEQ ID 497/711 HepG2 81 85 85 HLF 90 90 83 A549 84 59 ND SEQ ID 477/839 HepG2 87 76 75 HLF 96 92 62 A549 91 54 ND 

We claim:
 1. A double-stranded ribonucleic acid molecule for inhibiting the expression of a ribonucleotide reductase M2 (RRM2) gene, wherein the double-stranded ribonucleic acid molecule comprises a sense strand and an antisense strand, wherein the antisense strand and the sense strand are each less than about 30 nucleotides in length, wherein the antisense strand comprises the nucleotide sequence of any of SEQ ID NO:234-SEQ ID NO:466, wherein the sense strand is at least substantially complementary to the antisense strand, and wherein the sense strand and/or the antisense strand comprises at least one modified nucleotide.
 2. The double-stranded ribonucleic acid molecule of claim 1, wherein the antisense strand and the sense strand are each 19-24 nucleotides in length.
 3. The double-stranded ribonucleic acid molecule of claim 2, wherein the modified nucleotide is selected from the group consisting of: 2′-O-methyl modified nucleotide, nucleotide comprising a 5′-phosphorothioate group, 2′-deoxy-2′-fluoro modified nucleotide, 2′-deoxy-modified nucleotide, locked nucleotide, abasic nucleotide, inverted deoxythymidine, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, phosphoramidate, and non-natural base comprising nucleotide.
 4. The double-stranded ribonucleic acid molecule of claim 2, wherein the sense strand and the antisense strand each comprise at least one modified nucleotide.
 5. The double-stranded ribonucleic acid molecule of claim 4, wherein the modified nucleotide in the sense strand and the modified nucleotide in the antisense strand is independently selected from the group consisting of: 2′-O-methyl modified nucleotide, nucleotide comprising a 5′-phosphorothioate group, 2′-deoxy-2′-fluoro modified nucleotide, 2′-deoxy-modified nucleotide, locked nucleotide, abasic nucleotide, inverted deoxythymidine, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, phosphoramidate, and non-natural base comprising nucleotide.
 6. The double-stranded ribonucleic acid molecule of claim 1, wherein the sense strand comprises the nucleotide sequence of any of SEQ ID NO: 1-SEQ ID NO:233.
 7. The double-stranded ribonucleic acid molecule of claim 6, wherein the sense strand and/or the antisense strand further comprises a 3′ overhang of 1-5 nucleotides in length.
 8. The double-stranded ribonucleic acid molecule of claim 7, wherein the 3′ overhang comprises nucleotides linked by one or more phosphorothioate groups.
 9. The double-stranded ribonucleic acid molecule of claim 8, wherein the 3′ overhang comprises uracil.
 10. The double-stranded ribonucleic acid molecule of claim 1, wherein the antisense strand of the double-stranded ribonucleic acid molecule comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-deoxy-2′-fluoro modified nucleotide, and at least one nucleotide comprising a 5′-phosphorothioate group.
 11. The double-stranded ribonucleic acid molecule of claim 1, wherein the sense strand of the double-stranded ribonucleic acid molecule comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-deoxy-2′-fluoro modified nucleotide, and at least one nucleotide comprising a 5′-phosphorothioate group.
 12. The double-stranded ribonucleic acid molecule of claim 6, wherein the sense strand and the antisense strand of the double-stranded ribonucleic acid molecule each comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-deoxy-2′-fluoro modified nucleotide, and at least one nucleotide comprising a 5′-phosphorothioate group.
 13. The double-stranded ribonucleic acid molecule of claim 1, wherein the double-stranded ribonucleotic acid molecule is conjugated to a ligand.
 14. The double-stranded ribonucleic acid molecule of claim 6, wherein said double-stranded ribonucleotic acid molecule is conjugated to a ligand.
 15. The double stranded ribonucleic acid molecule of claim 1, wherein the antisense strand comprises any of SEQ ID NO:705-SEQ ID NO:985.
 16. The double stranded ribonucleic acid molecule of claim 6, wherein the sense strand comprises any of SEQ ID NO:467-SEQ ID NO:704.
 17. The double stranded ribonucleic acid molecule of claim 6, wherein the antisense strand comprises any of SEQ ID NO:705-SEQ ID NO:985, and wherein the sense strand comprises any of SEQ ID NO:467-SEQ ID NO:704.
 18. The double-stranded ribonucleic acid molecule of claim 15, wherein the double-stranded ribonucleotic acid molecule is conjugated to a ligand.
 19. The double-stranded ribonucleic acid molecule of claim 17, wherein the double-stranded ribonucleotic acid molecule is conjugated to a ligand.
 20. A pharmaceutical composition comprising: (i) the double-stranded ribonucleic acid molecule of claim 1, and (ii) a pharmaceutically acceptable carrier.
 21. A pharmaceutical composition comprising: (i) the double-stranded ribonucleic acid molecule of claim 6, and (ii) a pharmaceutically acceptable carrier. 